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3. Summary 
Proliferative vitreoretinopathy (PVR) is the major cause of failure of retinal reattachment 
surgery and may lead to permanent loss of vision. It is characterized by the proliferation, 
migration and epithelial-to-mesenchymal transition (EMT) of retinal pigment epithelial 
cells (RPE) in the vitreous. Currently there is no pharmacological adjuvant for preventing 
or treating PVR. The aim of this PhD project was to get deeper insights in the complex 
cellular events - especially EMT processes - underlying PVR development and to 
investigate the carbohydrate-binding proteins galectin (Gal)-1 and Gal-3 as potential 
pharmacological agents to treat PVR. Our results showed that EMT of RPE cells in vitro is 
not only accompanied by a transition from an epithelial to a stable mesenchymal 
phenotype but also by a glycomic shift to complex-type N-glycans of RPE cell surface 
glycoproteins, conferring increased binding of Gal-1 and Gal-3 on mesenchymal RPE cells 
compared to epithelial ones. Phenotype transition of primary RPE cells was blocked in 
vitro by diverse inhibitors of the TGFβ pathway; change to a complex N-glycan-structure 
was inhibited by blocking Golgi glycosyltransferase activity of α-mannosidase. Yet 
blocking one of those processes had no influence on the other one. Exogenously added 
Gal-1 and Gal-3 inhibited carbohydrate-dependently migration of mesenchymal RPE 
cells in scratch-wound healing assays, but EMT processes were not influenced by 
galectin treatment. Whereas Gal-1 and Gal-3 were upregulated upon EMT in RPE cells, 
no changes in glycan structures or galectin-binding efficacy were detectable in galectin 
knockdown cells compared to wildtype cells. In a proteome-wide comprehensive Gal-1 
and Gal-3 interactome screening approach we identified 131 Gal-3 interactors and 15 
Gal-1 interactors, mainly localized on the RPE cell surface and involved in PVR-associated 
molecular functions. Furthermore, two of the identified interactors, namely low-density 
lipoprotein receptor LRP1 and beta-type platelet-derived growth factor receptor 
PDGFRB, could be validated as Gal-1 and Gal-3 interactors by galectin-induced cross-
linking of LRP1, PDGFRB and the integrin ITGB1 on the RPE cell surface in a complex-type 
N-glycan-binding-dependent manner. Galectin binding also resulted in dynamin- and 
carbohydrate-dependent endocytosis of Gal-1 and Gal-3 and both ERK/MAPK and Akt 
signaling pathways were activated. In conclusion, analyzing changes of phenotype, 
proteome and cell surface glycan structures of RPE cells undergoing EMT in vitro and 
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identifying specific galectin interactors helped to get an increasing understanding in the 
pathogenesis of PVR and to unravel functional effects of galectins. The glycomic shift of 
RPE cell surface glycoproteins upon EMT may provide a basis for diagnostic 
glycophenotyping of cells isolated from the vitreous of patients suffering from early PVR 
and galectins may contribute to the development of a glycan-based therapy for PVR.  
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4. Zusammenfassung 
Die Proliferative Vitreoretinopathie (PVR) ist eine häufige Komplikation, die bei 
Netzhautablösungen sowie vitreoretinalen chirurgischen Eingriffen auftreten kann und 
schließlich zur Erblindung der Patienten führt. Proliferation, Migration und die epithelial-
mesenchymale Transition (EMT) von retinalen Pigmentepithelzellen (RPE) kennzeichnen 
das Krankheitsbild der PVR. Einen pharmakologischen Wirkstoff um die Entstehung der 
PVR zu verhindern oder zu behandeln gibt es momentan noch nicht. Das Ziel dieser 
Doktorarbeit war zum einen die zellulären Prozesse (insbesondere die EMT), die der PVR 
zugrunde liegen, zu untersuchen und zum anderen die zuckerbindenden Proteine 
Galektin-1 (Gal-1) und Galektin-3 (Gal-3) als mögliche pharmakologische Wirkstoffe zu 
testen. Die Ergebnisse zeigten, dass EMT von RPE Zellen in vitro nicht nur zu einer 
kompletten Änderung des Phänotyps, sondern auch zu einer höheren Expression von 
komplexen N-Glykanstrukturen an der RPE Zelloberfläche führte, sodass Gal-1 und Gal-3 
stärker an mesenchymale RPE Zellen binden. Während die Transition zu einem 
mensenchymalen Phänotyp in vitro durch Inhibitoren des TGFβ Signalweges verhindert 
werden konnte, wurde die Bildung von N-Glykanstrukturen durch Hemmung der Golgi-
Glykosyltransferase α-Mannosidase unterbunden. Durch die Inhibierung einer dieser 
Prozesse wurde der andere jedoch nicht beeinflusst. Die exogene Behandlung von RPE 
Zellen mit Gal-1 oder Gal-3 verlangsamte deren Migration in Wundheilungs-Assays, EMT 
Prozesse wurden nicht beeinflusst. Gal-1 und Gal-3 sind in mesenchymalen RPE Zellen 
überexprimiert. Galektin-knockdown Zellen zeigten jedoch keine Unterschiede in ihren 
Oberflächen-Glykanstrukturen oder in der Bindungsaffinität von Galektinen im Vergleich 
zu Wildtyp-Zellen. In einer Proteom-weiten Gal-1 und Gal-3  Interaktom-Studie wurden 
131 Gal-3 Interaktoren und 15 Gal-1 Interaktoren identifiziert. Diese Interaktoren waren 
überwiegend membranständige oder oberflächenassoziierte Glykoproteine und in vielen 
PVR-relevanten zellulären Prozessen involviert. Zwei der identifizierten Interaktoren – 
das Low Density Lipoprotein Receptor-related Protein 1 (LRP1) und der Beta-type 
platelet-derived growth factor receptor (PDGFRB) – konnten durch N-Glykan-abhängige 
Galektin-induzierte Cluster-Bildung unter Einbeziehung von Integrin ITGB1 an der RPE 
Zelloberfläche validiert werden. Es konnte ebenfalls gezeigt werden, dass Gal-1 und Gal-
3 auf einem Dynamin- und N-Glykan-abhängigen Weg über Endozytose in RPE Zellen 
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aufgenommen werden und dabei ERK/MAPK und Akt Signalwege aktiviert werden. 
Zusammenfassend zeigen die Ergebnisse dieser Arbeit, dass die Analysen von 
Veränderungen im Phänotyp, im Proteom und in der Glykanstruktur von RPE Zellen und 
die Identifizierung spezifischer Galektin-Interaktoren essentiell sind um die Pathogenese 
der PVR molekular zu verstehen, aber auch um funktionelle Effekte von Galektinen zu 
untersuchen. Die Veränderung der Zuckerstrukturen von Oberflächenproteinen der RPE 
Zellen können ein Ansatz für die Entwicklung von Biomarkern sein um anhand von 
Glaskörperzellen, die aus dem Auge von PVR Patienten in frühem Stadium isoliert 
wurden, die PVR frühzeitig zu erkennen und mithilfe von Galektinen eine Glykan-
basierte Therapie zu entwickeln.   
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5. Introduction 
 Proliferative vitreoretinopathy 
Proliferative vitreoretinopathy (PVR) is a blinding disease occurring as a complication 
after rhegmatogenous retinal detachment surgery1-4. The Retina Society Terminology 
Committee introduced in 1983 the term proliferative vitreoretinopathy4, which was 
formerly called “massive periretinal proliferation”5. PVR is not defined as specific clinical 
entity, but rather an end point of a number of intraocular diseases with various stimuli6. 
It is assumed that PVR is a reparative and scarring process primarily induced by retinal 
detachment, caused by a retinal break and accompanied by an excessive inflammatory 
reaction3. To classify different stages of PVR, it is divided into three grades: A, B and C 
with increasing severity of PVR7. Stage A describes the presence of retinal cells in the 
vitreous, stage B is associated with inner retinal surface wrinkling or formation of retinal 
tears, stage C is divided into posterior (CP) and anterior (CA) PVR and is reached by 
formation of retinal folds or subretinal strands CP or CA to equator7.  
Rhegmatogenous retinal detachment induces breakdown of the blood-retina barrier and 
triggers wound-healing processes, including cell migration and proliferation of distinct 
cell types: retinal pigment epithelial (RPE) and retinal Müller Glial (RMG) cells, fibrous 
astrocytes, fibroblasts, myofibroblasts, and macrophages (figure 1)8, 9. RPE cells as a 
main component of the PVR membranes are in focus of PVR research. Under 
physiological conditions RPE cells are mitotically quiescent and located in a monolayer 
between the neural retina and the choroid in the eye10. Early in disease development 
the integrity of the retina is broken and RPE cells dislodge from Bruch’s membrane, 
migrate in the vitreous and/or periretinal area and epithelial-to-mesenchymal transition 
(EMT) takes place2, 5, 11. During EMT RPE cells convert from epithelial into mesenchymal 
cells, lose their epithelial characteristics and acquire migratory mesenchymal properties, 
accompanied by formation of an extracellular matrix structure containing collagen, 
fibronectin, thrombospondin, and other matrix proteins8, 10, 12. Migration, proliferation 
and dedifferentiation of retinal cells promotes development of sub- and epiretinal 
fibrocellular membranes, which contract and lead to repetitive tractional retinal 
detachment (figure 1)2, 5, 6, 8, 13. The retinal break causes release of growth factors and 
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cytokines in the vitreous which contributes to cell-growth regulation in PVR8, 12, 14. It is 
assumed that platelet-derived growth factor (PDGF), tumor growth factor-beta (TGF-β), 
epidermal growth factor (EGF), tumor necrosis factor-alpha (TNF-α), TNF-β and 
fibroblast growth factor (FGF) as well as cytokines like interleukin-1 (IL-1), IL-6, IL-8, IL-
10, and interferon-gamma (INF-γ) may play a role in PVR development (figure 1)8, 15-21. 
Yet growth factors and cytokines are very multifunctional and involved in many different 
cellular processes. Increased understanding of the complex pathways and the interplay 
between growth factors and cytokines in PVR development remains a prerequisite for 
future prevention and treatment of PVR22.  
 
Figure 1: The growth factor/cytokine hypothesis for PVR development, published in Lei et al. 15. By 
retinal tear formation and retinal detachment, retinal cells can be exposed to vitreal growth factors and 
cytokines, which promote cellular processes like migration, proliferation, epithelial-to-mesenchymal 
transition (EMT) and extracellular-matrix (ECM) production. Sub- and epiretinal membranes are built 
and cells within the membranes are stimulated by growth factors and cytokines in the vitreous to 
contract and the retina re-detaches.  
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Even though knowledge about pathophysiology of PVR is increasing, it still remains the 
primary barrier to successful retinal detachment surgery23. 5%-10% of all 
rhegmatogenous retinal detachment processes are accompanied with PVR and after re-
attachment of the retina by surgical means, PVR occurs in 75% of all cases3, 8. The more 
advanced the PVR, the poorer is the outcome of the surgery and the lower the re-
attachment rate of the retina6. Surgery may even stimulate PVR because it triggers 
inflammation processes inducing extensive proliferation of retinal cells8, 23. Nevertheless 
vitreous surgery is still the standard treatment method for PVR6. Identification of a 
pharmacological agent that is capable to prevent or interfere with cellular processes 
underlying PVR development is necessary to improve the final outcome. Most of the 
recent experimental therapeutic approaches attempted to control PVR development by 
anti-proliferative or anti-inflammatory compounds or by inhibition of single growth 
factors and their signaling pathways24-31. However, PVR is caused by an interplay 
between different cytokines and growth factors, matrix proteins and the various cell 
types, resulting in formation of tractional membranes8. Consequently, counteracting 
PVR requires a multimodal concept6. 
5.1.1. The retinal pigment epithelium 
The retinal pigment epithelium (RPE) is a monolayer of highly pigmented cells found 
between Bruch’s membrane and the photoreceptor layer of the neural retina (figure 
2)32. RPE cells are strongly polarized, have a hexagonal shape and they fit together in a 
tight matrix33, 34. The RPE has a barrier function to prevent large molecules and particles 
from entering the vitreous from the bloodstream35. The function as blood-retina-barrier 
is to some extend similar to that of the blood-brain barrier, because the RPE separates 
neural and vascular tissue, which is critical for the correct function of the neuroretina35. 
On the apical side of the RPE, highly specialized photoreceptors are embedded in an 
interphotoreceptor matrix35-37. The light-sensitive outer segments of the photoreceptors 
are in close structural interaction with long apical microvilli of RPE cells36. On the basal 
side, an elastogenesis product of the RPE and choroid, called Bruch’s membrane, is 
located, which separates the RPE from the endothelium of the choriocapillaris35, 36. 
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Figure 2: A schematic model of the RPE structure, as published in Bonilha 33. RPE interacts at the apical 
surface with photoreceptor cells and on the basal side with the Bruch’s membrane. The shape of 
individual RPE cells is maintained by their cytoskeleton components.  
The RPE is involved in many complex processes in the visual cycle. It is involved in the 
uptake, processing – including re-isomerization of all-trans-retinal to 11-cis-retinal –, 
transport and release of retinal (vitamin A), in phagocytosis of shed photoreceptor outer 
segments and in rebuilding of light-sensitive outer segments from the base of 
photoreceptors36, 38. Physiologically, the RPE absorbs excess light entering the eye to 
reduce photo-oxidative stress32. It regulates the development of the retina and the 
supply with nutrients such as glucose, retinol, and fatty acids from the choroid to the 
photoreceptor cells as well as transportation of metabolites and fluids in the opposite 
direction33, 36. RPE are part of the innate immune system and thus involved in immune 
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responses of the eye; RPE also secretes growth factors like vascular endothelial growth 
factor (VEGF) and pigment epithelium-derived growth factor (PEDF)35, 39, 40. Because of 
its various functions in physiological processes, the RPE plays a role in many ocular 
disorders, including Retinitis Pigmentosa, diabetic retinopathy and macular 
degeneration32.   
5.1.2. Epithelial to mesenchymal transition 
The epithelial-to-mesenchymal-transition (EMT) of RPE cells plays a key role in PVR 
development11. EMT is a cellular process naturally occurring during development and 
differentiation of distinct tissues and organs or as a physiological response to injury, but 
it is also associated with distinct pathological processes as tissue fibrosis, tumor 
invasiveness and metastasis41, 42. During EMT, epithelial cells lose their epithelial cell 
characteristics, change their morphology and phenotype and acquire mesenchymal-like 
properties22, 42, 43. Epithelial cells are characterized by their tight cell-cell contacts 
mediated by adherens junctions, desmosomes and tight junctions as well as by an 
apicobasal axis of polarity, which promotes the function of epithelia as barriers in 
absorption41. By EMT, cells increase their production of ECM components, their 
resistance to apoptosis and their migratory and invasive properties by losing their 
organized cell-cell structures and cell polarity41, 42. EMT is reversible and is accordingly 
called mesenchymal-to-epithelial-transition (MET). EMT and MET processes are 
characterized by change of the expression of specific cell-surface proteins, 
reorganization of cytoskeletal proteins or activation of distinct transcription factors 
(figure 3)42. Epithelial markers such as zonula occludens-1 (ZO-1) and E-cadherin are up- 
and downregulated in epithelial and mesenchymal cells respectively. Approved 
mesenchymal cell markers are α-smooth muscle actin (α-SMA), vimentin, and 
fibronectin44. Those factors are suitable biomarkers to define the state of a cell 
undergoing EMT or MET (figure 3).  
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Figure 3: Epithelial to mesenchymal transition and the corresponding cell markers, published in Kalluri 
and Weinberg 42. Polarized epithelial cells transform into mobile mesenchymal cells. ZO-1: zona 
occludens 1; MUC1: mucin 1; SMA: smooth muscle actin. 
Three types of EMT can be distinguished. Type 1 EMT is characterized by the transition 
of epithelial cells into primary mesenchymal cells, which in turn undergo MET, form 
secondary epithelia or undergo apoptosis42, 44. In these processes the cells don’t obtain 
an invasive phenotype and are not spread via circulation42. Type 2 EMT is associated 
with organ fibrosis, tissue regeneration and wound healing processes accompanied by 
inflammation42. Epithelial cells transform into fibroblasts as part of a repair-associated 
event, but if there is persistent inflammation over extended periods of time affected 
organs can be destroyed42, 44. Type 3 EMT is seen in metastatic processes. Epithelial cells 
can transform in epithelial tumor cells and undergo EMT, which enables migration and 
metastasis42, 44. The metastatic tumor cells reform as a secondary tumor nodule, 
generating the final, life-threatening manifestations of cancer progression42, 44.  
In context of PVR, RPE cells are exposed to many cytokines and growth factors in the 
vitreous by retinal break. Those factors stimulate EMT, migration and proliferation of 
RPE cells and lead to the formation of fibrotic tissue on the retina. Recent studies 
indicated that EMT in RPE cells contributes mainly to PVR and it is presumably caused by 
many different factors, such as changes in cell-cell adhesion profile, modified growth 
factor signaling or loss of ECM adhesion10, 43. In vitro, EMT occurs by cultivation of 
primary RPE cells on plastic in serum-containing media45. Cultured human RPE cells are a 
well-accepted in vitro model system for early PVR. Triggered by distinct growth factors 
contained in fetal bovine serum (FBS), RPE cells begin to dedifferentiate and to 
transform into a fibroblast-like phenotype43, 45. One of the key drivers of EMT is TGFβ46. 
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TGFβ is a multifunctional cytokine that exists in three isoforms (TGFβ1, TGFβ2 and 
TGFβ3) and is involved in many biological processes like differentiation, apoptosis, 
migration, immune cell function and ECM synthesis and thus it plays a role in many 
distinct diseases47. TGFβ signaling pathways are divided in the canonical Smad signaling 
pathway48 and non-canonical pathways, but the different types of pathways can interact 
with each other and contribute to EMT22. Non-canonical pathways include the mitogen-
activated kinase (MAPK), the extracellular signal-regulated kinase 1/2(ERK1/2) and the 
phosphatidyl inositol 3-kinase (PI3-K)/Akt22. TGFβ2 is the most important isoform driving 
EMT and PVR processes and it is often used to induce EMT in vitro30.  
EMT processes are also very dependent on cell-cell contacts. Disruption of such contacts 
triggers EMT, whereas intact and close cell-cell contacts maintain the epithelial 
phenotype of cells43, 45. Tamiya et al. 43 showed that mainly loss of cell-cell contacts 
initiates EMT in RPE cells and that TGFβ2 treatment promotes EMT, but has no effect on 
RPE cells when cell-cell contacts are retained. Besides, transcription factors, intracellular 
signaling pathways and microRNAs are critical for EMT induction in PVR in vitro and in 
vivo22, 49, 50. Preventing EMT processes by inhibiting those distinct factors is one 
important therapeutic approach in PVR research22.   
 Galectins 
Galectins constitute a family of soluble animal lectins and are β-galactoside binding 
proteins, which share homology in a highly conserved 130 amino acid sequence of their 
carbohydrate recognition domain (CRD) 51-54. Based on this conserved galectin CRD many 
galectins were identified in the last 40 years55. Galectins are expressed in many different 
organisms, for example in vertebrates (fish, birds), invertebrates (insects, worms) and 
even in fungi, sponges, plants, viruses and bacteria54, 56. In mammals, 15 proteins of this 
family are characterized so far, 12 of them in humans 55, 57. The nomenclature for 
galectins in mammals was introduced in 1994 and the members of this protein family 
were numbered consecutively by order of their discovery51.  
5.2.1. Structure of galectins 
Crystallography has been used to determine the three-dimensional structure of the 
CRDs of some mammalian galectins and all of them have in common, that they have a 
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globular fold of anti-parallel β-sheets with five to six strands respectively58-62. Four 
adjacent β-strands are involved in carbohydrate binding, either by formation of 
hydrogen bonds or van der Waals interactions with the sugar moiety58.  
Regarding their molecular structure, galectins are clustered in three groups: proto-, 
chimera- and tandem-repeat-type54. Prototype galectins (galectin-1, 2, 5, 7, 10, 11, 13, 
14, (15)) consist of one CRD and usually form noncovalent dimers 52, 53, 57 (figure 4). 
Chimera type galectins, whose only member known so far is galectin-3, are 
characterized by two distinct domains, a C-terminal CRD and a N-terminal non-lectin 
proline-, tyrosine- and glycine-rich domain63, 64 (figure 4). Tandem-repeat galectins 
(galectin-4, 8, 9, 12) contain two different CRDs connected by a short peptide 53, 57.  
In general, galectins have a lot of features of cytosolic proteins. They are acetylated at 
their N-terminus, have no signal peptides or post-translational modifications (only Gal-3 
can be phosphorylated) and are synthesized at cytosolic ribosomes53. As galectins are 
present in the extracellular matrix or on cell surfaces, but lack secretion signal 
sequences, it is assumed, that galectins are secreted by non-classical (non ER-Golgi) 
pathways, which is not fully understood yet 52, 65.  
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Figure 4: The Galectin family as published in Liu and Rabinovich 66. The 15 mammalian galectins can be 
subdivided into three groups. Prototype galectins (galectin-1, 2, 5, 7, 10, 11, 13, 14, (15)) consist of one 
CRD. Gal-3, which consists of one CRD fused to an N-terminal non-lectin proline-, tyrosine- and glycine-
rich domain, is assigned to chimera type galectins. Tandem-repeat galectins (galectin-4, 8, 9, 12) contain 
two different CRDs connected by a short peptide. Galectins can crosslink and interact with cell-surface 
glycoconjugates by forming dimers or oligomers and thus trigger a cascade of signaling events. Galectins 
can also influence cell-cell and cell-matrix interactions by bridging cells among each other or by bridging 
cells to extracellular matrix proteins.  
5.2.2. Functions of galectins 
Galectins are very multifunctional proteins involved in many cellular processes under 
both physiological and pathophysiological conditions. Some mammalian galectins are 
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distributed over many different tissues, others are more specifically expressed66. Both 
intra- and extracellular functions have been described: cell-cell and cell-extracellular 
matrix interactions, cell signaling and intracellular trafficking, apoptosis, organization 
and clustering of membrane proteins, regulation of cell cycle, cancer progression, 
immune response and many more66. An overall biological function of galectins has not 
emerged yet and a knockout of Gal-1 and Gal-3 (single and double knockout) in mice 
doesn’t influence survival or fertilization of the animals. Still, some transient and very 
complex consequences of lacking galectins during development have been found53, 67.  
Whether the intra- and extracellular activities of galectins are connected or not, is not 
clarified yet53. Intracellularly, galectins interact through protein-protein interactions with 
cytoplasmic and nuclear proteins and thus may influence basic cellular processes like 
pre-mRNA splicing and cell-cycle progression66, 68. Yet, the exact mechanisms of these 
interactions are not known66. On the cell surface and ECM, galectins interact with their 
protein ligands by binding to β-galactoside containing moieties on the glycosylated 
peptide backbones (figure 4)51, 58, 69. Galectins can crosslink those glycoconjugates by 
forming dimers or oligomers, thus decipher the information stored in the glycan chains 
and trigger a cascade of signaling events and influence many cellular functions including 
attachment, spreading, migration and proliferation64, 66, 70. The assembly of these 
ordered arrays of lectins and saccharides on the cell surface is required for optimal 
transmission of signals into a cell and the galectin lattice regulates the diffusion, 
compartmentalization and endocytosis of plasma membrane glycoproteins and 
glycolipids71, 72. By their bivalent and multivalent properties galectins also influence cell-
cell and cell-matrix interactions by bridging cells to other cells or by attaching cells to 
extracellular matrix proteins (figure 4)66. Because of lectin multivalency, galectins are 
able to recognize multiple binding partners simultaneously, allowing to play leading 
roles in many different biological but also pathophysiological processes71.  
How galectins influence cellular processes is different within distinct biological systems 
and is dependent on many factors like galectin expression, concentration and 
oligomerization as well as glycan structure of the interactors58. The affinity of 
transmembrane glycoproteins to the galectin lattice is proportional to the number and 
branching of their N-glycans and thus the glycosylation pattern of cell surface proteins is 
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important for the role of galectins as agonist or antagonist in cell adhesion64, 72. Even 
though all members of the galectin family bind to galactose-β1,4-N-acetylglucosamine, it 
is assumed that the structural differences in their CRD domains not only lead to different 
specificities for distinct glycoproteins, but also to distinct biological activities73-75. 
Whereas Gal-3 for example is associated with antiapoptotic effects, Gal-1 induces 
apoptosis in several cell types 76, 77. On the other hand, binding to different interactors 
does not necessarily mean that different downstream mechanisms are influenced. In the 
literature it is shown that Gal-1 and Gal-3 can bind to distinct receptors but converge on 
similar downstream signaling in several analyses for induction of T cell death73 or of 
neutrophil respiratory burst78, 79. 
With respect to cell adhesion processes galectin concentration relative to the receptor 
glycoproteins is critical. At high concentrations galectins interact unspecifically with 
many receptors on the cell surface and thereby block them and prevent interaction with 
each other which is a prerequisite for cross-linking and adhesion processes58. At lower 
concentrations galectins interact more specifically with the preferred interactors on the 
cell surface58, 64. Depending on receptor availability on the specific cell type galectins 
bridge cells to ECM proteins or to other cells (figure 4)58, 70.  
Expression levels of galectins are naturally modulated during development of organisms 
and tissues as well as during differentiation of cells66. But the expression of galectins is 
also changed under pathological conditions and galectins are for example often 
overexpressed in cancerous cells66, 80. Interestingly, mainly those cell types, that express 
low levels of galectins under normal physiological conditions, overexpress galectins in 
disease state66, 68, 81. In contrast, when cells normally express high levels of a specific 
galectin isoform, these galectins are downregulated when those cells become 
abnormal66. The influence of galectins in various diseases such as cancer, fibrosis and 
inflammation makes them useful targets in medical interventions68, 81. It is also assumed 
that altered galectin expression correlates with the aggressiveness of tumor cells and 
influences disease outcome66. Yet, most cell types co-express different galectin isoforms, 
which may results in overlapping or opposite effects and the influence of one specific 
galectin can hardly be determined58, 66. 
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5.2.3. Galectin-1 
Gal-1 (∼14kDa) was the first protein discovered in this family and is assigned to the 
prototype galectins, consisting of one CRD82. The molecular structure of Gal-1 involves a 
β-sandwich with two anti-parallel β-sheets (figure 5)83. By hydrophobic interactions at 
the N-terminal amino acid residues, prototype galectins can self-associate their 
monomer subunits to form homodimers (∼29kDa) (figure 5)52, 61, 84. In solution, Gal-1 is 
mainly present in dimeric form84. Only at low concentrations (Kd ∼ 7 µM) Gal-1 
dissociates and thus glycan binding affinity is reduced84. By dimerization Gal-1 crosslinks 
specific multivalent carbohydrates or glycoconjugates, which result in the formation of 
cross-linked lattices and the activation of several cellular pathways 52, 85-88. Gal-1 binds 
preferentially to N-acetyllactosamine and binding avidity can be increased by 
arrangement of terminal lactosamine disaccharides in multi-antennary repeating chains 
(up to three branches, Kd ∼ 4 µM)75, 83, 89. Furthermore, affinity of Gal-1 to glycan 
structures can be enhanced when they are immobilized by location at cell surfaces or in 
ECM89. Gal-1 homodimers bind also to α3-sialylated and α2-fucosylated terminal N-
acetyllactosamine, but not α6-sialylated and α3-fucosylated terminal N-
acetyllactosamine83, 89.  
 
Figure 5: Ribbon diagram of the crystal structure of human galectin-1, based on X-ray crystallographic 
analyses of the protein complexed with lactose, as published in Cummings 90. The homodimer is shown 
with each monomer colored differently and orthogonal views are presented. The subunit interface is 
based on interactions between the carboxy- and amino-terminal domains of each subunit. 
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As Gal-1 has six free cysteine-residues, activity of Gal-1 is dependent on reducing 
conditions. Nishi et al 91 showed, that a removal of the six cysteine residues increases 
stability of Gal-1 under both reducing and non-reducing conditions, while not influencing 
carbohydrate binding activity. As many other galectin isoforms, Gal-1 is present both 
intra- and extracellularly, but lacks a typical secretion signal sequence. Nickel 92 
describes possible inside-out transportation mechanisms of Gal-1 similar to those of 
fibroblast growth factor-2 (FGF-2) and β-galactoside-containing surface molecules are 
used as export receptors for intracellular Gal-183, 92.  
As most galectins, Gal-1 has also many distinct ambiguous biological functions. Gal-1 
influences for example cell growth concentration-dependently. Low doses of Gal-1 
(≤1 nM) promote cell growth carbohydrate-dependently, whereas high doses (≥1 µM) 
inhibit cell proliferation carbohydrate-independently83, 93. Via cross-linking of 
glycoproteins on the cell surface with ECM components, Gal-1 can influence cell 
adhesion of many distinct cell types, including heterotypical interactions of tumor and 
endothelial cells94, 95. Gal-1 also influences cytoskeleton organization and thus motility of 
cells, which can be again associated with higher aggressiveness of tumor cells96, whereas 
Gal-1 enriched ECM structures decrease colon carcinoma cell motility83, 97. Gal-1 also 
plays a role in tissue development and differentiation93, 98, as well as in neuronal99, 100 
and immune system78. 
5.2.4. Galectin-3 
Gal-3, a ubiquitously expressed 34-kDa protein (in adult humans), is the only known 
chimera type galectin of the human lectin family51, 53, 82. It was previous known as  
epsilon BP for its IgE-binding activity and as Mac-2, a macrophage surface antigen, 
CBP35, CBP30, L-29, and L-3463, 101. Gal-3 consists of a C-terminal domain to bind specific 
carbohydrate branches, an N-terminal 12 amino acid leader sequence with two 
phosphorylation sites and a proline and glycine rich collagen like domain, which enables 
Gal-3 to multimerize (figure 6)51, 58, 102. The highly conserved N-terminal domain consists 
of 120 amino acids (in humans) and contains multiple homologous repeats63. The N-
terminal 12 amino acid leader sequence is assumed to be involved in secretion of Gal-3 
outside of cells and in Gal-3 anti-apoptotic signaling activity103, 104. In contrast to the C-
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terminal domain the N-terminal domain has no carbohydrate-binding activity, but is 
essential for full biological activity of Gal-359, 63. The C-terminal domain is composed of 
130 amino acids, shows the typical galectin CRD folding structure and thus is responsible 
for lectin activity of Gal-363. Whereas the C-terminal CRD is resistant to collagenase 
treatment, the N-terminal non-CRD region is susceptible105. 
 
Figure 6: Schematic representations of the monomeric structure of galectin-3, galectin-3 dimerization 
through its C-terminal CRD domain in the absence of a binding ligand and galectin-3 polymerization 
through its N-terminus in the presence of carbohydrate binding ligands, as published in Newlaczyl and 
Yu 106. CRD: carbohydrate recognition domain.  
Gal-3 binding is specific for N-acetyllactosamine and N-acetylglucosamine containing 
glycoproteins as well as polylactosaminoglycans105. Phosphorylation at serine residues of 
Gal-3 is assumed to influence binding affinity and thus act as a regulatory modification 
of biological intracellular effects107. By interaction with carbohydrate ligands, Gal-3 and 
especially the CRD domain is conformationally changed108. Ligand binding occurs via the 
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CRD domain which precedes the N-terminal domain induced multimerization of 
galectins and formation of cross-linked lattices (figure 6)102, 109.  
Gal-3 is a multifunctional protein with both intra- and extracellular functions. The 
expression of Gal-3 on both protein and mRNA level can be associated with distinct 
physiological and pathophysiological effects and is influenced by different stimuli63.  
Intracellularly, Gal-3 is for instance involved in mRNA-splicing and apoptotic processes77, 
110. Extracellularly, Gal-3 has the ability to bind cell surface and ECM glycans and thus 
affect many distinct physiologic and pathologic processes, including apoptosis, 
migration, angiogenesis, adhesion and inflammatory response111. Gal-3 is for example 
upregulated in proliferating fibroblasts compared to quiescent cells and its expression is 
also changed during differentiation of cells101, 112. 
5.2.5. Galectins in context of PVR 
Current research approaches indicate that galectins as β-galactoside-binding and cross-
linking lectins play important roles in diverse physiological and pathological processes68. 
Thus they may be suitable therapeutic targets but also therapeutic agents. In previous 
studies the capacity of Gal-1 and Gal-3 to inhibit early PVR-associated cellular events 
was explored. Gal-1 and Gal-3 were found to be upregulated in cultured mesenchymal 
RPE cells113, 114 and Gal-1 is also present in the extracellular matrix of PVR membranes 
and may be derived from dedifferentiated RPE cells115. Furthermore, Gal-1 expression 
levels can be influenced by stimulation with hepatocyte growth factor (HGF) and are 
related to the migratory phenotype of RPE cells115. However, direct influence of 
modulated galectin expression and PVR pathology is not proven yet.  
From a prognostic point of view we have recently identified that EMT of RPE cells leads 
to increased β-1,6-N-glycosylation on the cell surface and thus increased binding of Gal-
3116. These results may provide a basis for diagnostic glycophenotyping of cells isolated 
from the vitreous of patients suffering from early PVR. Consequently this can contribute 
to the development of prognostic markers to define the individual risk for development 
of PVR.  
From a therapeutic perspective, Gal-1 and Gal-3 bind to mesenchymal RPE cells in a 
dose- and carbohydrate-dependent manner and thus inhibit attachment and spreading 
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of these cells114, 117. Exogenous Gal-3 exerted its effect by interfering with adhesion-
related ERK-dependent signaling114. Therefore Gal-1 and Gal-3 bear a high potential to 
counteract PVR-associated cellular events and these findings may aid in development of 
an individualized galectin-based therapy for PVR. Additionally, it was shown, that Gal-3 
induces clustering of CD147 and integrin-β1 transmembrane glycoprotein receptors on 
the RPE cell surface 118. However, the functional relevance of galectin-binding on these 
different receptors is not explicitly analyzed in context of PVR. Most of the cell surface 
proteins on RPE cells targeted by specific galectins are largely unknown. This in-depth 
knowledge is a prerequisite to unravel the possible influence of galectins on the signal 
transduction mechanisms associated with PVR processes. 
5.2.6. Galectin interactors 
Even though all galectins share homology in their highly conserved CRD regions, each 
galectin is characterized by a distinct set of ligands and thus molecular interactors. The 
interaction with galactose is common for all galectins, but very weak (dissociation 
constants ~10−4 M)53, 71, 119. Disaccharides that contain galactose bound to glucose by β-
glyosidic bonds, N-acetyllactosamine (LacNAc) or N-acetylglucosamine (GlcNAc) interact 
with galectins with higher affinities58, 105, 119. Distinct galectin isoforms recognize 
different modifications of those saccharide ligands and thus certain galectins interact 
with specific ligands75, 83. Among the main binding partners of Gal-1 and Gal-3 are high-
glycosylated N-glycans120. Galectin binding affinities to complex N-glycans are 
proportional to their LacNAc content and to their GlcNAc branching71, 105.   
In many cell types several interactors for Gal-1 or Gal-3 have been identified: these 
include among others lysosomal-membrane-associated glycoproteins (LAMPs)-1 and -2, 
neural cell adhesion molecule (NCAM), cell adhesion molecule L1, CD43, CD45, CD71, 
mucin-1 and receptors for distinct growth factors like the epidermal growth factor (EGF), 
transforming growth factor beta (TGF-β) or vascular endothelial growth factor (VEGF)58, 
63, 73, 118, 121-128. Extracellular matrix (ECM) proteins like laminin, fibronectin or vitronectin 
as well as members of the β1 integrin family are also known Gal-1 and Gal-3 
interactors58, 63, 125, 129-131. Integrins play a major role in cell-matrix-interactions. As 
transmembrane proteins they are able to bind to the ECM by their extracellular part and 
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induce several signal transduction cascades in the cell, e.g. remodeling of the 
cytoskeleton or proliferation129, 132. Priglinger et al. 118 showed that Gal-3 induces 
clustering of CD147 and integrin-β1 (ITGB1) transmembrane glycoprotein receptors on 
the RPE cell surface.  
 Glycosylation and Glycan structures 
Glycosylation is a posttranslational modification that is universal in living organisms. 
Most secreted and membrane-anchored proteins are glycosylated and extracellular 
matrix (ECM) structures are rich in glycans and glycoconjugates133. Glycans are essential 
for the interaction between cells and the extracellular milieu and they are among the 
most diverse, complex and flexible molecules to react rapidly on intra- and extracellular 
changes133. Glycans are involved in biological processes such as cell signaling, 
embryogenesis, protein folding as well as proliferation of cells134, 135. Yet glycosylation 
also plays a role in pathogen recognition, immune responses and cancer136-139. Most of 
the naturally occurring glycan structures can be classified as N- or O- linked glycosides140. 
N-glycans are initiated by linkage of an N-acetylglucosamine (GlcNAc) to the amide side 
chain of an asparagine residue (figure 7)139-141. O-glycan synthesis is characterized by 
linking a saccharide (usually N-acetylgalactosamine, GalNAc) to the hydroxyl residue of 
serine, threonine or tyrosine (figure 7)139, 140.  
N-glycan biosynthesis starts in the ER by the transfer of a dolichol-linked glycan to an 
asparagine moiety of an Asn-Xaa-Ser/Thr sequon of a polypeptide139, 142. Quality control 
of the protein biosynthesis is done in the ER by Calnexin (CNX)139, 143. Properly folded 
proteins with a Man9GlcNAc2 structure are transported to the Golgi. In the stacks of the 
Golgi complex, various glycosyltransferases diversify the glycan structures of the 
glycoproteins, resulting in complex glycan structures (figure 7)139, 141, 144.These complex-
type N-linked glycoproteins are then transported to the cell surface or are secreted139. 
Complex glycan structures are characterized by glycans with multiple, extended 
branches, often containing N-acetyllactosamine units145. Crucial for galectin-binding and 
lattice formation are the number of glycoprotein ligands and the branching of their N-
glycans72. In detail, the amount and the branching of N-acetyllactosamine (LacNAc) 
residues in the glycan pattern are decisive for affinity. 
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O-glycan synthesis begins in the Golgi by attaching a GalNAc residue to the hydroxyl of 
serine or threonine of the respective polypeptide, catalyzed by GalNAc transferase139. 
The resulting glycoprotein can be converted into various core structures that can be 
diversified by a range of glycosyltransferases (figure 7). 
 
Figure 7: Schematic representation of N- and O-glycan biosynthesis, as published in Rabinovich and 
Toscano 146. Glycosyltransferases like GCNT1, ST3Gal1, GnT5 and ST6Gal1 (illustrated in red) generate or 
mask common glycosylated ligands for galectins (such as N-acetyllactosamine (LacNAc) or poly-LacNAc 
residues in complex N-glycans or core 2 O-glycans). GCNT1: 2 N-acetylglucosaminyltransferase 1, GnT5: 
N-acetylglucosaminyltransferase 5, ST3Gal1: 2,3 sialyltransferase 1, ST6Gal1: 2,6 sialyltransferase 1.  
Expression and activity of glycosyltransferases is essential for the availability of distinct 
glycan structures. N-glycans are substrates for N-acetylglucosaminyltransferases (Mgat 
genes). Among the most important glycosyltransferases with respect to galectin-glycan-
interactions is the β-N-acetylglucosaminyltransferase 5 (Mgat5)63. Mgat5 induce 
addition of LacNAc on N-glycans and thus create preferred ligands of galectins (figure 
7)63. Gal-3 for instance interacts with Mgat5-modified N-glycans on EGF and TGFβ 
receptors and induces cross-linking and thus prevents removal by constitutive 
endocytosis124. 
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 Proteomics 
Many general and global biologic research fields and application areas are described by 
use of the “omics” ending – genomics, transcriptomics, proteomics, metabolomics, 
oncogenomics and many more. In 1995, the term “proteomics” was introduced as a 
“protein complement of the genome” and describes the analysis of a specific population 
of proteins at a given state and time-point within an experimental system147-149. Yet the 
proteome is more than the mere translation of the protein-coding regions of a 
genome150. Compared to the static genome, the proteome is very dynamic and can be 
influenced by any genetic and environmental changes151. One of the most popular 
examples is for instance the largely different proteome of a caterpillar and a butterfly, 
while the genome remains the same151. Due to splicing and editing processes at the RNA 
level as well as post-translational modifications and complex protein regulation 
processes the proteome is much more complex than the genome149. A crucial drawback 
of protein based techniques is that no amplification of proteins is possible before 
analysis and proteins highly distinguish in their physiochemical properties. Besides, 
protein abundances can span up to ten orders of magnitude (e.g. in human plasma) 
within a given proteome152. Identifying low abundant proteins in the presence of a large 
excess of many other proteins is always a challenge for all analytical methods149. Taken 
together, proteome based analysis is much more complex and difficult than genomics or 
transcriptomics, but it is also much closer to the functional level149. The smallest change 
of protein levels can lead to considerable biological consequences and by proteomic 
approaches it is possible to analyze these processes151.  
5.4.1. Proteomic workflow 
The increasing complexity of biological samples in proteomic studies asks for fast and 
accurate analytical tools153. Conceptual breakthroughs and technical advances in 
separation techniques, protein chemistry, bioinformatics and sequencing techniques 
have contributed to the improvement of the science of proteomics149. Mass 
spectrometry (MS) has become the analytical instrumentation of choice for proteomic 
analyses because of its speed, wide dynamic signal range, quantitative capability and 
compatibility with chromatographic separation methods153, 154. Generally, mass 
spectrometry is an analytical technique that measures the mass-to-charge ratio (m/z 
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ratio) of ions in a mass spectrometer155. Biological samples are ionized by distinct 
procedures in the gas phase and separated according to their m/z ratios based on their 
motion in an electric or magnetic field155. Generally, it is distinguished between top-
down and bottom-up proteomic approaches. In top-down strategies intact proteins are 
introduced into the gas phase, fragmented and identified. Yielding accurate mass 
measurements of the protein as well as of protein ion fragments, the complete primary 
structure of the protein can be generated156. The widely-used bottom-up protein 
analysis refers to the characterization of proteins by analysis of peptides released from 
the digestion of the protein156, 157. While a bottom-up approach is suitable for identifying 
a large number of proteins, it provides very limited molecular information about intact 
proteins158. Complete sequence coverage of proteins is rarely achieved and the 
identification of site-specific mutations and post-translational modifications is limited157. 
However, top-down proteomic approaches have significant limitations compared to 
bottom-up strategies. Protein fractionation, ionization and fragmentation in the gas 
phase, especially of large proteins, are very challenging159. In comparison, peptides are 
more easily fractionated, ionized and fragmented and thus bottom-up proteomic 
approaches can be more universally adopted for protein analysis and was also used in 
this study159.  
Basically, a bottom-up proteomic experiment is composed of the following main 
technical steps: sample preparation including protein digestion, peptide separation and 
ionization followed by identification and quantification of distinct proteins within a 
biological sample (figure 8)160. 
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Figure 8: Proteomic workflow as published in Domon and Aebersold 150. Protein samples are isolated 
from a biological source, prepared and digested. After protein digestion peptides are separated by HPLC 
with single or multiple dimensions. Peptides are then ionized by electrospray ionization (ESI) and 
analyzed in mass spectrometers. The acquisition of full MS spectra is followed by the selection of 
specific precursor ions to be fragmented, the collision induced fragmentation and the acquisition of 
MS/MS spectra. The data are processed to either quantify distinct proteins or the received MS/MS 
spectra are matched to peptide sequences in a database on the basis of the observed and expected 
fragment ions. MS: mass spectrometry; HPLC: high-performance liquid chromatography; CAD: collision-
activated dissociation; DB: Database.  
 Sample preparation 
A protein sample is isolated from a biological source (e.g. cell culture or organs) and 
needs to be prepared concerning both the sample characteristics (e.g. pH, temperature 
stability, hydrophobicity) and the biological question to be addressed (post-translational 
modification, membrane proteins, protein interaction)161. Sample preparation in MS-
based workflows typically includes multiple steps such as sample desalting, 
concentration, sub-fractionation, and further separation and purification by gel 
electrophoresis or chromatography161. In “bottom-up” proteomic workflows proteins 
are proteolysed before separation. A high variety of endoproteases can be used for 
proteolysis. Most commonly used is trypsin which preferentially cleaves peptide bonds 
that are C-terminal to the basic amino acid residues arginine and lysine161. Peptides with 
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an average size of 800 to 2000 Da are generated and thus they are highly amenable to 
high sensitive MS/(MS) analysis161. Tryptic peptides are separated by high performance 
liquid chromatography (HPLC) – e.g. based on their hydrophobicity on a reverse phase 
(RP) C18 analytical column – and  subsequently ionized by electrospray ionization (ESI) 
and introduced into the mass spectrometer162.  
 Mass spectrometry 
Originally in the so called “top-down” proteomic workflow, two-dimensional (2D) 
electrophoresis coupled with matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry was used for protein identification155. Yet, due to reproducibility problems 
and the limited identification rates, 2D-gel based approaches are nowadays mainly 
replaced by LC-MS/MS based processes154. Ionization of the peptides by ESI takes place 
in three steps which are nebulization of the sample into droplets, emission of ions from 
the droplets and transportation of ions from atmospheric pressure to vacuum (figure 
9)163.  
 
Figure 9: Electrospray ionization (ESI) in proteomics as published in Steen and Mann 160. The solved 
analytes are eluted from a chromatography column and ionized by applying them to a narrow capillary 
tube and exposing to a high potential (1-2kV) relative to the inlet of the mass spectrometer. This 
generates highly positively charged droplets which explode into nanometer-sized droplets by Coulomb 
explosion and subsequently are transferred to mass analyzers.  
The analytes are ionized out of solution by applying them to a narrow capillary tube and 
exposing them to a high potential (1-2kV) relative to the inlet of the mass 
spectrometer154. By the potential difference the liquid is extended to form a Taylor cone 
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from the capillary tip, from which a fine mist of charged droplets will emerge155. In the 
positive ion mode, which is usually applied in proteomics, positive ions are enriched at 
the surface of a droplet161. Due to increasing Coulombic repulsion between the positive 
charges on the surface and by exceeding the liquid surface tension (Raleigh limit) the 
droplets “explode” into nanometer-sized droplets (Coulomb explosion)161. The 
nebulization process continues until any ions become completely desolvated155. 
Whereas evaporation of the droplets reduces droplet size, the charge on the droplets 
remains constant, enabling the formation of multiply charged ions155. The analytes 
remain stable in the gas phase and thus ESI is considered as a soft ionization 
technique161. Besides, by producing multiply charged analyte molecules the mass range 
of analysis can be extended in proportion to the extent of the multiplicity of such 
charging161.  
 
Figure 10: Scheme of a Thermo Scientific LTQ Orbitrap XL. Peptides are separated via a nano HPLC C18 
column and ionized by electrospray ionization (ESI). The first part after the ion source is a LTQ linear ion 
trap. Ions are accumulated there and can be transferred into a C-Trap. In the orbitrap mass analyzer 
precursor ions are selected and MS spectra are recorded. Precursor ions are fragmented by collision 
induces dissociation and the corresponding MS/MS spectra are measured in the LTQ Linear Ion Trap 
(source of the scheme: Thermo Fisher Scientific, www.planetorbitrap.com). 
After ionization peptides are transferred to mass analyzers to separate ions according to 
their mass-to-charge ratios. There are four basic types of mass analyzer used in 
proteomics research: ion trap, time-of-flight (TOF), quadrupole and Fourier transform 
ion cyclotron (FT-MS), which are mainly characterized by their sensitivity, resolution, 
mass accuracy and the ability to generate information-rich ion mass spectra from 
peptide fragments154. In mass spectrometers the mass analyzers can be used alone or 
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put together in tandem154. In this project the samples were measured either on a LTQ 
Orbitrap XL (Thermo Scientific, figure 10), combining the LTQ linear ion trap with the 
orbitrap technology, or on a Q Exactive™ HF (Thermo Scientific, figure 11) with hybrid 
quadrupole-Orbitrap features.  
 
Figure 11: Scheme of a Thermo Fisher Q Exactive™ HF. Peptides are separated via a nano HPLC C18 
column and ionized by electrospray ionization (ESI). The Q Exactive HF contains a mass selection pre-
filter and a segmented quadrupole combined with a C-Trap and an ultra-high field orbitrap mass 
analyzer. Precursor ions are fragmented by collision induced dissociation in the HCD cell and the 
corresponding MS/MS spectra are analyzed in the Orbitrap, (source of the scheme: Thermo Fisher 
Scientific, www.planetorbitrap.com).  
The Orbitrap analyzer radially traps ions in an electrostatic field about a central spindle 
electrode (figure 10)164.The ions orbit around the central electrode and oscillate back 
and forth along the central electrode’s long axis165. The oscillation frequencies are 
proportional to (m/z)-1/2 and the accurate masses are extracted by Fourier 
Transformation165. Orbitrap analyzers are characterized by high resolution, high mass 
accuracy and increased dynamic range and high sensitivity155. Coupled with a linear ion 
trap both mass analyzers are capable to detect ions and record spectra. Thus the 
analyzers can be used independently or in conjunction as required155. In the linear ion 
trap ions are confined in a two-dimensional quadrupole field: radially by a two-
dimensional radio frequency (RF) field and axially by stopping potentials applied to end 
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electrodes166. By adapting distinct potentials the linear ion trap can be used as a mass 
filter or as a trap166. Quadrupoles consists of four parallel metal rods and by time-varying 
electric fields only ions of a particular desired m/z ratio have a stable trajectory154. 
 Protein identification and quantification 
For protein identification two different approaches can be used: peptide mass 
fingerprinting (PMF) and tandem mass spectrometry (MS/MS)155. PMF is based on the 
measurement of m/z ratios and the calculated masses are indicative of the composition 
of the measured analytes155. In MS/MS analysis ions of a particular m/z value are 
selected and fragmented within the mass spectrometer160. First, the masses of intact 
tryptic peptides are determined and afterwards the peptide ions are fragmented in the 
gas phase to produce information on their sequence and modifications156. Typically, 
fragmentation is done by collision induced dissociation (CID/HCD) (figure 10). Due to 
collisions with an inert gas (such as nitrogen, argon or helium) covalent bonds of the 
peptide ions break resulting in fragmentation of the molecular ion into smaller 
fragments and thus the tandem MS spectrum (MS/MS or MS²) is acquired160. The ion 
that is fragmented is called “precursor ion” and the ions in the tandem-MS spectrum are 
called “product ions”160. When a fixed number of precursor ions are selected 
automatically from the ions detected in a survey scan and analyzed by tandem mass 
spectrometry, this process is referred to as data-dependent analysis (DDA)150.  Whereas, 
when all ions within a selected m/z range are fragmented and analyzed, it is called data-
independent acquisition (DIA)167. Most commonly fragmentation takes place at the 
amide bond between amino acids and the resulting ions are called b-ions when the 
charge is retained by the amino-terminal part and y-ions if the charge is retained by the 
carboxy-terminal part160 (figure 12). 
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Figure 12: Peptide fragmentation as published in Steen and Mann 160.  By collisions with residual gas, 
bond breakage mainly occurs at the amide bonds. The resulting ions are called b-ions when the charge is 
retained by the amino-terminal part and y-ions if the charge is retained by the carboxy-terminal part.  
Theoretically, the amino-acid sequence of the precursor ions can be determined 
because each peptide fragment in a series differs from its neighbor by one amino 
acid160. Yet the tandem-MS spectra are often not complete. Therefore, peptide-
fragmentation spectra are matched to peptide sequences in a database on the basis of 
the observed and expected fragment ions160. The origin of the investigated sample has 
to be considered and is digested in silico under the respective workflow settings 
concerning the chosen enzyme and introduced modifications. One exemplary search 
algorithm to search sequence databases with MS/MS-spectra data is Mascot, which was 
also used in this study. In Mascot the accuracy of peptide identification is reported in 
terms of a probability score and by searching against a decoy sequence database the 
false discovery rate (FDR) can be calculated. Low FDR values can be obtained by using 
high-quality data, characterized by high mass accuracy, high number of fragments and 
high signal-to-noise ratios. Furthermore, the number of unique peptides identified for a 
specific protein is also an important parameter.  
A typical proteomic study compares protein expression under different conditions and 
thus quantitative proteomics are fundamental. Many different quantitation techniques 
have been invented in the last years and incorporated into proteomic workflows. 
Proteins can for instance be metabolically labeled with heavy or light isotope-containing 
growth media or labeled proteins may be spiked in following lysis (figure 13)168. 
Enzymatic labeling can be done during digestion and chemical labeling or isobaric 
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tagging of peptides may occur further downstream. These protein identification 
strategies permit relative (comparison to a reference sample) or absolute 
quantification154. Label-free quantification is performed during or after data analysis and 
relies on advanced software analysis168. There are two major categories of label-free 
methods: extracted ion chromatogram (XIC)-based quantitation and spectral 
counting168. Spectral counting is based on the expectation that the number of peptide-
identifying MS/MS spectra correlates directly with the abundance of protein168. XIC-
based quantitation, which was used in this thesis, assumes that higher peptide 
concentrations will generate greater area-under-the-curve values in the MS spectra168. 
By measuring the relative concentrations of individual precursor ions within two or more 
samples and matching these abundances proteomic differences between biological 
conditions can be revealed. Absolute quantification can be done by use of internal 
standard peptides that have been synthetically prepared for selected or multiple 
reaction monitoring (SRM, MRM)168.  
 
Figure 13: Quantitation strategies in a proteomic workflow as published in Smith 168. Cell culture or 
animal model samples can be labeled metabolically at the protein level. Further down-stream labeled 
proteins can be spiked in or peptides can be enzymatically labeled during digestion. Following digestion, 
chemical labeling or isobaric tagging of peptides may be done. Label-free quantitation occurs during or 
after data analysis.  
 Aims of the study 
Proliferative vitreoretinopathy (PVR) is one of the most common failures after retinal 
detachment surgeries and is characterized by the migration, adhesion and epithelial-to-
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mesenchymal transition (EMT) of retinal pigment epithelial cells (RPE) and the 
subsequent formation of sub- and epiretinal fibrocellular membranes1-3. Currently there 
is no pharmacological adjuvant for preventing or treating PVR. In this PhD project the 
carbohydrate-binding proteins Gal-1 and Gal-3 were investigated as potential 
therapeutic agents for PVR with respect to modulated glycomic surface fingerprints of 
RPE cells upon PVR development. This work can be subdivided into 2 parts: 
(1) Characterization of EMT processes and glycomic fingerprints of RPE cells during 
dedifferentiation 
EMT is one of the key cellular events in PVR development. During EMT RPE cells convert 
from epithelial into mesenchymal cells and lose their epithelial characteristics and 
acquire migratory mesenchymal properties10. Here we analyzed changes in phenotype, 
proteome and cell surface glycan structures of RPE cells undergoing EMT in vitro. The 
impact of the glycomic shift associated with acquisition of a myofibroblastic phenotype 
of RPE cells for the pathogenesis of PVR was analyzed and interpreted and its relevance 
for the high efficacy of Gal-1 and Gal-3 in preventing PVR-associated cellular events was 
determined. A further aim was to develop a stable cell culture model for epithelial RPE 
cells.   
(2) Functional impact of galectin treatment in correlation with glycomic surface 
fingerprints 
a. Impact of galectins on the cellular behavior of RPE cells 
In correlation of changed glycomic surface fingerprints upon EMT, functional impact of 
galectin treatment on RPE cells was analyzed. Furthermore Gal-1 and Gal-3 knockdown 
cells were established and investigated based on their glycan structure on the cell 
surface and on the reactivity to exogenously added galectin.  
b. Identification of galectin-specific glycoprotein ligands in RPE cells 
The cell surface proteins targeted by specific galectins on RPE cells are largely unknown. 
Here, we aimed to identify galectin ligands to unravel the functional effects of galectins 
on cellular behavior and to get new insights in the highly specific binding of galectins to 
dedifferentiated but not native RPE cells and the following prevention of PVR-associated 
cellular events. Relevance of glycosylation of these interactors for the functional galectin 
binding and the crosslinking activity was also analyzed.  
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6. Materials 
 Chemicals  
Chemicals Manufacturer 
Acetid acid Merck Millipore, Darmstadt, Germany 
acetonitrile (ACN) Sigma Aldrich, Steinheim, Germany 
Acrylamide/Bis Serva, Heidelberg, Germany 
Ammonium bicarbonate Sigma Aldrich, Steinheim, Germany 
Ammonium persulphate (APS) Bio-Rad, Munich, Germany 
Asialofetuin Sigma Aldrich, Steinheim, Germany 
Biotinamidohexanoic acid N-
hydroxysuccinimide ester (NHS) 
Sigma Aldrich, Steinheim, Germany 
β-lactose Sigma Aldrich, Steinheim, Germany 
β-mercaptoethanol Sigma Aldrich, Steinheim, Germany 
bromphenolblue Merck Millipore, Darmstadt, Germany 
Bovine serum albumin (BSA) Fraction V Biomol, Hamburg, Germany 
Complete Sigma Aldrich, Steinheim, Germany 
Coomassie Brilliant Blue R250 Serva, Heidelberg, Germany 
Cyanogen bromide-activated Sepharose 4B GE Healthcare, Uppsala, Sweden 
L-Cystein Roth, Karlsruhe, Germany 
dimethyl sulfoxide (DMSO) Sigma Aldrich, Steinheim, Germany 
Dithiotreitol (DTT) Merck Millipore, Darmstadt, Germany 
DMNJ Sigma Aldrich, Steinheim, Germany 
Ethanol Merck Millipore, Darmstadt, Germany 
Ethanolamin Sigma Aldrich, Steinheim, Germany 
ethylenediaminetetraacetic acid (EDTA) Merck Millipore, Darmstadt, Germany 
Forskolin Biomol, Hamburg, Germany 
FluorSave VWR, Radnor, USA 
Glycerin Merck Millipore, Darmstadt, Germany 
Goat serum Thermo Fisher Scientific, Waltham, USA 
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HCl Merck Millipore, Darmstadt, Germany 
Hoechst Thermo Fisher Scientific, Waltham, USA 
HPLC grade H20 Merck Millipore, Darmstadt, Germany 
Iodacetamide Merck Millipore, Darmstadt, Germany 
Kifunensine Sigma Aldrich, Steinheim, Germany 
Lipofectamine 2000 Life Technologies, Carlsbad, USA 
Methanol Merck Millipore, Darmstadt, Germany 
MTT Thermo Fisher Scientific, Waltham, USA 
NaCl Sigma Aldrich, Steinheim, Germany 
Na2CO3 Sigma Aldrich, Steinheim, Germany 
NH4HCO3 Sigma Aldrich, Steinheim, Germany 
Na2HPO4 Sigma Aldrich, Steinheim, Germany 
NaN3 Sigma Aldrich, Steinheim, Germany 
NaOH AppliChem, Darmstadt, Germany 
Non-fat dried milk Bio-Rad, Munich, Germany 
NP-40 Roche, Basel, Switzerland 
PageRuler™ Prestained Protein Ladder Thermo Fisher Scientific, Waltham, USA 
Paraformaldehyde Sigma Aldrich, Steinheim, Germany 
Phosphatase inhibitor cocktail 2 and 3 Sigma Aldrich, Steinheim, Germany 
Plus Reagent Life Technologies, Carlsbad, USA 
ProteinG-Sepharose beads GE Healthcare, Uppsala, Sweden 
SB 431542 TGFβ inhibitor R&D systems, Minneapolis, USA 
Sodium dodecyl sulfate (SDS) Sigma Aldrich, Steinheim, Germany 
Sodium acetate Sigma Aldrich, Steinheim, Germany 
Sodium Deoxycholate Sigma Aldrich, Steinheim, Germany 
Sodium hydrogencarbonate Merck Millipore, Darmstadt, Germany 
Sodium orthovanadate Sigma Aldrich, Steinheim, Germany 
Swainsonine Sigma Aldrich, Steinheim, Germany 
Tetramethylethylenediamine (TEMED) Bio-Rad, Munich, Germany 
Trifluoroacetic acid (TFA) Applied Biosystems, Foster City, USA 
Tris GE Healthcare, Uppsala, Sweden 
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Triton X-100 Sigma Aldrich, Steinheim, Germany 
Tween20 Sigma Aldrich, Steinheim, Germany 
Urea Sigma Aldrich, Steinheim, Germany 
yeast extract Roth, Karlsruhe, Germany 
Y-27632 ROCK-inhibitor Biomol, Hamburg, Germany 
 
 General lab equipment 
Lab equipment Manufacturer  
Centrifuge 5424 Eppendorf, Hamburg, Germany 
Electrophoresis & blotting chamber  Bio-Rad, Munich, Germany 
Electrophoresis chamber SubCell GT Bio-Rad, Munich, Germany 
Ibidi heating systems Ibidi, Munich, Germany  
Incubator Heracell 150i  Thermo Fisher Scientific, Waltham, USA 
Incubator/Shaker E.coli Memmert, Schwabach, Germany 
Laminar flow Weiss Pharmatechnik GmbH, 
Sonnenbühl, Germany 
Magnetic Stirrer IKA Labortechnik, Staufen, Germany 
Multichannel Electronic Pipette Mettler-Toledo, Greifensee, Switzerland 
PCR machine Peqstar Peqlab, Erlangen, Germany 
pH Electrode inlab micro Mettler-Toledo, Greifensee, Switzerland 
Pipette 1 ml, 200 µl, 20 µl, 10 µl Eppendorf, Hamburg, Germany 
Power supply PowerPac HC Bio-Rad, Munich, Germany 
Power supply PowerPac 300 Bio-Rad, Munich, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
Tube Rollers Stuart, Staffordshire, UK 
Tube Rotator Stuart, Staffordshire, UK 
Vortex Genius 3 IKA Labortechnik, Staufen, Germany 
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 Consumables 
Consumables Manufacturer 
Cell culture flask, 75 cm2, 25 cm2 Greiner, Frickenhausen, Germany 
Cell culture dishes, 10 cm2 Greiner, Frickenhausen, Germany 
Cell scraper 25 cm Sarstedt, Nümbrecht, Germany 
Falcon conical tubes BD Bioscience, San Jose, USA 
Filter 0.2 µm, 0.45 µm Merck Millipore, Darmstadt, Germany 
Glass coverslips VWR, Radnor, USA 
Hybond-P PVDF membrane Amersham, Little Chalford, UK 
Pipette 5 ml, 10 ml, 25 ml, 50 ml Greiner, Frickenhausen, Germany 
Pipette tips Thermo Fisher Scientific, Waltham, USA 
Pipette tips Eppendorf, Hamburg, Germany 
Slide-a-lyzer dialysis cassettes Thermo Fisher Scientific, Waltham, USA 
Six well plates Nunc, Wiesbaden, Germany 
U-shaped 96 well plates Corning, New York, USA 
96 well plates BD Bioscience, San Jose, USA 
30kDa cut-off centrifuge filter Pall Corporation, New York, USA 
 
 Kits and Standards 
Kit Manufacturer 
ECL Plus enhanced chemiluminescence kit GE Healthcare, Uppsala, Sweden 
Human Phospho-Kinase Array R&D systems, Minneapolis, USA 
PierceTM BCA (bicinchoninic acid assay) 
Protein Assay Kit 
Thermo Fisher Scientific, Waltham, USA 
Pierce™ NHS-Fluorescein Antibody Labeling 
Kit 
Thermo Fisher Scientific, Waltham, USA 
Plasmid DNA MiniPrep Kit Thermo Fisher Scientific, Waltham, USA 
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 Enzymes 
Enzyme Manufacturer 
BsmBI Thermo Fisher Scientific, Waltham, USA 
Fast Alkaline Phosphatase Thermo Fisher Scientific, Waltham, USA 
Lys-C  Wako Chemicals GmbH, Neuss, Germany 
Papain  Worthington, Lakewood, USA 
Trypsin-EDTA 0.05% (w/v) Gibco, Paisley, UK 
Trypsin (Sequencing grade modified trypsin) Promega, Mannheim, Germany 
T4 Polynucleotide Kinase  New England Biolabs, Massachusetts, 
USA 
 
 Cell culture reagents and media 
Medium or Reagent Manufacturer 
Bovine serum albumin (BSA) for cell culture GE Healthcare, Uppsala, Sweden 
DMEM high glucose  Gibco, Paisley, UK 
FCS Gibco, Paisley, UK 
Kanamycin Sigma Aldrich, Steinheim, Germany 
LB Medium Self-made (10 g/l NaCl, 10 g/l Tryptone, 
5 g/l Yeast extract) 
MEMα Sigma Aldrich, Steinheim, Germany 
MEGM  PromoCell, Heidelberg, Germany 
OptiMEM  Life Technologies, Carlsbad, USA 
PBS without Ca2+/Mg2+ Gibco, Paisley, UK 
Penicillin/Streptomycine 10,000 U/mL Gibco, Paisley, UK 
Puromycin Sigma Aldrich, Steinheim, Germany 
Trypsin-EDTA 0.05% (w/v) Gibco, Paisley, UK 
ZYM 5052 auto-induction medium  Self-made, based on Studier 169 
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 Buffers 
Buffer  Manufacturer 
Acetate buffer Self-made, 0.1 M NaAc, 0.5 M NaCl, pH 3-4 
Ammonium bicarbonate 
buffer 
Self-made, 50 mM ABC in H2O 
Buffer for galectin expression 
and purification  
Self-made, 20 mM Tris-HCl, 150 mM NaCl, 0.03% (v/v) 
CHAPS, pH 7.5 
Coupling buffer Self-made, 0.1 M NaHCO3, 0.5 M NaCl, pH 8.3 
E.coli lysis buffer Self-made, 20 mM Tris-HCl, 150 mM NaCl, 10 mM 
MgSO4, 10  µg/ml DNaseI, 1  mM AEBSF.HCl, 0.03% (v/v) 
CHAPS, 1 mg/ml lysosyme, pH 7.5 
FACS buffer Self-made, PBS +1% BSA 
Fast digestion buffer  Thermo Fisher Scientific, Waltham, USA 
Fixing solution Coomassie 
staining 
Self-made, 50% methanol, 12% acetic acid 
Laemmli buffer Self-made, 5% (w/v) SDS, 250 mM Tris-HCl pH 6,8, 50% 
(v/v) glycerol, 500 mM β-Mercaptoethanol, 0,025% 
(w/v) bromphenol-blue 
RIPA Self-made, 50  mM Tris-HCl pH 7.4, 150  mM NaCl, 
0.1%(w/v) SDS, 0.5% (w/v) Sodium Deoxycholate, 1% 
(v/v) NP-40, Complete 1X 
Solubilisation solution MTT 
assay  
10% SDS in 0.01 M HCl 
T4 DNA Ligase Puffer New England Biolabs, Massachusetts, USA 
Urea Buffer Self-made, 8 M urea in 0.1 M Tris/HCl pH 8.5 
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 Analytical instruments 
Instrument Manufacturer 
Digital Developer Fusion FX VilberLourmat, Eberhardzell, Germany 
EMax Plus Microplate Reader Molecular Devices, Sunnyvale, USA 
FACS Fortessa BD Biosciences, Heidelberg, Germany 
RSLC Ultimate 3000 Dionex, Idstein, Germany 
Lactose-agarose column J-Oil Mills, Tokyo, Japan 
Mass spectrometer Orbitrap XL Thermo Fisher Scientific, Waltham, USA 
Mass spectrometer Q Exactive HF Thermo Fisher Scientific, Waltham, USA 
Microscope DMI8 Leica Microsystems, Wetzlar, Germany 
Nano trap column LC Packings, Sunnyvale, USA 
PepMap100 C18 HPLC column LC Packings, Sunnyvale, USA 
AcquityM UPLC, HSST3 column  Waters, Eschborn, Germany 
Plate Reader Synergy HT Biotek, Bad Friedrichshall, Germany 
 
 Antibodies 
Primary antibody host species Manufacturer  
anti-E-Cadherin, ab15148 rabbit Abcam, Cambridge, UK 
anti-GAPDH, MAB374 mouse Merck Millipore, Darmstadt, Germany 
anti-Gal-1, 25B11 mouse Monoclonal Antibody 
Core Facility, HMGU, Germany 
anti-Gal-3, 15B6 rat Monoclonal Antibody 
Core Facility, HMGU, Germany 
anti-ITGB1, AIIB2 rat DSHB, Iowa, USA 
anti-LRP1, ab92544 rabbit Abcam, Cambridge, UK 
anti-PDGFRB, ab32570 rabbit Abcam, Cambridge, UK 
anti-phospho-ERK p44/p42, 
#4370 
rabbit Cell signaling, Danvers, USA 
anti-Vimentin, V6630   mouse Sigma Aldrich, Steinheim, Germany 
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Secondary antibody Host species Manufacturer  
anti-rabbit AlexaFluor647, 
#111-607-008 
goat Dianova, Hamburg, Germany 
anti-rat AlexaFluor568,      #112-
297-020 
goat Dianova, Hamburg, Germany 
anti-rabbit AlexaFluor488, 
#111-547-008 
goat Dianova, Hamburg, Germany 
anti-mouse AlexaFluor568, 
#115-297-003 
goat Dianova, Hamburg, Germany 
HRP-coupled secondary 
antibodies 
rat, mouse, 
rabbit 
Jackson ImmunoResearch, West 
Grove, USA 
 
 Lectins 
Lectin Manufacturer  
Human Gal-1 Arie Geerlof, Institute of Structural Biology, HMGU, Germany 
Human Gal-3 Arie Geerlof, Institute of Structural Biology, HMGU, Germany 
Human Gal-8 Arie Geerlof, Institute of Structural Biology, HMGU, Germany 
Human Gal-9 Arie Geerlof, Institute of Structural Biology, HMGU, Germany 
Biotinylated PHAL  Vector laboratories, Burlingame, USA 
Biotinylated ConA Vector laboratories, Burlingame, USA 
Biotinlyated Mal2 Vector laboratories, Burlingame, USA 
Biotinylated PNA Vector laboratories, Burlingame, USA 
 
Secondary antibody Manufacturer  
Streptavidin-Alexa488  Thermo Fisher Scientific, Waltham, USA 
Streptavidin-HRP Vector laboratories, Burlingame, USA 
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 Cell lines 
Cell line Species Supplier 
ARPE19 (CRL-2302™) Human, eye ATCC, Virginia, USA 
HEK293T Human, kidney Life Technologies, Carlsbad, USA 
 
 Mammalian cells 
Cell  Species Source 
RPE cells Human, eye Eye Bank of the Department of Ophthalmology, Linz 
General Hospital (Austria); Ludwig-Maximilians-
University (Munich, Germany) 
RPE cells Porcine, eye Schlachthof München, Munich, Germany 
 
 E. coli strains 
Strain Supplier 
BL21 (DE3) New England Biolabs, Massachusetts, USA 
StbL3 Thermo Fisher Scientific, Waltham, USA 
 
 Guide RNAs 
gRNA Sequence 
Gal-1  CCACCTCGCCTCGCACTCGA 
GTGCCTTCGAGTGCGAGGCG 
GATGGTGTTGGCGTCGCCGT 
 
Gal-3 CATGATGCGTTATCTGGGTC 
 GGCTGGTTCCCCCATGCGCC 
 GCCCAGCAGGGGCGCCATAG 
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 Plasmids 
Construct Function Resistance Provided by 
lentiCRISPRv2  Transfer plasmid Puromycin lentiCRISPR v2 was a gift 
from Feng Zhang 
(Addgene plasmid # 
52961)170  
pETM-11  Expression vector Kanamycin Constructed by G. Stier, 
European Molecular 
Biology Laboratory  
pMD2.G   Packaging plasmid Ampicillin pMD2.G was a gift from 
Didier Trono (Addgene 
plasmid # 12259)  
psPAX2 Packaging plasmid Ampicillin psPAX2 was a gift from 
Didier Trono (Addgene 
plasmid # 12260)  
 
 Software 
Software Version Manufacturer 
ACAS - Ibidi + MetaviLabs, Germany + USA 
CRISPR design tool - Zhang Lab, MIT, USA 
Cytoscape 3.4.0 Institute of Systems Biology, Seattle, USA 
FACS Diva  8.0.1 BD Biosciences, Heidelberg, Germany 
FlowJo  7.6 TreeStar, Inc., Ashland, USA 
FunRich 2.1.2 Open source, New York, USA 
GeneRanker 2016 Genomatix, Munich, Germany 
Huygens Essentials 16.05 Scientific Volume Imaging BV, Netherlands 
ImageJ 1.50i National Institute of Health, USA 
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Leica Appl. Suite 2.0 Leica Microsystems, Wetzlar, Germany 
Mascot 2.5.1 MatrixScience, London, UK 
Perseus 1.5.3.2 Computational Systems Biochemistry, Germany 
Phobius - Karolinska Institutet, Sweden 
Progenesis QI 2.0 Waters, Eschborn, Germany 
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7. Methods 
 Isolation of human and porcine RPE cells and RPE cell culture 
Human cadaver eyes of organ donors were received by the Eye Bank of the Department 
of Ophthalmology at the Linz General Hospital (Linz, Austria) or at the Ludwig-
Maximilians-University (LMU) (Munich, Germany) and were processed within 24 hours 
after death by an ophthalmologist in accordance with the institutions standard 
operating procedures. The securing process was authorized by the ethics committees of 
the hospital of the LMU Munich and of the Land Oberoesterreich and it was complied 
with the Declaration of Helsinki and approved by the relatives. Porcine eyes were 
provided by a local abattoir (Schlachthof München, Munich, Germany) and processed 
within 6 hours after slaughtering of the pics. As described in Priglinger et al. 118, 
Priglinger et al. 116 and Obermann et al. 171, porcine and human eyes were cleaned from 
periocular tissue and disinfected by incubation in 80% ethanol. After removal of the 
front segment of the eye, the vitreous body was also removed, the inner part of the 
eyecup was filled with phosphate-buffered saline (PBS, Gibco) and the retina was 
aspirated and removed. The eyecup was rinsed and incubated for 15-20 min at room 
temperature with pre-warmed 1 mM EDTA in PBS (37 °C), pH 7.4, to get rid of residual 
vitreous, remaining retina and photoreceptor outer segments. PBS/1 mM EDTA was 
discarded and the eyecup was filled with dissociation buffer (3 mM L-Cystein, 1 µg/µl 
BSA in PBS/1 mM EDTA), containing 45 µg papain (Worthington) per 1 ml dissociation 
buffer. After incubation for 23 minutes at 37 °C, the RPE cells were resuspended by 
pipetting up and down within the eyecup to dispense as much RPE cells as possible. To 
stop activity of papain, the loosened RPE cells were transferred in Dulbecco’s modified 
Eagles medium (DMEM, Gibco) supplemented with 10% fetal calf serum (FCS, Gibco) and 
1 % penicillin/streptomycine (P/S). After centrifugation for 5 minutes at 930 rpm at 
room temperature, the resulting cell pellet was resuspended and cultivated at high cell 
densities in DMEM, 10% FCS, 1% P/S at 37 °C and 5% CO2. RPE cells isolated from one 
eye were cultivated in dishes with a surface area of 1.5 cm². If required, the cell culture 
medium was supplemented with 10 µM Kifunensine (Sigma Aldrich), 3 µM ROCK 
Inhibitor Y-27632 (biomol), 10 µM TGF-β inhibitor SB 431542 (R&D Systems), 10 µM 
Forskolin (biomol), 1 mM DMNJ (Sigma Aldrich) or 1 µg/ml Swainsonine (Sigma Aldrich) 
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for the respective time period. Passage numbers of 3 to 7 of the primary RPE cells were 
used for experiments. Regarding the limited availability of especially human RPE cells, 
the human RPE cell line ARPE19 (ATCC® CRL-2302™) was used for some experiments. 
ARPE19 cells are often used in RPE cell research, since they express RPE-specific markers 
such as the retinal pigment epithelium-specific 65kDa protein (RPE65) and having 
structural and functional RPE cell characteristics172, 173. ARPE19 cells were cultivated 
under the same cell culture conditions as primary human and porcine RPE cells, namely 
in DMEM, supplemented with 10% FCS and 1% P/S. Passage numbers between 10 and 
20 were used for experiments. For some experiments FCS concentration in the medium 
was reduced to 3%.  
To prevent EMT processes during cell culture, the minimum essential medium MEMα 
Sigma Aldrich), supplemented with 1% or 0% FCS, and the Mammary Epithelial Cell 
Growth Medium MEGM (PromoCell, 0% FCS) were tested as RPE cell culture media, 
compared to DMEM. As described in Maminishkis et al. 174 MEMα also contained: N1 
supplement (Sigma Aldrich) 1:100 ml/ml, glutamine-penicillin-streptomycin (Sigma 
Aldrich) 1:100 ml/ml and nonessential amino acid solution (Sigma Aldrich) 1:100  ml/ml. 
Hydrocortisone (20 μg/l), taurine (250 mg/l), and triiodo-thyronin (0.013 μg/l) (THT) 
were dissolved in PBS to a final concentration of 1:500 (ml/ml) and added to the RPE 
medium. 
 Preparation of cell lysates  
For preparation of protein lysates, ARPE19 and primary RPE cells were washed twice 
with ice-cold PBS and lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 
0.1%(w/v) SDS, 0.5% (w/v) Sodium Deoxycholate, 1% (v/v) NP-40, Complete 1X) at 4 °C. 
For analysis of ERK phosphorylation 1 mM sodium orthovanadate and phosphatase 
inhibitor cocktail 2 and 3 (1:100, Sigma Aldrich) was added to RIPA buffer. After 
centrifugation at 12000 rpm for 15 minutes at 4 °C, the supernatant of the lysates was 
stored at -20 °C for further use.   
 
 
Methods 
 
   56 
 
 Determination of protein concentrations 
Protein concentrations were determined by PierceTM BCA (bicinchoninic acid assay) 
Protein Assay Kit (Thermo Fisher, 23225). Bovine serum albumin (BSA) was used as a 
reference protein and a standard curve was used to calculate the unknown protein 
concentrations. 5 µl of the BSA dilutions (concentrations of 0.25 to 8 mg/ml) and of each 
unknown protein sample or dilutions thereof were pipetted into 96-well flat bottom 
plates. BCA working reagent (WR) was prepared by mixing 50:1 Reagent A:B. Reagent A 
contains sodium carbonate, sodium bicarbonate, BCA and sodium tartrate in 0.1M 
sodium hydroxide. Reagent B contains 4% cupric sulfate. 200 µl of WR was added to 
each well. After incubation at 37 °C for 30 min, absorbance was measured at 562nm on 
a plate reader. For each analysis a new standard curve was prepared based on the 
measured absorbance of the BSA dilutions and the protein concentrations were 
calculated by linear regression. As a blank the respective dilution buffer of the protein 
samples was used.  
 Expression and purification of human galectins 
Recombinant human Gal-1, Gal-3, Gal-8 and Gal-9 were kindly produced and provided 
by Dr. Arie Geerlof (Protein Expression and Purification Facility, Institute of Structural 
Biology, Helmholtz Center Munich). As described in Priglinger et al. 118, Priglinger et al. 
116 and Obermann et al. 171, the bacterial pETM-11 expression vector was used for 
cloning. pETM-11/hgalectin-1(-3, -8, -9) were transformed respectively into the E. coli 
strain BL21 (DE3). After cultivation at 20 °C in 2-L flasks containing 500 ml ZYM 5052 
auto-induction medium169 and 100 µg/ml kanamycin, E. coli cells were harvested by 
centrifugation when saturation was reached. Cells were divided in three pellets and 
stored at -20 °C. For lysis of the cells by sonication, the pellet was resuspended in 30 ml 
lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 10  mM MgSO4, 10 µg/ml DNaseI, 
1  mM AEBSF.HCl, 0.03% (v/v) CHAPS, 1 mg/ml lysosyme, pH 7.5). After centrifugation 
(40,000 x g) and filtration (0.2 µm), the supernatants were applied to 2 ml lactose-
agarose columns (J-Oil Mills, Tokyo, Japan), equilibrated in buffer A (20 mM Tris-HCl, 
150  mM NaCl, 0.03% (v/v) CHAPS, pH 7.5). Before elution, the columns were washed 
three times with 25 ml buffer A. Bound proteins were eluted twice with 5 ml buffer A 
supplemented with 0.2 M β-lactose and protein containing fractions were pooled. His6-
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tagged hGalectin-1 was dialyzed against 1 L PBS containing 5 mM β-mercaptoethanol 
over night at 4 °C, his6-tagged hGalectin-3, hGalectin-8 and h-Galectin-9 against 1 L PBS 
without β-mercaptoethanol. After filtration (0.2 µm), the dialysates were stored at 4 °C. 
Protein concentrations were calculated after measuring the absorbance at 280 nm by 
the following formula: 
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A280: absorbance at 280nm 
b: path length [cm] 
  protein molar extinction coefficient [
$
%$∗&%
] 
'($)*  8855 M
-1cm-1 
'($)+  35870 M
-1cm-1. 
  Biotinylation of human Gal-1 and Gal-3 
For biotinylation, 150 mM β-lactose was added to 1 mg of purified Gal-1 and Gal-
3, respectively, to stabilize the galectins. The proteins were dialyzed at 4 °C in Slide-A-
lyzer dialysis cassettes (3.5 kDa cut off, Thermo Fisher) against 0.1 M 
sodiumhydrogencarbonate with 50 mM ß-Lactose, pH 9.2., for 2 hours. After a following 
1 hour biotinylation at RT with 100 µg biotinamidohexanoic acid N-hydroxysuccinimide 
ester (NHS) according to the manufacturer´s instructions (Sigma Aldrich), the galectins 
were dialyzed again overnight at 4 °C against PBS. Activity of the biotinylated galectins 
was monitored by agglutination assay.  
 NHS-Fluorescein galectin labeling 
Galectins were labeled with Fluorescein for FACS analysis with the Pierce™ NHS-
Fluorescein Antibody Labeling Kit (Thermo Fisher). Based on the manufacturer’s 
instructions, 1 mg of Gal-1 and Gal-3 was coupled to Fluorescein via N-
hydroxysuccinimide ester (NHS) respectively. Protein concentration was calculated by 
the following formula after measuring the absorbance at 280 nm and 495 nm: 
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A495: absorbance at 495 nm  
CF: Correction Factor = 
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'($)*  8855 M
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 Activity control of human Gal-1 and Gal-3 
Activity of purified and biotinylated galectins was determined semi-quantitatively by 
hemagglutination assays, adapted from Nowak et al. 175 and St-Pierre et al. 176. Type 0 
blood samples were kindly provided by Dr. Stefanie Hauck and Dr. Christine von Törne 
(Research Unit Protein Science, Helmholtz Centre Munich). 6 ml whole blood samples 
were collected in EDTA tubes and centrifuged at 3500 rpm for 5 min. The resulting 
transparent layer was removed and the red blood cells (RBC) were washed three times 
with PBS. After 10-fold dilution in PBS-3% glutaraldehyde, RBCs were rotated for 1h at 
RT and washed five times in PBS-0.0025% NaN3. Resuspended in 4% PBS-0.0025 NaN3, 
RBCs were stable for up to three months when stored at 4°C. For hemagglutination 
assay, serial dilutions of galectins in PBS were put in U-shaped 96 well plates and 10 µl 
RBCs were added per well. The minimum active concentration of each galectin, that 
prevented sedimentation of the RBCs, was evaluated visually, after incubation at 37 °C 
for 30 min (figure 14). For all experiments the respective Gal-1 and Gal-3 preparations 
were used in sufficiently active concentrations, as indicated.  
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Figure 14: Activity of Gal-1 and Gal-3 determined semi-quantitatively by hemagglutination assays175, 176. 
Serial dilutions of galectins in PBS were put in U-shaped 96 well plates and 10 µl red blood cells (RBCs) 
were added per well. After incubation at 37 °C for 30 min, the minimum active concentration of each 
galectin, that prevented sedimentation of the RBCs, was evaluated visually.  
 MTT Assay 
Cells were cultivated in 96-Well plates until 90% confluence was reached and then 
treated for 48h with 0, 6.25, 12.5, 25, 31, 62.5, 75 µg/ml Gal-1, Gal-3, Gal-8 and Gal-9 
respectively, in DMEM plus 2% FCS. To 100 µl DMEM medium 10 µl MTT (3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide, 5 mg/ml in PBS) was added for 4 
hours at 37 °C. The yellow tetrazolium MTT was reduced by metabolically active cells to 
purple formazan, which could be solubilized by adding 100 µl of the solubilisation 
solution (10% SDS in 0.01 M HCl) to each well and incubating at 37 °C overnight. The 
absorbance was measured at 580 nm and color formation is a useful and convenient 
marker of the viable cells177. Thus, the viability of the cells correlated with the 
absorbance: the lower the absorbance at 580 nm, the lower cell viability.  
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 Induction of Gal-1 and Gal-3 knockdown in ARPE19 cells by Lenti-
CRISPR/Cas9 
The CRISPR/Cas9 system (clustered regularly interspaced short palindrome repeats) was 
used to induce knockdown of Gal-1 and Gal-3 in ARPE19 cells. Based on publications 
from the Zhang group170, 178, 179, lentiviral particles were used as vectors to integrate an 
expression cassette in the genome of ARPE19 cells and to introduce frame shift 
mutations in the coding sequence of the target genes. The expression cassette includes 
the guide RNA (gRNA - guides the Nuclease to the respective gene), the Nuclease Cas9 
and a marker protein for puromycin resistance.  
7.9.1. Target guide sequence cloning protocol 
The CRISPR design tool (http://crispr.mit.edu/) was used to select appropriate gRNAs. 
The algorithm underlying this tool was published in Hsu et al. 178. The sequences of the 
gRNAs of Gal-1 were 
CCACCTCGCCTCGCACTCGA 
GTGCCTTCGAGTGCGAGGCG 
GATGGTGTTGGCGTCGCCGT 
and for Gal-3  
CATGATGCGTTATCTGGGTC 
GGCTGGTTCCCCCATGCGCC 
GCCCAGCAGGGGCGCCATAG. 
In order to clone the target sequence into the lentiCRISPRv2 vector (addgene #52961), 
two oligonucleotides were created for each gRNA expression vector. Based on protocols 
described in Sanjana et al. 170 and published at http://genome-engineering.org/gecko/, a 
CACCG sequence was added to the 5’ end of the forward oligonucleotide (oligo-1) and 
an AAAC sequence to the 5’ end and a C to the 3’ end of the reverse oligonucleotide 
(oligo-2). 10 µg of lentiCRISPRv2 was digested and dephosphorylated at 37 °C for 
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30 minutes with 3 µl fast digest BsmBI (Thermo Fisher), 1 µl Fast Alkaline Phosphatase 
(FastAP, Thermo Fisher) in 7 µl 10x Fast digestion buffer (Thermo Fisher) and 0.7 µl 
100  mM DTT with 6.3 µl H2O. For the phosphorylation and annealing of the two 
oligonucleotides, 1 µl of oligo-1 (100 µM) and 1 µl of oligo-2 (100 µM) were merged with 
1 µl of 10x T4 DNA Ligase Puffer (NEB), 6.5 µl H2O and 0.5 µl T4 Polynucleotide Kinase 
(PNK, NEB) and put in a thermocycler for 30 minutes at 37 °C, followed by 5 minutes at 
95 °C and ramped down to 25 °C at 5 °C/min. As negative control two forward or two 
reverse primers were used. Annealed oligos were diluted 1:200 in sterile H2O. 3 µl of the 
BsmBI digested lentiCRISPRv2 vector and 1 µl of the 1:200 dilution of the annealed oligo 
mix were ligated in 1 µl T4 DNA Ligase buffer (10x) with 4 µl H2O and 1 µl T4 DNA Ligase 
(NEB) at room temperature for 1 hour. Afterwards, 3 µl of the lentiviral transfer 
plasmids were transformed in 50 µl chemically competent cells StbL3 (E.coli) on ice for 
30 minutes. After a heat shock for 30 seconds at 42 °C and a following incubation on ice 
for 2 minutes, 950 µl of lysogeny broth (LB) medium was added and the mixture was 
centrifuged for 45 minutes at 37 °C (300 rpm) and afterwards for 2 minutes at 4000 rpm 
at RT. The pellets were resuspended in 100 µl LB medium and plated on LB-Agar-plates 
(with Ampicillin). Plasmid DNA was amplified with a Plasmid DNA MiniPrep Kit (Thermo 
Fisher), following the manufactorer’s instruction. The correct sequences of the vectors 
were verified by sequencing. 
7.9.2.   Lentivirus production 
By co-transfection of three plasmids lentiviruses were created in 80% confluent HEK293T 
cells (Life Technologies)170, 179. In a 75cm2 flask, 5 µg of packaging plasmids pMD2.G 
(addgene #12259) and 7.5 µg of psPAX2 (addgene #12260) were co-transfected with 
10 µg of the respective created transfer plasmid “lentiCRISPRv2”, using 100 µl Plus 
Reagent (Life Technologies) and 50 µl Lipofectamine 2000 (Life Technologies) in 8 ml 
OptiMEM (Life Technologies). As control, a virus was created with the two packaging 
plasmids and the “empty” plasmid lentiCRISPRv2 (addgene #52961) not coding for a 
functional gRNA (this plasmid contains a 2 kb “filler” sequence, which is not 
incorporated into a functional ribonucleoprotein complex of RNA and Cas9). A medium 
change after 6 hours to DMEM (Life Technologies) with 10 % fetal bovine serum (Life 
Technologies) and 1% bovine serum albumin (GE Healthcare) followed and after 
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60 hours lentiviral supernatants were harvested by centrifugation at 4 °C, 2000 g for 
15 minutes and purified by 0.45 µm filtering. Lentiviral supernatant was stored at -80 °C 
and 750 µl of this supernatant was used to transduce 40% to 50% confluent ARPE19 cells 
in 10 cm² dishes. To select for transduced cells, 2 µg/ml puromycin was added to the cell 
culture media after one day. Gal-1 and Gal-3 knockdown was verified by Western Blot 
analysis. FACS analyses for galectin binding studies were performed between 12 to 20 
days after transfection in order to allow sufficient knock-down.  
 Galectin pull-down experiments 
Galectin pull-down assays were performed as described in Obermann et al. 171. 1 mg Gal-
1 and 1 mg Gal-3 were respectively coupled to 300 mg cyanogen bromide-activated 
Sepharose 4B (GE Healthcare). To activate the sepharose beads, they were washed 15 
times with 1 mM HCl, followed by a single washing step in coupling buffer (0.1 M 
NaHCO3, 0.5 M NaCl, pH 8.3), including a centrifugation step at 3000 rpm for 1 minute 
after each washing step. To couple the respective galectin isoforms to the beads, they 
are mixed 1:1 with coupling solution and were incubated on a rotating wheel with the 
activated beads at 4 °C overnight. Unreacted binding sites were blocked with 1 M 
ethanolamine (pH 8) for 2 hours at RT, after washing in a 5-fold volume of coupling 
buffer. The galectin-beads were washed several times at different pH values (3x coupling 
solution, 3x acetate buffer (0.1 M NaAc, 0.5 M NaCl, pH 3-4), 3x coupling buffer, 3x 
acetate buffer, 3x PBS). Stored in 20% ethanol, the beads were stable for several 
months. For each galectin pull-down experiment, activity of galectins, coupled to the 
beads, was tested. 100 µl beads-slurry (50% beads) was incubated with 200 µg 
asialofetuin (Sigma Aldrich) for 1 h at RT in absence and presence of 0.1 M ß- lactose. By 
incubation with 3x Laemmli buffer at 95 °C for 5 min, bound proteins were eluted and 
eluates were separated by SDS-PAGE (10% gels) and asialofetuin was detected by 
Coomassie staining. For galectin pull-downs, galectin-beads were washed three times 
with PBS to get rid of 20% ethanol and 20 µl beads-slurry (galectin-beads and ProteinG 
control beads (GE Healthcare)) were respectively incubated with 250 µg total proteins 
from human mesenchymal RPE cell lysates in PBS for 1h at 37 °C, with gentle mixing 
every 10 min. To get rid of weak bound proteins, beads were washed 4 times with PBS 
including centrifugation at 1000 rpm for 5 minutes. Bound proteins were eluted by 0.5 
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M β-lactose (Sigma Aldrich) and eluates were analysed by label-free quantitative LC-
MS/MS. Five independent Gal-3 and five independent Gal-1 as well as the corresponding 
control ProteinG pull-down experiments with 3 or 4 technical replicates each were 
performed using RPE cell lysates derived from nine different human donors. 
 Sample preparation for mass spectrometry 
10 µg of whole cell extracts and complete ß-lactose eluates of the Gal-1, Gal-3 and 
ProteinG pull-down experiments were proteolysed with Lys-C and trypsin (Promega, 
Mannheim, Germany) using a modified filter aided sample preparation protocol180, as 
also described in Obermann et al. 171. Protein samples were diluted to a final volume of 
100 µl with ammonium bicarbonate buffer (ABC, Sigma Aldrich) and reduced for 30 min 
at 60 °C using 1 µl 1M dithiothreitol (DTT). When samples reached room temperature, 
100 µl 8 M Urea Buffer (UA, Sigma Aldrich), pH 8.5, was added, followed by alkylation 
with 10 µl 300 mM iodoacetamide (Merck) for 30 min at RT in the dark.  To quench 
unreacted iodacetamide 2 µl 1 M DTT was again added. 30 kDa cut-off centrifuge filter 
(Pall Corporation, NY) were equilibrated with UA buffer and protein samples were 
transferred to filters. Three washing steps with 400 µl UA buffer and two with 100 µl 
50 mM ABC followed. Proteins were digested on the filters for 2h at RT with 1 µg Lys-C 
and afterwards with 2 µg trypsin overnight at 37 °C. By centrifugation through the filters, 
peptides were collected and after acidification with trifluoroacetic acid (TFA) (pH 2), 
samples were restored at -20 °C until mass spectrometry analysis.  
 Liquid chromatography and mass spectrometry (LC-MS/MS) 
LC-MS/MS analysis for galectin pull-down samples was performed on a LTQ OrbitrapXL 
(Thermo Fisher Scientific Inc.) as also described previously171, 181-184.  Every sample was 
automatically loaded onto an Ultimate3000 nano RSLC system (Dionex) with a nano trap 
column (300 μm inner diameter × 5 mm, packed with Acclaim PepMap100 C18, 5 μm, 
100 Å; LC Packings, Sunnyvale, CA) in HPLC buffer containing 0.1% trifluoroacetic acid 
(TFA). The flow rate was 30 µl/min for 5 minutes. Using increasing acetonitrile (ACN) 
concentrations in 0.1% formic acid, peptides were separated on a reversed phase 
chromatography (PepMap, 25 cm, 75 µm ID, 1 µm/100 Å pore size, LC Packings) over 80 
or 140 minutes at a flow rate of 300 nl/min. Maximal injection time for MS spectra was 
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100 ms, for MSMS spectra 500 ms. From the high resolution MS prescan the 10 most 
abundant peptide ions for fragmentation in the HCD trap were acquired. Yet, they had 
to be at least doubly charged and to have an intensity of 200 counts or more. The 
dynamic exclusion was 45 seconds and the isolation width was 2 amu. MS spectra were 
recorded within a mass range from 300 to 1500 m/z at a resolution of 60,000 full widths 
at half-maximum.  
LC-MS/MS analysis for native and mesenchymal whole cell extracts was performed on a 
Q Exactive HF (Thermo Fisher Scientific Inc.). Samples were automatically loaded onto an 
Ultimate300 nano RSLC system (Thermo Fisher Scientific/Dionex) with a nano trap 
column (300 μm inner diameter × 5 mm, packed with Acclaim PepMap100 C18, 5 μm, 
100 Å; LC Packings, Sunnyvale, CA) in HPLC buffer containing 0.1% trifluoroacetic acid 
(TFA). The flow rate was 30 µl/min for 5 minutes. Different concentrations of buffer A 
(2% ACN in 0.1% FA) and buffer B (100% ACN in 0.1% FA) were used to separate the 
peptides by increasing ACN concentrations on a reversed phase chromatography 
(AcquityMST3 column, 25 cm, 1.8 µm, Waters) over 130 minutes at a flow rate of 
250 nl/min. The gradient was as followed:  
0-5min:       3% buffer B 
5min:         3% - 5% buffer B 
5-85min:      25% buffer B 
85-100min:    40% buffer B 
100-105 min:  85% buffer B 
105-110 min:  85% buffer B 
110-112min:   85% - 3% buffer B 
112-130min:   3% buffer B 
Maximal injection time for MS and MS/MS spectra was 50 ms. From the high resolution 
MS prescan the 10 most abundant peptide ions for fragmentation in the HCD cell were 
acquired. Yet they had to be at least doubly charged, but not higher than 7 times 
charged and the AGC target was set to 1*105. The dynamic exclusion was 30 seconds 
and the isolation width was 1.6 m/z. MS spectra were recorded within a mass range 
from 300 to 1500 m/z at a resolution of 60,000 for MS spectra and 15,000 for MS/MS 
spectra. 
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 Protein identification and label-free quantification 
Progenesis QI software for proteomics (Version 2.0, Nonlinear Dynamics, Waters, 
Newcastle upon Tyne, U.K.) was used to analyze the acquired spectra of the different 
samples for precursor intensity-based label-free quantification, as previously 
described181-184. Out of the profile data of the MS scans peak lists incorporating m/z 
values, intensities, abundances and m/z width were generated. Additionally, MS/MS 
spectra were transformed and stored in peaks lists with respective m/z values and 
abundance. The retention times of all samples were aligned to one reference sample. 
After automatic and manual alignment to a maximal overlay of all 2D features and 
exclusion of features without charges between 2 and 7, samples were grouped 
according to experimental groups. Raw abundances of all features were normalized. 
Using the Ensembl human protein database (homo sapiens, release: 75, 105287 
sequences; release: 80, 100208 sequences) peptide identification was performed with 
Mascot (MatrixScience, London, UK; version 2.5.1). 10 ppm peptide mass tolerance and 
0.6 Da (20 mmu for samples measured on Q Exactive HF) fragment mass tolerance were 
the used search parameters. Carbamidomethylation was set as fixed modification, and 
methionine oxidation and deamidation of asparagine and glutamine as variable 
modifications and one missed tryptic cleavage was allowed. When searches were 
performed with a mascot score cut-off of 15 and an appropriate significance threshold p, 
an average false discovery rate (FDR) of <1.25% was calculated by the Mascot-integrated 
decoy database search. After reimporting peptide assignments into Progenesis QI, all 
normalized abundances of unique peptides of an identified protein were summed to 
calculate the total cumulative normalized abundance of the respective protein. Based on 
these abundances, the enrichment factors of the quantified proteins to respective 
control samples were calculated. For all other settings the default values were used. 
 Statistics 
Statistical analysis was performed using normalized abundances of all identified proteins 
as determined by Progenesis QI (see 10.13). Proteins without unique peptides were 
excluded of the analysis. The enrichment factors of distinct proteins were calculated 
with the determined protein abundances compared to the respective control samples. 
Normal distribution was assumed and significance was determined by Student’s t-test 
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(galectin pull-downs) or by q-value determination by Progenesis QI software (nat/ded). 
Proteins with p-values/q-values lower than 0.05 were regarded as significantly changed, 
and lower than 0.01 as highly significantly changed.  
 Proteomic tools 
MS data were analyzed and illustrated by different proteomic and statistical tools. 
Volcano plot representations were done with Excel. The log2 transformed ratios 
between normalized abundances of distinct proteins in two comparable groups were 
plotted against the negative log10 transformed p- or q-value of the respective same two 
comparisons. Infinite fold changes were set to the highest measured ratio plus 1 and 
were equalized to the lowest measured ratio.  
Cluster analysis of log2 transformed normalized abundances of all identified proteins 
was done with Perseus185 applying hierarchical clustering based on Euclidean distance. 
Missing values were excluded. Principal Component analysis (PCA) was also done in 
Perseus185 based on log2 transformed normalized abundances of all identified proteins.  
Phobius analysis was used to predict based on the amino acid sequence of a protein, 
how many signal peptides and transmembrane domains a respective protein has186.  
Identified proteins were analyzed based on their cellular components or molecular 
functions for example by Genomatix (GO) software suite. Cellular component analysis of 
the 15 identified Gal-1 interactors and the 131 Gal-3 interactors was performed based 
on the gene ontology (GO) annotation “cellular component” in FunRich187. For protein 
network generation, the Cytoscape App ClueGO-CluePedia188 was used. The 
corresponding gene names of the Gal-1 and Gal-3 interactors were clustered by the GO 
term “molecular function” using homo sapiens as the organism for background list. The 
respective functional groups are represented by their most significant (leading) term and 
the network reflects the relationship between them. The size of the nodes represents 
the enrichment significance of the respective terms based on the predefined kappa 
score threshold of 0.4.  
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 Scratch assay 
Cells were cultivated in 24 well plates until 100% confluence was reached. Before 
treatment with 60 µg/ml Gal-3 and 120 µg/ml Gal-1, cells were starved at least 4 hours 
in serum-free DMEM. Medium was aspirated and a linear scratch was made in the 
confluent cell layer. To get rid of cell debris, cells were washed with PBS and DMEM + 
3% FCS was added with the respective galectin concentrations. Cells were transferred to 
the ibidi heating systems (ibidi, Germany) for multi-well plates coupled to the Leica 
DMi8 microscope with a HCX PL APO 10x/1.20 objective lens. Cells were cultivated at 37 
°C at 5% CO2 and life cell imaging was performed, taking pictures every 20 minutes of 
the defined scratch region over a time period of up to 5 days. Migration of the cells into 
the scratch wound healing area could be analyzed over time with ACAS (Automated 
Cellular Analysis System, ibidi, MetaviLabs) by measuring the gap covered area.  
 FACS analysis 
ARPE19 or human and porcine RPE cells were cultivated up to a confluence of 80% and 
washed with PBS. Cells were detached by incubation with 0.05% trypsin-EDTA (Thermo 
Fisher) for 3 minutes at 37 °C and then transferred to DMEM+10% FSC to inhibit activity 
of trypsin. After centrifugation at 930 rpm for 5 minutes, cells were washed with and 
resuspended in PBS. Cells were counted and divided to 1*105 cells per reaction tube. 
After centrifugation at 1000g for 3 minutes, cells were washed with 170 µl FACS buffer 
(PBS + 1% BSA). The binding compounds were prepared in the respective concentrations 
in FACS buffer and cells were incubated with them for 20 minutes at 4 °C, followed by a 
washing step with 170 µl FACS buffer. The used compounds were:  
• 60 µg/ml biotinylated Gal-1 
• 60 µg/ml biotinylated Gal-3 
• 3 µg/ml of the biotinylated plant lectins PHAL, ConA, Mal2, PNA (vector 
laboratories) 
After incubation with Streptavidin-Alexa488 (1:200, Thermo Fisher) for 20 minutes at 
4 °C, cells were again washed with 170 µl FACS buffer and resuspended in 500 µl FACS 
buffer for measuring. FACS analysis was performed using a BD Fortessa (BD Biosciences) 
flow cytometer with FACSDiva software (BD Biosciences). Flow cytometry data were 
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exported in the format 3.0 and analyzed using FlowJo 7.6 cell analysis software (Tree 
Star, Inc.).  
For the analysis of endocytosis of Gal-1 and Gal-3, ARPE19 cells were treated with 
Fluorescein-labeled galectins for 5, 15 and 30 minutes or with Fluorescein-transferrin 
(Thermo Fisher, T2871) for 30 minutes at 37 °C to enable endocytosis. Prior to that, 
ARPE19 cells were treated with 10 µM kifunensine to inhibit α-mannosidase I or with 
400 µM dynasore (abcam) to inhibit dynamin-mediated endocytosis. After trypsinisation 
of the cells to get rid of transferrin, Gal-1 and Gal-3, bound on the cell surface, but not 
endocytosed, FACS analysis was performed as described above.  
 Immunocytochemical staining 
7.18.1. EMT analysis 
Porcine RPE (pRPE) cells were treated with 3 µM ROCK Inhibitor Y-27632, 10 µM TGF-β 
inhibitor SB 431542, 10 µM Forskolin, 30 µg/ml Gal-1, 30 µg/ml Gal-3 or with 1 µg/ml of 
the mannosidase-inhibitor Swainsonine directly after isolation of the eyes up to 
passage 6. pRPE cells were cultivated on glass coverslips (VWR) until 80-90% confluence 
in DMEM+10% FCS. After fixation with 4% paraformaldehyde, coverslips were blocked 
with Tris-buffered saline with 0.1% Tween20 (TBS-T) + 1% bovine serum albumin (BSA) + 
0.5% goat serum for 45 minutes at RT and incubated with the respective antibody 
mouse anti-Vimentin (1:50, Sigma Aldrich) and rabbit anti-E-Cadherin (1:50, abcam) at 4 
°C overnight. After two washing steps in TBS-T, an incubation with the secondary 
antibodies goat-anti-rabbit-AlexaFluor488 and goat anti-mouse AlexaFluor568 (1:1000, 
Dianova) followed for 1h at RT. Coverslips were washed again two times with TBS-T, 
counterstained with Hoechst (1:5000, ThermoFisher) for 8 minutes at RT, mounted with 
FluorSave (VWR) and photographed on a Leica DMi8 microscope with a HCX PL APO 
20x/1.20 objective lens. Filter cubes for GFP, TXR and DAPI detections were used (JH 
Technologies). All images were captured using a Leica DFC365 FX camera and constant 
settings for gain and exposure time were maintained for all samples within an 
experimental set-up. Images were processed by the Leica Application Suite LASX (version 
2.0, Leica). As control, cells were stained under equal conditions without primary 
antibodies and only with secondary antibodies. No unspecific labeling was observed. The 
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immunocytochemical staining of pRPE cells treated with different components was 
repeated at least three times. Phase-contrast microscopy was also done with cultivated 
RPE cells on a Leica DMi8 microscope with HC PL FL 10x/0.3 or 20x/0.4 objective lenses. 
7.18.2. Co-localisation of galectin with ITGB1, LRP1 and PDGFRB 
Mesenchymal human RPE cells were cultivated on glass coverslips (VWR) upon 60-70% 
confluence in DMEM+10% FCS with or without 10 µM Kifunensine (Sigma Aldrich) up to 
passage 4-7. Cells were washed and starved for at least two hours in serum-free DMEM 
medium before Galectin-treatment. 120 µg/ml Gal-1 and 60 µg/ml Gal-3 were incubated 
with the cells for 30 minutes at 37 °C. As control no galectin was added. Cells on the 
coverslips were fixed with 4% paraformaldehyde, washed with TBS-T and incubated with 
blocking solution (Tris-buffered saline with 0.1% Tween20 (TBS-T) + 1% bovine serum 
albumin (BSA) + 0.5% goat serum) for 45 minutes at RT. Galectin binding was visualized 
by incubation with Streptavidin-Alexa488 (1:500, ThermoFisher) for 1h at RT. 
Immunocytochemical staining with rabbit anti-LRP1 (1:50, abcam), rabbit anti-PDGFRB 
(1:50, abcam) or rat anti-ITGB1 (1:60, DSHB) diluted in TBS-T was performed overnight at 
4 °C. After washing twice with TBS-T, coverslips were incubated with the secondary 
antibodies goat-anti-rabbit-AlexaFluor647 or goat anti-rat AlexaFluor568 (1:1000, 
Dianova) for 1h at RT. Nuclei were stained with Hoechst (1:5000, ThermoFisher) for 8 
minutes at RT and coverslips were mounted with FluorSave (VWR) and photographed on 
a Leica DMi8 microscope with a HCX PL APO 63x/1.20 objective lens. Filter cubes for 
GFP, Y5, TXR and DAPI detections were used (JH Technologies). All images were 
captured under constant settings for gain and exposure time within an experimental set-
up using a Leica DFC365 FX camera. Images were processed by the Leica Application 
Suite LASX (version 2.0, Leica) and the deconvolution software Huygens Essential using 
the classic maximum likelihood estimation (CMLE) algorithm with a signal to noise ratio 
of 40 and 50 iterations (version 16.05, Scientific Volume Imaging B.V., Netherlands, 
http://svi.nl). As control, cells were stained under equal conditions without primary 
antibodies and only with secondary antibodies. No unspecific labeling was observed 
(data not shown). Immunocytochemical staining of human RPE cells was repeated at 
least three times with cells from three different donors. 
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 Western blot analysis 
10 µg of the respective whole cell extracts were used for Western Blot analysis. For the 
analysis of the phosphorylation of ERK 15 µg of the respective protein sample were 
used. For the galectin pull-down experiments with lysates of mesenchymal RPE cells 
from three different donors, treated or untreated with 10 µM Kifunensine for up to 4 
weeks, whole protein eluates were applied. Protein samples were separated by SDS-
PAGE (10% gels) and blotted onto PVDF membranes. After blocking with 3% BSA in TBS-T 
for Western blots using phospho-specific antibodies or with 5% non-fat dried milk in 
TBS-T for 1h at RT, blots were incubated with antibodies against rabbit anti-LRP1 
(1:20,000, abcam), rabbit anti-PDGFRB (1:1,000, abcam), mouse anti-GAPDH (1:10,000, 
Millipore), mouse anti-Vimentin (1:500, Sigma Aldrich), rabbit anti-E-Cadherin (1:200, 
abcam), rabbit anti-phospho-ERK p44/p42 (1:2,000, cell signaling, #4370), mouse anti-
Gal-1 (1:2, in house), rat anti-Gal-3 (1:2, in house) or with the biotinylated plant lectin 
PHAL (1:1,000, vector laboratories) at 4 °C overnight. After washing three times with 
TBS-T, blots were incubated with the appropriate HRP-coupled secondary antibodies 
(1:7,500, Jackson ImmunoResearch) or with Streptavidin-HRP (1:20,000, vector 
laboratories) for 1h at RT and binding was visualized by signal development with ECL 
Plus enhanced chemiluminescence kit (GE Healthcare). All Western Blot experiments 
were repeated at least 3 times.   
 Coomassie staining 
For Coomassie staining of a SDS-PAGE, Coomassie Brilliant Blue R250 Powder (Serva) 
was used. The gel was fixed for 30 minutes in the fixing solution (50% methanol, 12% 
acetic acid). 0.4% Brilliant BlueR250 was diluted in fixing solution. A 1:10 dilution thereof 
was used to stain the gel for 30 minutes. After destaining the gel with fixing solution for 
30 minutes, it was washed at least twice for 15 minutes in H2O.  
 Analysis of phosphorylation profiles 
For the simultaneous analysis of changes in relative site-specific phosphorylation profiles 
of 43 kinases and 2 related total proteins after galectin treatment, the Human Phospho-
Kinase Array (R&D Systems, ARY003B) was used. Selected phospho-specific capture 
antibodies are spotted in duplicate on nitrocellulose membranes. According to the 
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manufacturer´s instructions (R&D systems), 300 µg of whole cell extracts of ARPE19 cells 
untreated or treated for 15 minutes with 120 µg/ml Gal-1 or 60 µg/ml Gal-3 were 
incubated with the nitrocellulose membranes overnight at 4 °C. After subsequent 
incubation with a cocktail of biotinylated detection antibodies and Streptavidin-
Horseradish Peroxidase, the amount of phosphorylated protein bound at the respective 
capture spot was visualized by signal development with chemiluminescent detection 
reagents. Pixel density of each spot was determined with ImageJ189 considering 
background subtraction189. Mean pixel density, standard deviation and statistical 
significance (Student’s t-test) were determined. P-values lower than 0.05 were 
considered as significant (*), p-values lower than 0.01 as highly significant (**).  
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8. Results 
 Characterization of EMT processes and glycomic fingerprints of 
RPE cells during dedifferentiation 
Epithelial-to-mesenchymal transition (EMT) is one of the key cellular events in PVR 
development. To get deeper insights in cellular processes underlying EMT, we analyzed 
changes in phenotype, proteome and cell surface glycan structures of RPE cells 
undergoing EMT in vitro. We also examined the impact of glycomic shifts on binding of 
Gal-1 and Gal-3 on epithelial and mesenchymal RPE cells. To prevent EMT in vitro and to 
develop a stable cell culture model for epithelial RPE cells, we tried to interfere with 
both phenotype transition and glycan synthesis.   
8.1.1. Primary RPE cells undergo morphologic changes during sub-cultivation  
Because of the limited availability of human RPE cell samples derived from patients 
suffering PVR, cultured primary human or porcine RPE cells were used as a well-
accepted in vitro model system for early PVR45. Dulbeccos modified Eagle Medium 
(DMEM, high glucose, pyruvate) with 10% FCS was routinely used to cultivate primary 
RPE cells on tissue culture plastic. After isolation of RPE cells from eyes, they were 
routinely plated at a high density to keep the cells in a homogenous cell monolayer. 
100% confluence was normally reached after 5 days.  
Directly after isolation, the cells were pigmented and had a well-differentiated epithelial 
morphology (passage 1, figure 15). During sub-cultivation, from passage 2 or 3 on, the 
RPE cells began to dedifferentiate and transformed into a mesenchymal-like phenotype 
(figure 15). 6th- or higher passage-cells had totally lost their epithelial characteristics, 
their cell-cell contacts and spreading was increased (figure 15). Changes in the 
cytoskeleton structure were also visible. Cell culture conditions with lower cell densities 
enabled higher degrees of cell spreading and faster dedifferentiation of the cells.  
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Figure 15: Primary RPE cells undergo EMT during culture. Phase-contrast images (10x objective lense) of 
porcine RPE cells at different passages cultivated in Dulbeccos modified Eagle Medium (DMEM, high 
glucose, pyruvate) with 10% FCS, scale bar 500 µm. 
8.1.2. Clear differences in protein expression of native and mesenchymal RPE 
cells 
To get deeper insights into epithelial-to-mesenchymal transition (EMT) processes during 
sub-cultivation of RPE cells, a proteome-wide screening approach was done. Whole cell 
extracts of native RPE cells, freshly isolated of human cadaver eyes, or of cultivated 
human RPE cells (passage number 5-7) were analyzed by label-free quantitative LC-
MS/MS. Four different human donors for native RPE cells and four different donors for 
mesenchymal RPE cells were used. To identify those proteins that were up- or 
downregulated in mesenchymal RPE cells compared to native ones, ratios of the means 
of all protein abundances in all native and all mesenchymal RPE cells were calculated. 
Statistical analysis was done using FDR adjusted p-values (q-values). Proteins with a q-
value <0.01 and enrichment factors (fold change, FC) of ≥ 5 or ≤ 0.2 in native cells 
compared to mesenchymal RPE cells were regarded as highly significantly changed.  
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Figure 16: Proteomic analysis of native and mesenchymal human RPE cells reveals clear differences in 
protein expression. A: Cluster analysis based on the normalized abundances of all identified proteins of 
4 different human mesenchymal RPE samples (passage number 5-7) and 4 different human native RPE 
samples. High abundant proteins were colored in red, low abundant proteins in blue. B: Volcano Blot 
analysis: ratios of the means of all protein abundances in all native and all mesenchymal RPE cells were 
calculated and plotted against the corresponding negative log10 transformed FDR adjusted p-values (q-
values). Those proteins with a q-value <0.01 and enrichment factors of ≥ 5 (red dots) or ≤ 0.2 (blue dots) 
in native cells compared to mesenchymal RPE cells were regarded as significantly changed. C: Principal 
Component Analysis of the 4 native RPE and the 4 mesenchymal RPE cell samples. nat: native, mes: 
mesenchymal. 
Clustering of the identified and relatively quantified proteins showed a clear difference 
in protein expression in native and mesenchymal human RPE cells (figure 16A). 2454 
proteins could be identified in all 8 samples. 336 proteins were highly significantly 
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(q<0.01) over five-fold upregulated (FC nat/mes>5) in native RPE cells (red dots, figure 
16B). Using the corresponding cut-off, 225 proteins were over five-fold upregulated 
(FC<0.2) in mesenchymal RPE cells (blue dots, figure 16B). Even though there was a 
biological variance in the human samples, a clear difference in protein expression was 
visible between native and mesenchymal RPE cells in Principal Component Analysis 
(figure 16C). Only 174 of 2454 proteins were expressed at similar levels in native and 
mesenchymal cells (enrichment factor between 0.8 and 1.2), which means that 93% of 
all identified proteins were changed upon sub-cultivation of RPE cells. Epithelial cell 
markers like Claudin-19 and E-Cadherin were downregulated in mesenchymal cells as 
expected, whereas mesenchymal cell markers like Vimentin and N-Cadherin were 
upregulated in mesenchymal cells (figure 17). Thus, sub-cultivation of RPE cells led not 
only to a complete change of phenotype of RPE cells, but also to an impressive change in 
protein expressions. 
 
Figure 17: Epithelial cell markers are downregulated, mesenchymal cell markers are upregulated in 
cultured RPE cells of passage 5-7. Box plot analysis of normalized abundances of Vimentin, Claudin-19, 
N-Cadherin and E-Cadherin in 4 human native RPE cell samples and 4 human mesenchymal RPE cell 
samples; *significantly changed (q<0.05), **highly significantly changed (q<0.01). nat: native, mes: 
mesenchymal.  
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8.1.3. Expression of complex-type N-glycans increases upon EMT conferring 
increased Gal-1 and Gal-3 binding on mesenchymal RPE cells 
Besides a complete change of the proteome, we have identified that EMT of RPE cells 
leads to increased β-1,6-N-glycosylation on the cell surface and thus increased binding of 
Gal-3, as published in Priglinger et al. 116. The specificity of the plant lectin 
phytohemagglutinin-L (PHAL) for complex-type N-glycans was used to visualize an 
increased expression of β1,6-N-acetylglucosamine (GlcNAc)-branched tri- and 
tetraantennary complex-type N-glycans upon EMT (figure 18A).  
 
Figure 18: Expression of complex-type N-glycans increases upon EMT conferring increased Gal-1 and 
Gal-3 binding on mesenchymal RPE cell. A: 10 µg of native (nat) and mesenchymal (mes) porcine RPE 
(pRPE) whole cell extracts were separated respectively by SDS-PAGE and Lectin Blot analysis was 
performed with the biotinylated plant lectin phytohemagglutinin-L (PHAL). GAPDH was used as loading 
control. A representative blot of at least three different experiments is shown. B+C: Flow cytometric 
analysis of binding of Gal-1, Gal-3 and PHAL to native (nat) and mesenchymal (mes) porcine RPE cells (B) 
and to mesenchymal RPE cells untreated or treated with deoxymannojirimycin (DMNJ) (C). 
Representative results of at least two independent FACS experiments are shown. rel: relative.   
This glycomic change during EMT came along with increased binding of Gal-1 and Gal-3 
to mesenchymal RPE cells (figure 18B). By FACS analysis it could be confirmed that 
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native RPE cells exhibited little binding of PHAL, Gal-1 and Gal-3 compared to the 
unstained cells (neg. control), whereas PHAL, Gal-1 and Gal-3 binding to mesenchymal 
RPE cells was evident (figure 18B). Native RPE cells showed increased background 
fluorescence compared to mesenchymal RPE due to their intense pigmentation (see neg. 
control panel in figure 18B).  
To proof that complex-type N-glycans are required for Galectin binding, mesenchymal 
RPE cells were treated with deoxymannojirimycin (DMNJ) to block N-glycan elongation, 
followed by staining with Gal-1, Gal-3 or PHAL (figure 18C). Effectiveness of 1 mM DMNJ 
treatment was measurable by decreased staining with the plant lectin PHAL compared 
to untreated cells (figure 18C, blue solid line). Reduction of complex-type N-glycans on 
RPE cells resulted also in decreased Gal-1 and Gal-3 binding (figure 18C, red and black 
solid line), verifying that tetra- or triantennary complex type N-glycans (β1,6-(GlcNAc)-
branched N-glycans) were necessary for effective Galectin binding on the RPE cell 
surface.   
8.1.4. Gal-3 binds to the RPE cell surface via complex-type N-glycans but not O-
glycans 
Gal-3 binding was less decreased by inhibition of N-glycan synthesis by DMNJ than Gal-1 
binding. To determine potential further oligosaccharide preferences of Gal-3 on 
myofibroblastic RPE cells, dedifferentiated human RPE cells were treated besides DMNJ 
with BenzylGalNAc to inhibit elongation of O-glycans (figure 19C). BenzylGalNAc can also 
compete with sialyltransferases resulting in decreased O-glycan sialylation. Decreased O-
glycan sialylation was verified by increased staining with the plant lectin peanut 
agglutinin (PNA) compared to untreated controls (figure 19C, black dotted line). 
Treatment of RPE cells with Vibrio cholera neuraminidase resulted in  removal of sialic 
acids on glycoproteins as shown by reduced binding of Maackia Amurensis Lectin-2 
(Mal-2, specific for α2,3 sialic acid residues) after treatment with neuraminidase (figure 
19B, black dotted line). Reduction of complex-type N-glycans on RPE cells, as shown 
before in figure 18C, resulted in decreased Gal-3 and PHAL binding (figure 19A, red and 
black dotted line), whereas decreased accessibility of branched O-glycans didn’t alter 
binding of Gal-3 to RPE cells (figure 19C, red line). Binding of Gal-3 to RPE was increased 
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by removal of sialic acids by Vibrio cholera neurominidase (figure 19B, red line). These 
results indicate, that binding of Gal-3 to the RPE cell surface strongly depends on the 
interaction of Gal-3 with complex-type N-glycans (β1,6-(GlcNAc)-branched N-glycans) 
but not on complex-type O-glycans and sialylation of glycans. 
 
Figure 19: Gal-3 binds to the RPE cell surface via complex-type N-glycans but not complex-type O-
glycans. Flow cytometric analysis of binding of Gal-3 compared to binding of different plant lectins 
(PHAL: phytohemagglutinin-L, Mal2: Maackia Amurensis Lectin-2, PNA: peanut agglutinin) to human 
RPE cells untreated or treated with deoxymannojirimycin (DMNJ), Vibrio cholera neuraminidase or 
BenzylGalNac. Representative results of at least three independent experiments are shown. 
8.1.5. EMT inhibitors maintain the epithelial phenotype of RPE cells in vitro 
As shown in figure 15, it was difficult to keep primary RPE cells in their epithelial state 
under routinely used cell culture conditions. Because of the limited availability of native 
RPE cells in adequate amounts to analyze the impact of galectins on cellular processes – 
especially EMT –, it was necessary to create a stable cell culture model of epithelial RPE 
cells. Different cell culture media – suitable for cultivation of epithelial cells – were 
tested to prevent EMT processes during cultivation: the minimum essential medium 
MEMα and the mammary epithelial cell growth medium MEGM, compared to the 
standardly used DMEM. Besides, different concentrations of FCS were tested.  
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Figure 20: RPE cells are only able to attach and proliferate when cultivated in DMEM. Phase-contrast 
images of porcine RPE cells (passage 1) cultivated in DMEM supplemented with 10% FCS (A), 1% FCS (C), 
0% FCS (E) or in MEMα with 1%FCS (B), 0% FCS (D) or in MEGM with no FCS (F). FCS: fetal calf serum, 
DMEM: Dulbeccos modified Eagle Medium, MEMα: Minimum Essential Medium, MEGM: Mammary 
Epithelial Cell Growth Medium. Scale bar 200 µm. 
RPE cells were only able to attach and proliferate when they were cultured in DMEM 
medium (figure 20A and 20C) with at least 1% FCS. When no FCS was added to the 
medium, RPE cells didn’t attach to the surface of the cell culture dishes, they died and 
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strong morphologic changes took place (figure 20E). Both, MEMα and MEGM, were also 
not suitable to cultivate RPE cells, even with higher concentrations of FCS (figures 20B, 
20D, 20F). Cultivation in DMEM with 1% FCS was possible for shorter periods of 1 or 2 
days, but for long-term cultivation 10% FCS was necessary to prevent cell growth arrest 
of the RPE cells. Consequently, RPE cells were cultivated in DMEM added with 10% FCS 
and for short-term experiments the FCS concentration was reduced to 3% or 0%. Yet, 
during sub-cultivation EMT took place under these conditions (figure 15). 
As the tested epithelial cell culture media MEMα and MEGM were not suitable for 
primary RPE cell culture and especially not suitable for prevention of EMT, different EMT 
inhibitors were tested to keep RPE cells in their epithelial phenotype during RPE cell 
cultivation: 3 µM ROCK Inhibitor Y-27632, 10 µM TGF-β inhibitor SB 431542 and 10 µM 
Forskolin (figure 21). Immunocytological staining of untreated porcine RPE cells (passage 
5) revealed high expression of vimentin (mesenchymal cell marker) and very low 
expression of E-Cadherin (epithelial cell marker) (figure 21AE). A clear E-Cadherin 
expression on the cell membrane could be detected, when the cells were treated with 
ROCK Inhibitor Y-27632 (figure 21AG), TGF-β inhibitor SB 431542 (figure 21AF) or 
Forskolin (figure 21AH). Even at passage 5 (in DMEM, 10%FCS) porcine RPE cells 
maintained epithelial cell characteristics, including cell-cell contacts, by treatment with 
the EMT inhibitors. These results could be verified by Western Blot analysis, showing a 
clear E-Cadherin expression in these cells (figure 21C). 
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Figure 21: EMT inhibitors stabilize the epithelial phenotype of RPE cells in vitro. A+B: 
Immunocytochemical staining of porcine RPE cells (A: passage 5; B: passage 3) with anti E-Cadherin 
Alexa488 (green) and anti-Vimentin Alexa568 (red) after treatment with 10 µM TGF-β inhibitor SB 
431542, 3 µM ROCK Inhibitor Y-27632 and 10 µM Forskolin (A) or with 30 µg/ml Gal1, Gal-3 or 1 µg/ml 
Swainsonine (B). Scale bar: 50 µm. C+D: Western Blot analysis of pRPE cell lysates (C: passage 5; D: 
passage 3) untreated or treated with 10 µM TGF-β inhibitor SB 431542, 3 µM ROCK Inhibitor Y-27632 
and 10 µM Forskolin (C) or with 30 µg/mlGal1, Gal-3 or 1 µg/ml Swainsonine (D) against E-Cadherin and 
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Vimentin. GAPDH was used as a loading control. E: Flow cytometry analysis of PHAL binding to pRPE 
cells untreated or treated with 1 µg/ml Swainsonine. Representative results of at least three 
independent experiments are shown.  
8.1.6. Gal-1, Gal-3 and complex-type N-glycan inhibitors are not able to prevent 
EMT 
As shown in figure 18, EMT of RPE cells is accompanied by a glycomic shift to complex-
type N-glycans on the cell surface. To analyze if there is a correlation in inhibiting N-
glycan synthesis and thus EMT processes, RPE cell were treated with 1 µg/ml of the 
mannosidase-inhibitor Swainsonine directly after isolation. Additionally, to test if Gal-1 
or Gal-3 binding has an impact on EMT of RPE cells, porcine RPE cells were also treated 
with 30 µg/ml Gal-1 or Gal-3. After passage 3 the cells developed a stable mesenchymal 
phenotype. No E-Cadherin expression was identified by immunocytochemistry and 
Western Blot analyses, verifying that neither Gal-1 and Gal-3 nor Swainsonine were 
suitable to prevent EMT processes (figure 21B and 21D). Inhibition of mannosidase I and 
reduced N-glycan synthesis by Swainsonine treatment could be confirmed by reduced 
PHAL binding in FACS analysis (figure 21E).  
8.1.7. EMT-inhibitors do not influence glycomic change of RPE cells and 
galectin-binding 
To analyze the impact of EMT inhibition by the ROCK Inhibitor Y-27632, TGF-β inhibitor 
SB 431542 or Forskolin on the glycosylation pattern of the cells and on galectin binding, 
pRPE (treated and untreated with EMT inhibitors) were stained with PHAL, Concanavalin 
A (ConA), Gal-3 or Gal-1 (figure 22A-D). PHAL, ConA, Gal-1 and Gal-3 binding was evident 
to mesenchymal pRPE cells (figure 22A-D, black solid lines). Treatment of pRPE cells with 
10 µM Kifunensine reduced PHAL, Gal-1 and to a lesser extend Gal-3 binding, ConA 
(specific for mannose and glucose) binding was not influenced (figure 22A-D, red lines). 
Gal-1, Gal-3 and PHAL bound slightly less to RPE cells treated with TGFβ-inhibitor (figure 
22A-D, blue solid lines), whereas the EMT-inhibitors Forskolin and the ROCK-inhibitor 
exhibited no change in binding of Gal-1 and Gal-3 (figure 22A-D, blue and black dotted 
lines). Additionally, clear PHAL binding to EMT-inhibitor treated cells revealed that the 
glycomic shift to complex-type N-glycans couldn’t be prevented by all three tested EMT-
inhibitors (figure 22E). Consequently, EMT-inhibitor treatment of native RPE cells 
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stabilized the epithelial phenotype of RPE cells, but the glycosylation pattern didn’t 
correlate to the pattern of native RPE cells. 
 
Figure 22: EMT-inhibitors do not influence glycomic change of RPE cells and Galectin-binding. A-D: Flow 
cytometric analysis of Gal-1, Gal-3, PHAL and Concanavalin (ConA) binding on pRPE cells untreated or 
treated with 10 µM TGF-β inhibitor SB 431542, 3 µM ROCK Inhibitor Y-27632, 10 µM Kifunensine and 
10 µM Forskolin. E: Lectin Blot analysis with the plant lectin PHAL binding to pRPE cells untreated or 
treated with 10 µM TGF-β inhibitor SB 431542, 3 µM ROCK Inhibitor Y-27632 and 10 µM Forskolin. 
GAPDH was used as a loading control. Representative results of at least three independent experiments 
are shown. 
 Functional impact of galectin treatment on RPE cells in correlation 
with surface glycome 
To analyze functional impact of galectin treatment on RPE cells in correlation of changed 
glycomic surface fingerprints upon EMT, influence of Gal-1 and Gal-3 on migration of 
RPE cells was examined in scratch-wound-healing assays. Furthermore, we established 
Gal-1 and Gal-3 knockdown cells and investigated based on their glycan structure on the 
cell surface their reactivity to exogenously added galectin.  
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8.2.1. Gal-1 and Gal-3 are not cytotoxic to RPE cells 
Gal-1, Gal-3, Gal-8 and Gal-9 are expressed in RPE cells. To test if the respective isoforms 
have cytotoxic effects on RPE cells when added exogenously, a MTT assay was 
performed with the ARPE19 cell line as well as with primary human and porcine RPE 
cells. The yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium 
bromide) was reduced by metabolically active cells to purple formazan, which was 
solubilized and quantified by spectrophotometry177. Viability of the cells correlated with 
color formation: the lower the absorbance at 580 nm, the lower cell viability. Gal-1 and 
Gal-3 were not toxic towards ARPE19, human and porcine RPEs up to a concentration of 
70 µg/ml after a 48h treatment (figures 23A and 23B). A modest toxicity towards those 
cells could be seen with Gal-8 (>31µg/ml) (figure 23C), while Gal-9 was highly toxic at 
concentrations above 12.5 µg/ml (figure 23D). With respect to potential application of 
galectins in therapeutic approaches, Gal-8 and Gal-9 were considered too toxic and all 
subsequent analysis and experiments were performed only with Gal-1 and Gal-3. 
 
Figure 23: Gal-1 and Gal-3 are not cytotoxic to RPE cells. MTT assay was done with the ARPE19 cell line, 
primary human (huRPE) and porcine RPE cells (pRPE) treated with increasing concentrations of Gal-1 
(A), Gal-3 (B), Gal-8 (C) or Gal-9 (D) (in triplicates). After 48h treatment MTT (5 mg/ml in PBS) was added 
for 4 hours at 37 °C and the formed crystals were solubilized at 37 °C overnight with 10% SDS in 0.01M 
HCl. The  viability of the cells positively correlated with the absorbance (580 nm) . 
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8.2.2. Gal-1 and Gal-3 inhibit migration of RPE cells in a carbohydrate-
dependent manner 
Gal-1 and Gal-3 are known to inhibit attachment and spreading of mesenchymal RPE 
cells 114, 117. Here we performed scratch-wound-healing assays to analyze the effect of 
Gal-1 and Gal-3 on RPE cell migration. A confluent layer of RPE cells was scratched and 
directly treated with Gal-1 and Gal-3. Migration of RPE cells into the scratch area was 
monitored by live-cell imaging over time and normalized gap covered area was 
determined. Gal-1 and Gal-3 diminished migration of RPE cells in scratch-wound-healing 
assays (figures 24B and 24C). This effect was rescued by treatment of the cells with 10 
µM Kifunensine. Inhibition of complex-type-N-glycan formation by Kifunensine led to 
less galectin and PHAL binding on the cell surface (figure 24A) and thus to decreased 
inhibition of migration by Gal-1 and Gal-3 in scratch-wound-healing assays (figures 24B 
and 24C).  
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Figure 24: Gal-1 and Gal-3 diminished migration of RPE cells in a carbohydrate-dependent manner. A: 
Flow cytometry analysis of PHAL, Gal-1 and Gal-3 binding on human RPE cells untreated or treated with 
10 µM Kifunensine to inhibit complex-type-N-glycan formation. B+C: Scratch-wound healing assay with 
human RPE cells treated with or without Kifunensine. RPE cells were scratched and directly treated with 
60 µg/ml Gal-3 or 120 µg/ml Gal-1. Migration of RPE cells into the scratch area was monitored over time 
and the normalized gap covered area [%] was determined. Scale bar: 250 µm. Kif: Kifunensine, PHAL: 
phytohemagglutinin-L. Representative results of at least three independent experiments are shown.   
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8.2.3. Knockdown of endogenous Gal-1 and Gal-3 has no impact on galectin-
binding 
Endogenous Gal-1 and Gal-3 are by trend upregulated in mesenchymal RPE cells 
compared to native ones (figure 25A)113 and Cao et al. 190 describe that exogenous Gal-3 
stimulates re-epithelialization of corneal wounds in wildtype mice but not in Gal-3 
knockout mice190. Thus, we wanted to analyze if intrinsic expression of Gal-1 and Gal-3 
has any effects on surface glycosylation and galectin-binding. Gal-1 and Gal-3 knock-
down cells were produced by the Lenti-CRISPR/Cas9 system, and knock-down was 
verified by Western Blot analysis (figure 25B). FACS analysis revealed that knock-down of 
Gal-1 and Gal-3 induced no change on Galectin-binding compared to non-infected cells 
or cells transduced with the lentiviral vector expressing a non-coding filler guide RNA 
(LV) (figure 25C). Besides, Gal-1 and Gal-3 knock-down had no influence on complex 
type-N glycans on the cell surface, since no change of PHAL-binding could be observed 
(figure 25C). 
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Figure 25: Knock-down of endogenous Gal-1 and Gal-3 has no impact on Galectin-binding. A: Box-plot 
analysis of normalized abundances of Gal-1 and Gal-3 in native (nat) and mesenchymal (mes) human 
RPE cells, revealed by proteomic analysis of native and mesenchymal human RPE cells (results 8.1.2, 
figure 16). B: ARPE19 cells were not infected (n.i.) or infected with lentiviral vectors expressing 
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“lentiCRISPRv2” plasmids coding for functional gRNAs to knockdown Gal-1 (Gal1 ko) and Gal-3 (Gal3 ko) 
or without functional gRNA (LV). Knock-down of Gal-1 and Gal-3 in ARPE19 cells by the 
LentiCRISPR/Cas9 system was verified by Western Blot analysis with antibodies against Gal-1 (25B11) 
and Gal-3 (15B6). GAPDH was used as a loading control. C: FACS analysis of Gal-1, Gal-3 and PHAL 
binding on ARPE19 cells not transduced or transduced with lentiviral vectors expressing “lentiCRISPRv2” 
plasmids coding for functional gRNAs to knockdown Gal-1 (Gal1 ko) and Gal-3 (Gal3 ko) or without 
functional gRNA (LV). Nat: native, mes: mesenchymal, norm: normalized, PHAL: phytohemagglutinin-L. 
Representative results of at least three Western Blot analyses and three FACS analyses are shown. 
 Proteome-wide identification of glycosylation-dependent 
interactors of Gal-1 and Gal-3 on mesenchymal RPE cells 
The cell surface proteins targeted by specific galectins on RPE cells are largely unknown. 
To identify Gal-1 and Gal-3 specific interactors on the RPE cell surface, a galectin pull-
down assay was established and we analyzed the cellular component distribution and 
molecular functions of the identified galectin ligands. Relevance of glycosylation of 
galectin interactors for the functional galectin binding and the crosslinking activity was 
also determined. To analyze functional and signal modulating effects of galectins on RPE 
cells, simultaneous determination of changes in phosphorylation profiles of distinct 
proteins due to galectin binding was performed. 
8.3.1. Gal-3 revealed more interacting binding partners than Gal-1 
To identify Gal-1 and Gal-3 specific interactors on the RPE cell surface, a galectin pull-
down assay was established. For the pull-down experiments, Gal-1 and Gal-3 were 
coupled to CnBr-activated sepharose beads. To test if the galectins are still active after 
coupling to Sepharose beads, galectin-beads were incubated with asialofetuin, a known 
interactor of galectins, in absence and presence of 0.1 M ß- lactose, which act as a 
competitor. Bound asialofetuin was eluted with Laemmli buffer and eluates were 
separated by SDS-PAGE. Asialofetuin was detected by Coomassie staining (figure 26), 
verifying active Gal-1 and Gal-3 coupled to the beads.  
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Figure 26: Gal-1 and Gal-3 are still active after coupling to sepharose beads. After incubation of Gal-1 
(Gal1PD) and Gal-3 (Gal3PD) sepharose beads with asialofetuin in absence and presence of 0.1 M β-
lactose (-/+ Lactose), eluates were separated by SDS-Page and asialofetuin was detected by Coomassie 
staining.   
To identify Gal-1 and Gal-3 interacting binding proteins, whole cell extracts of 
dedifferentiated mesenchymal human RPE cells were incubated with the respective 
galectin-sepharose beads. Specific galectin binding proteins were eluted by β-lactose as 
a competitor for specific carbohydrate binding. The same pull-down experiments were 
done with ProteinG-coupled sepharose beads to exclude unspecific ligands. A 
subsequent proteomic screening of all lactose eluates was performed. In 5 independent 
Gal-3 pull-down experiments (with 3 or 4 technical replicates each) 1429 different 
proteins and in 5 independent Gal-1 pull-down experiments (3 or 4 technical replicates 
per experiment) 1528 proteins with an overlay of 1272 proteins were identified (figure 
27A). Those proteins, that were significantly (p<0.05) at least 2-fold (fold-change (FC)≥2) 
enriched in Gal-1 or Gal-3 eluates compared to the unspecific control, were selected as 
the most promising Gal-1 and Gal-3 interacting proteins. In Gal-3 pull-down 
experiments, more significant interacting binding partners were revealed, as shown in 
volcano plot analysis of one exemplary Gal-1 (figure 27D) and one exemplary Gal-3 
(figure 27E) pull-down experiment. While 771 proteins were over 2-fold enriched in Gal-
3 eluates (FC≥2), 332 of these proteins could also be determined as significantly bound 
to Gal-3 (FC≥2, p<0.05) (figure 27B). Compared to that, 698 proteins were specifically 
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enriched in Gal-1 lactose eluates (FC≥2) but only 60 of these proteins reached also 
significance (FC≥2, p<0.05) (figure 27B). For further analysis and validation we only used 
those proteins, that could be detected in 2 or more independent experiments (FC≥2, 
p<0.05, n≥2) (figure 27C), which were 15 Gal-1 interactors (table 1) and 131 Gal-3 
interactors (table 2) fulfilling these strict criteria. 
 
Figure 27: Gal-3 reveals more significant interacting binding partners than Gal-1. A-C: Numbers of 
protein identifications in all Gal-1 (red) and Gal-3 (blue) pull-down experiments (A); numbers of protein 
identifications of all significantly enriched (p<0.05) proteins with an enrichment factor over or equal 2 in 
the galectin ß-lactose eluates compared to negative control (FC≥2) (B) and of all significantly enriched 
proteins (p<0.05, FC≥2 ), that could be detected in 2 or more independent pull-down experiments (C). 
Numbers of overlapping protein identifications are represented (violet). D+E: Volcano plot 
representation of one exemplary Gal-1 (D) and one exemplary Gal-3 (E) pull-down experiment (with 3 
replicates each). The log2 transformed ratios between normalized abundances of all proteins identified 
in lactose eluates of galectin pull-down compared to unspecific control (Protein-G pull-down) are 
plotted against the respective negative log10 transformed p-values of the t-test. P-values of p<0.05 and 
additional regulation of ≥ two fold were regarded as significant (red dots). Infinite fold changes were set 
to the highest measured ratio plus 1 (dots on the right site of the plot), fold changes with a value of 0 
were equalized with the lowest measured ratio (dots on the left site of the plot).  
Results 
 
   92 
 
Table 1: List of RPE cell proteins with high affinity to Galectin-1. 
1st Accession Number Gene name 
Ratio 
Gal1/neg. 
control 
P-value TMD SP Protein name 
ENSP00000333298 LAMP1 1065.8 0.006 1 Y 
lysosomal-associated 
membrane protein 1  
ENSP00000307513 MRC2 136.4 0.049 1 0 mannose receptor, C type 2 
ENSP00000007722 ITGA3 104.6 0.021 1 Y integrin, alpha 3 
ENSP00000261023 ITGAV 59.2 0.016 1 Y integrin, alpha V  
ENSP00000303351 ITGB1 53.9 0.014 1 Y integrin, beta 1 
ENSP00000233714 LANCL1 52.2 0.001 0 0 
LanC l antibiotic synthetase 
component C-like 1 
(bacterial)  
ENSP00000314508 GBA 34.8 0.000 0 Y glucosidase, beta, acid  
ENSP00000331544 FBLN1 34.1 0.018 0 Y fibulin 1  
ENSP00000243077 LRP1 31.1 0.019 1 Y 
low density lipoprotein 
receptor-related protein 1  
ENSP00000258341 LAMC1 21.3 0.002 0 Y 
laminin, gamma 1 (formerly 
LAMB2)  
ENSP00000262776 LGALS3BP 19.0 0.043 0 Y 
lectin, galactoside-binding, 
soluble, 3 binding protein  
ENSP00000228506 MLEC 18.1 0.037 1 Y malectin  
ENSP00000265304 SSBP1 6.1 0.045 0 0 
single-stranded DNA 
binding protein 1, 
mitochondrial  
ENSP00000200639 LAMP2 5.9 0.001 1 Y 
lysosomal-associated 
membrane protein 2  
ENSP00000258733 GPNMB 5.3 0.049 1 Y 
glycoprotein 
(transmembrane) nmb  
 
15 identified Gal-1 interactors in order of their enrichment factors in the ß-lactose eluates of galectin 
pull-downs compared to unspecific controls. For calculation the mean of all technical replicates within 
one experiment was used. Significance was determined by Student’s t-test. Proteins with p-values of 
p<0.05, enrichment of ≥ two-fold in galectin pull-down eluates (FC ≥ 2) and additional identification in 
two or more independent pull-down experiments (n ≥ 2), were regarded as significant. The ratios 
represent the maximum fold changes of all experiments and the corresponding p-values. TMD: 
transmembrane domain. SP: signal peptide. FC: fold change. 
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Table 2: List of RPE cell proteins with high affinity to Galectin-3. 
 
1st Accession 
Number 
gene 
name 
 
Ratio 
Gal3/neg. 
control 
P-value 
 
TMD 
 
SP 
 
Protein name 
 
ENSP00000273784 AHSG infinity 0.016 0 Y alpha-2-HS-glycoprotein  
ENSP00000222374 CADM4 infinity 0.047 1 Y cell adhesion molecule 4  
ENSP00000312435 DAG1 infinity 0.004 1 Y 
dystroglycan 1 (dystrophin-associated 
glycoprotein 1)  
ENSP00000321573 DCBLD2 infinity 0.007 3 Y discoidin, CUB and LCCL domain containing 2  
ENSP00000334145 F3 infinity 0.003 1 0 
coagulation factor III (thromboplastin, tissue 
factor)  
ENSP00000314508 GBA infinity 0.014 0 Y glucosidase, beta, acid  
ENSP00000282588 ITGA1 infinity 0.002 1 Y integrin, alpha 1  
ENSP00000264106 ITGA6 infinity 0.015 1 Y integrin, alpha 6  
ENSP00000266041 ITIH4 infinity 0.014 0 Y 
inter-alpha-trypsin inhibitor heavy chain family, 
member 4  
ENSP00000258341 LAMC1 infinity 0.016 0 Y laminin, gamma 1 (formerly LAMB2)  
ENSP00000231004 LOX infinity 0.046 0 Y lysyl oxidase  
ENSP00000374135 LRP1B infinity 0.029 1 Y 
low density lipoprotein receptor-related protein 
1B  
ENSP00000199940 MAP2 infinity 0.035 0 0 microtubule-associated protein 2  
ENSP00000217939 MXRA5 infinity 0.012 0 Y matrix-remodelling associated 5  
ENSP00000294785 NCSTN infinity 0.009 1 Y nicastrin  
ENSP00000324270 OXTR infinity 0.041 7 0 oxytocin receptor  
ENSP00000319782 PODXL infinity 0.020 1 Y podocalyxin-like  
ENSP00000356572 QSOX1 infinity 0.007 0 Y quiescin Q6 sulfhydryl oxidase 1  
ENSP00000266771 SLC15A4 infinity 0.014 13 0 
solute carrier family 15 (oligopeptide 
transporter), member 4  
ENSP00000444408 SLC1A5 infinity 0.017 9 0 
solute carrier family 1 (neutral amino acid 
transporter), member 5  
ENSP00000004531 SLC7A2 infinity 0.042 14 0 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 2  
ENSP00000335300 TPCN1 infinity 0.002 12 0 two pore segment channel 1  
ENSP00000351190 ITIH2 527961.6 0.006 0 Y inter-alpha-trypsin inhibitor heavy chain 2  
ENSP00000418725 ITGB1 20223.9 0.011 0 Y 
integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12)  
ENSP00000269141 CDH2 4103.6 0.003 1 Y cadherin 2, type 1, N-cadherin (neuronal)  
ENSP00000257857 CD63 3186.1 0.032 4 0 CD63 molecule  
ENSP00000329797 CADM1 2304.6 0.003 1 Y cell adhesion molecule 1  
ENSP00000333298 LAMP1 1591.0 0.003 1 Y lysosomal-associated membrane protein 1  
ENSP00000231368 LNPEP 1439.2 0.031 1 0 leucyl/cystinyl aminopeptidase  
ENSP00000257879 ITGA7 1433.6 0.000 1 0 integrin, alpha 7  
ENSP00000256689 SLC38A2 910.1 0.015 11 0 solute carrier family 38, member 2  
ENSP00000268613 CDH13 900.6 0.008 0 0 cadherin 13  
ENSP00000368752 PRNP 737.3 0.024 2 Y prion protein  
ENSP00000263398 CD44 581.2 0.017 1 Y CD44 molecule (Indian blood group)  
ENSP00000382340 ABCC1 521.0 0.002 10 0 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 1  
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ENSP00000293379 ITGA5 477.1 0.002 1 Y 
integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide)  
ENSP00000230418 PTK7 231.3 0.005 1 Y protein tyrosine kinase 7  
ENSP00000261978 LTBP2 219.4 0.002 0 Y 
latent transforming growth factor beta binding 
protein 2  
ENSP00000280527 CRIM1 218.6 0.003 1 Y 
cysteine rich transmembrane BMP regulator 1 
(chordin-like)  
ENSP00000308727 SUSD5 218.1 0.001 1 Y sushi domain containing 5  
ENSP00000336888 SLC44A2 208.8 0.006 10 0 
solute carrier family 44 (choline transporter), 
member 2  
ENSP00000258733 GPNMB 202.7 0.007 1 Y glycoprotein (transmembrane) nmb  
ENSP00000256997 ACP2 198.2 0.026 1 Y acid phosphatase 2, lysosomal  
ENSP00000357190 PTPRK 197.0 0.040 1 Y protein tyrosine phosphatase, receptor type, K  
ENSP00000356787 ATP1B1 188.5 0.044 
1 
0 
ATPase, Na+/K+ transporting, beta 1 
polypeptide  
ENSP00000310206 SEZ6L2 184.0 0.041 1 Y seizure related 6 homolog (mouse)-like 2  
ENSP00000306864 VASN 180.9 0.024 1 Y vasorin  
ENSP00000348307 SIRPA 146.7 0.044 1 Y signal-regulatory protein alpha  
ENSP00000421922 LRPAP1 141.9 0.001 0 Y 
low density lipoprotein receptor-related protein 
associated protein 1  
ENSP00000320084 CD276 121.5 0.010 1 Y CD276 molecule  
ENSP00000305988 ALCAM 121.5 0.007 1 Y activated leukocyte cell adhesion molecule  
ENSG00000125730 C3 119.1 0.042 0 Y complement component 3  
ENSP00000290401 NPTN 115.6 0.002 1 Y neuroplastin  
ENSP00000378392 PSAP 111.3 0.002 0 Y prosaposin  
ENSP00000264036 MCAM 109.0 0.022 1 Y melanoma cell adhesion molecule  
ENSP00000311502 HEG1 101.8 0.003 0 0 
heart development protein with EGF-like 
domains 1  
ENSP00000331544 FBLN1 100.3 0.015 0 Y fibulin 1  
ENSP00000311402 SLC4A2 96.9 0.046 13 0 
solute carrier family 4 (anion exchanger), 
member 2  
ENSP00000228506 MLEC 96.6 0.000 1 Y malectin  
ENSP00000053867 GRN 85.3 0.013 0 Y granulin  
ENSP00000296181 ITGB5 84.8 0.001 1 Y integrin, beta 5  
ENSP00000265077 VCAN 83.4 0.003 0 Y versican  
ENSP00000295633 FSTL1 77.8 0.008 0 Y follistatin-like 1  
ENSP00000413922 ITIH3 76.7 0.024 0 Y inter-alpha-trypsin inhibitor heavy chain 3  
ENSP00000352288 PLXNB2 75.0 0.005 1 Y plexin B2  
ENSP00000318557 SLC12A4 74.5 0.013 14 0 
solute carrier family 12 (potassium/chloride 
transporter), member 4  
ENSP00000324101 CD151 72.1 0.028 4 0 CD151 molecule (Raph blood group)  
ENSP00000266718 LUM 65.3 0.001 0 Y lumican  
ENSP00000273258 ARL6IP5 60.8 0.049 4 0 
ADP-ribosylation-like factor 6 interacting 
protein 5  
ENSP00000269228 NPC1 60.7 0.009 13 Y Niemann-Pick disease, type C1  
ENSP00000347596 EFEMP1 57.1 0.004 0 Y 
EGF containing fibulin-like extracellular matrix 
protein 1  
ENSP00000333697 
TMEM17
9B 52.2 0.007 3 Y transmembrane protein 179B  
ENSP00000312506 CSPG4 44.1 0.003 1 Y chondroitin sulfate proteoglycan 4  
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ENSP00000188790 FAP 43.6 0.022 0 Y fibroblast activation protein, alpha  
ENSP00000323534 FN1 43.3 0.002 0 Y fibronectin 1  
ENSP00000262776 LGALS3BP 41.9 0.004 0 Y 
lectin, galactoside-binding, soluble, 3 binding 
protein  
ENSP00000243077 LRP1 41.5 0.001 1 Y 
low density lipoprotein receptor-related protein 
1  
ENSP00000315130 CLU 39.7 0.002 0 Y clusterin  
ENSP00000206423 CCDC80 38.8 0.001 0 Y coiled-coil domain containing 80  
ENSP00000318646 RPS15A 37.8 0.003 0 0 ribosomal protein S15a  
ENSP00000200639 LAMP2 37.6 0.004 1 Y lysosomal-associated membrane protein 2  
ENSP00000307513 MRC2 37.5 0.002 1 0 mannose receptor, C type 2  
ENSP00000261023 ITGAV 32.1 0.015 1 Y integrin, alpha V  
ENSP00000341730 RPL10 31.6 0.003 0 0 ribosomal protein L10  
ENSP00000371626 TRA2B 31.4 0.006 0 0 transformer 2 beta homolog (Drosophila)  
ENSP00000323929 A2M 30.9 0.002 0 Y alpha-2-macroglobulin  
ENSP00000333769 BSG 26.8 0.000 1 Y basigin (Ok blood group)  
ENSP00000007722 ITGA3 26.7 0.001 1 Y 
integrin, alpha 3 (antigen CD49C, alpha 3 
subunit of VLA-3 receptor)  
ENSP00000349437 IGF2R 26.5 0.003 1 Y insulin-like growth factor 2 receptor  
ENSP00000084795 RPL18 25.6 0.000 0 0 ribosomal protein L18  
ENSP00000222399 LAMB1 24.9 0.000 0 Y laminin, beta 1  
ENSP00000226359 AFP 22.1 0.013 0 Y alpha-fetoprotein  
ENSP00000252804 PXDN 21.3 0.006 0 Y peroxidasin  
ENSP00000275730 SLC12A9 20.8 0.003 13 0 solute carrier family 12, member 9  
ENSP00000359602 LMBRD1 19.6 0.013 7 0 LMBR1 domain containing 1  
ENSP00000366460 PLXDC2 19.2 0.007 1 Y plexin domain containing 2  
ENSP00000286371 ATP1B3 18.8 0.035 1 0 
ATPase, Na+/K+ transporting, beta 3 
polypeptide  
ENSP00000264896 SCARB2 15.7 0.026 1 Y scavenger receptor class B, member 2  
ENSP00000340815 SLC3A2 15.6 0.012 1 0 
solute carrier family 3 (amino acid transporter 
heavy chain), member 2  
ENSP00000327290 ITGA11 15.2 0.016 1 Y integrin, alpha 11  
ENSP00000260356 THBS1 15.2 0.002 0 Y thrombospondin 1  
ENSP00000341861 SERPING1 13.7 0.041 0 Y 
serpin peptidase inhibitor, clade G (C1 
inhibitor), member 1  
ENSP00000376899 PTGFRN 13.3 0.016 1 Y prostaglandin F2 receptor inhibitor  
ENSP00000377047 PTPRZ1 13.1 0.048 1 Y 
protein tyrosine phosphatase, receptor-type, Z 
polypeptide 1  
ENSP00000296585 ITGA2 12.1 0.003 1 Y 
integrin, alpha 2 (CD49B, alpha 2 subunit of 
VLA-2 receptor)  
ENSP00000261799 PDGFRB 11.7 0.012 1 Y 
platelet-derived growth factor receptor, beta 
polypeptide  
ENSP00000355330 TGM2 11.4 0.001 0 0 transglutaminase 2  
ENSP00000222247 RPL18A 10.2 0.001 0 0 ribosomal protein L18a  
ENSP00000344456 CTNNB1 9.1 0.000 0 0 
catenin (cadherin-associated protein), beta 1, 
88kDa  
ENSP00000272317 RPS27A 8.8 0.006 0 0 ribosomal protein S27a  
ENSP00000264832 ICAM1 6.7 0.000 1 Y intercellular adhesion molecule 1  
ENSP00000296674 RPS23 6.4 0.016 0 0 ribosomal protein S23  
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ENSP00000346015 RPL27A 5.9 0.000 0 0 ribosomal protein L27a  
ENSP00000369743 RPS6 4.8 0.001 0 0 ribosomal protein S6  
ENSP00000253788 RPL27 4.8 0.003 0 0 ribosomal protein L27  
ENSP00000416293 SLC2A1 4.5 0.010 12 0 
solute carrier family 2 (facilitated glucose 
transporter), member 1  
ENSP00000311430 RPL4 4.3 0.027 0 0 ribosomal protein L4  
ENSP00000277865 GLUD1 4.2 0.036 0 Y glutamate dehydrogenase 1  
ENSP00000345689 RAB5C 4.2 0.026 0 0 RAB5C, member RAS oncogene family  
ENSP00000363018 RPL10A 3.8 0.006 0 0 ribosomal protein L10a  
ENSP00000348849 RPS26 3.8 0.024 0 0 ribosomal protein S26  
ENSP00000225698 C1QBP 3.4 0.027 0 0 
complement component 1, q subcomponent 
binding protein  
ENSP00000346022 RPL9 3.4 0.011 0 0 ribosomal protein L9  
ENSP00000295598 ATP1A1 3.3 0.003 8 0 
ATPase, Na+/K+ transporting, alpha 1 
polypeptide  
ENSP00000379888 RPS8 3.2 0.026 0 0 ribosomal protein S8  
ENSP00000305920 GLB1 3.1 0.047 0 Y galactosidase, beta 1  
ENSP00000325136 HADHB 3.1 0.030 0 Y 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-
CoA thiolase/enoyl-CoA hydratase (trifunctional 
protein), beta subunit  
ENSP00000346027 RPL21 3.1 0.036 0 0 ribosomal protein L21  
ENSP00000366156 SRM 3.1 0.038 0 0 spermidine synthase  
ENSP00000251453 RPS16 2.5 0.040 0 0 ribosomal protein S16  
ENSP00000342070 CTSB 2.5 0.004 0 Y cathepsin B  
 
131 identified Gal-3 interactors in order of their enrichment factors in the lactose eluates of galectin 
pull-downs compared to unspecific controls. For calculation the mean of all technical replicates within 
one experiment was used. Significance was determined by Student’s t-test. Proteins with p-values of 
p<0.05, enrichment of ≥ two-fold in galectin pull-down eluates (FC ≥ 2) and additional identification in 
two or more independent pull-down experiments (n ≥ 2), were regarded as significant. The ratios 
represent the maximum fold changes of all experiments and the corresponding p-values. TMD: 
transmembrane domain. SP: signal peptide. FC: fold change. 
8.3.2. Gal-1 and Gal-3 interactors play a role in multiple binding processes and 
are mainly localized in membranes 
To analyze the cellular component distribution of the 131 identified Gal-3 and the 15 
Gal-1 interactors, GeneRanker analysis was performed (table 3) and visualized by 
FunRich classifications187 (figure 28A). Classifications to subcellular localizations of 
interactors of both galectins are equally spread. Both, Gal-1 and Gal-3 interacting 
proteins were mainly localized in membranes, exosomes and lysosomes (figure 28A). 
Gal-1 interactors are represented on the inner ring, Gal-3 interactors are represented on 
the outer ring in figure 28A. 
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Figure 28: Galectin interactors play a role in multiple binding processes and are mainly localized in 
membranes. A: Comparison of the 15 Galectin-1 interactors (inner chart) and the 131 Galectin-3 
interactors (outer chart), based on the gene ontology (GO) annotation “cellular component” in 
FunRich187. B+C: Network of Galectin-1 (B) and Galectin-3 (C) interactors, clustered by the GO term 
“molecular function” in the cytoscape app ClueGo-CluePedia188. The size of the nodes represents the 
statistical significance of the enrichment of the terms. The group heading term is the most significant 
within a group (default). The color code reflects the functional groups. The edges show the connection 
of distinct genes to specific molecular functions. Not connected to other proteins in the Gal-1 interactor 
network: LGALS3BP, LAMP2, GBA, LANCL1, MLEC, SSBP1. Not connected to other proteins in the Gal-3 
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interactor network: PLXDC2, TGM2, BSG, SRM, RAB5C, QSOX1, PTGFRN, ACP2, MCAM, LOX, LGALS3BP, 
SEZ6L2, MXRA5, NCSTN, AFP, DCBLD2, ARL6IP5, TMEM179B. 
GeneRanker analysis revealed that 7 Gal-1 interactors and 67 of the 131 identified Gal-3 
interactors are localized to the plasma membrane or on the cell surface. Additionally, 9 
of the 15 Gal-1 interactors and 71 Gal-3 interactors have at least one transmembrane 
domain, assigned by Phobius analysis (table 1 and table 2). Based on the GO term 
“molecular functions” (table 3), Gal-1 and Gal-3 interactors were clustered in the 
Cytoscape ClueGo-CluePedia188 network (figures 28B and 28C). Both, Gal-1 and Gal-3 
interactors play a role in multiple binding processes. Whereas Gal-3 interactors comprise 
functions like glycosaminoglycan and growth factor binding among others (figure 28C), 
Gal-1 interactors are more involved in integrin, collagen and fibronectin binding 
processes (figure 28B).  
Besides known Gal-1 and Gal-3 interactors like for example LAMP1, basigin (BSG) and 
different members of the integrin family, many novel interactors could be identified 
with this approach. Two of them are of great interest: the low density lipoprotein 
receptor-related protein 1 (LRP1) and the platelet-derived growth factor receptor beta 
(PDGFRB). LRP1 is involved in the regulation of growth factor homeostasis, cell migration 
and invasion and mainly acts as an endocytotic receptor191-194. In PVR, LRP1 is 
overexpressed in RPE and RMG cells194. In this study, LRP1 was identified as significant 
Gal-1 interactor with an enrichment factor of 31.1 and of 41.5 as Gal-3 interactor (table 
1 and table 2). It is known, that the PDGF receptor and LRP1 associate in endosomal 
compartments, which modulates signaling pathways like the MAPK and 
Akt/phosphatidylinositol 3-kinase pathways195. In PVR development, PDGF and PDGFR as 
key regulators of cell migration and proliferation play a significant role196. In this 
approach PDGFRB could only be identified as significant Gal-3 interactor with an 
enrichment factor of 11.7 (table 2).  
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Table 3: Galectin interactors play a role in adhesion and binding processes and are mainly localized in 
membranes. 
Gal-1 interacting proteins Gal-3 interacting proteins 
GO-Term P-value GO-Term P-value 
cellular 
components 
integral component of plasma 
membrane 6.79E-05 intrinsic component of membrane 1.70E-18 
intrinsic component of plasma 
membrane 8.02E-05 integral component of membrane 9.26E-18 
integrin alpha3-beta1 complex 9.91E-05 
intrinsic component of plasma 
membrane 7.08E-16 
receptor complex 2.51E-04 
integral component of plasma 
membrane 6.09E-14 
integral component of membrane 2.99E-04 plasma membrane part 8.46E-13 
protein complex involved in cell 
adhesion 3.01E-04 cell surface 3.11E-12 
integrin complex 3.01E-04 membrane part 4.27E-10 
external side of plasma membrane 3.17E-04 external side of plasma membrane 6.21E-10 
intrinsic component of membrane 3.60E-04 
protein complex involved in cell 
adhesion 1.12E-08 
invadopodium 5.88E-04 integrin complex 1.12E-08 
molecular 
functions fibronectin binding 2.47E-06 receptor activity 5.21E-09 
protease binding 1.19E-04 molecular transducer activity 1.44E-07 
integrin binding 1.82E-04 cell adhesion molecule binding 2.99E-07 
extracellular matrix binding 5.80E-04 collagen binding 3.54E-07 
receptor binding 6.86E-04 integrin binding 1.01E-06 
collagen binding 9.54E-04 
transmembrane signaling receptor 
activity 1.81E-05 
receptor activity 1.04E-03 glycosaminoglycan binding 3.39E-05 
cell adhesion molecule binding 1.35E-03 receptor binding 4.83E-05 
macromolecular complex binding 2.10E-03 growth factor binding 5.95E-05 
lipoprotein particle receptor 
binding 2.77E-03 
protein binding involved in cell-
matrix adhesion 8.31E-05 
      
signal 
transduction 
pathway 
associations matrix metalloproteinase 1.75E-04 integrin 1.19E-11 
integrin 1.94E-04 
low density lipoprotein receptor 
related protein 2.74E-06 
lysosomal 4.82E-04 matrix metalloproteinase 1.38E-05 
sphingomyelin phosphodiesterase 
1, acid lysosomal 2.20E-03 focal adhesion kinase 1 5.88E-05 
endocytic 9.83E-03 lysosomal 8.62E-05 
interleukin 18 (interferon gamma 
inducing factor) 1.31E-03 
platelet derived growth factor 1.42E-03 
vascular endothelial growth factor 
receptor 1.65E-03 
endocytic 3.04E-03 
lymphotoxin alpha (tnf 
superfamily) 3.77E-03 
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biological 
processes 
integrin-mediated signaling 
pathway 6.31E-05 cell adhesion 9.80E-12 
cellular defense response 1.04E-04 biological adhesion 1.88E-11 
negative regulation of Rho protein 
signal transduction 1.04E-04 extracellular structure organization 7.46E-11 
cell-substrate adhesion 1.91E-04 extracellular matrix organization 7.46E-11 
negative regulation of Ras protein 
signal transduction 3.08E-04 cell-substrate adhesion 3.27E-10 
negative regulation of small GTPase 
mediated signal transduction 3.08E-04 cell migration 1.89E-09 
formation of primary germ layer 5.91E-04 cell motility 7.36E-09 
regulation of body fluid levels 8.44E-04 localization of cell 7.36E-09 
negative regulation of intracellular 
signal transduction 8.48E-04 cell-matrix adhesion 9.67E-09 
cell adhesion 9.57E-04 locomotion 1.74E-08 
 
GeneRanker analysis of Gal-1 and Gal-3 interacting proteins based on the GO terms “cellular 
component”, “molecular function”, “signal transduction pathway associations” and “biological 
processes”.  Top ten results with the according p-values are listed. GO: gene ontology. 
8.3.3. Gal-1 induces cross-linking of LRP1, Gal-3 induces cross-linking of LRP1 
and PDGFRB including ITGB1 on the surface of RPE cells 
In order to validate LRP1 and PDGFRB as potential targets for Gal-1 and Gal-3 
continuative functional experiments have been performed. It is known that Gal-1 and 
Gal-3 can form dynamic lattices on the cell surface by cross-linking and clustering of 
transmembrane glycoproteins and thus influence many cellular processes85, 86, 102. To 
check if LRP1 and PDGFRB are involved in these galectin lattices, mesenchymal human 
RPE cells were treated with biotinylated Gal-1 or Gal-3 for 30 minutes before fixation. 
Immunocytochemical staining of these cells revealed large speckle staining patterns of 
both galectins (figures 29B1, C1, E1), LRP1 (figures 29B2, C2), PDGFRB (figure 29E2) and 
ITGB1 (figures 29B3, C3, E3) in cells treated with Gal-1 and Gal-3 compared to diffuse 
staining patterns in untreated cells (figures 29A1-A3, 29D1-D3). The staining pattern of 
ITGB1 as a known galectin interactor indicated a clear overlay with Gal-1 and Gal-3 
staining, visible by yellow speckles (figure 29B5, C5, E5). There was also a strong overlay 
of the staining patterns of Gal-1/Gal-3 and LRP1/PDGFRB, as shown by clear white 
speckles (figures 29B4, C4, E4). Cross-linking of the respective galectin, LRP1/PDGFRB 
and ITGB1 could also be verified by clear overlay of the staining patterns (figures 29B6, 
C6, E6). Without addition of exogenous galectin, no obvious cluster formation could be 
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seen (figures 29A6, D6), showing that exogenously added galectin induces the cross-
linking of the respective interactors.  
 
Figure 29: Exogenous Gal-1 and Gal-3 induce cross-linking of LRP1, PDGFRB and ITGB1 on the cell 
surface of human mesenchymal RPE cells. Immunocytochemical staining of human RPE cells, pretreated 
before fixation with or without biotinylated Gal-1 or Gal-3 for 30 min. Galectin-binding was visualized 
by Streptavidin-Alexa488 (green), LRP1 and PDGFRB by Alexa647 (magenta) and ITGB1 by Alexa568 
(red). Gal-1 and Gal-3 (B1, C1 and E1), LRP1 (B2 and C2), PDGFRB (E2) and ITGB1 (B3, C3, and E3) 
stainings show a pronounced punctuate staining pattern. Double staining of RPE cells with Gal-1/Gal-3 
and LRP1/PDGFRB as well as with Gal-1/Gal-3 and ITGB1 indicated a clear overlay of both staining 
patterns, visible by white (B4, C4 and E4) and yellow (B5, C5 and E5) spots. For visualization of the 
clustering of galectin, LRP1/PDGFRB and ITGB1, LRP1 and PDGFRB staining was changed in silico to blue 
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and the overlay is seen in white (B6, C6 and E6). Whereas exogenous addition of galectin led to clear co-
localization of LRP1 and ITGB1 on human RPE cells, no crosslinking could be seen without exogenous 
galectin (A6 and D6). Representative images from 4 independent experiments are shown. Scale bar: 
10 µm. 
8.3.4. Binding of Gal-1 and Gal-3 on LRP1 and PDGFRB is glycosylation-
dependent 
As shown before, Gal-1 and Gal-3 bind preferentially to β1,6-(GlcNAc)-branched N-
glycans (figure 18). To analyze if binding and cross-linking of Gal-1 and Gal-3 with LRP1 
and PDGFRB are dependent on complex-type N-glycan structures on the glycoprotein 
ligands, human RPE cells were treated for up to 4 weeks with 10 µM Kifunensine to 
inhibit Golgi-class I α-mannosidases197-199. Galectin-pull down experiments were 
repeated with RPE cell lysates of cells, treated with or without 10 µM Kifunensine. 
Inhibition of complex-type-N-glycosylation led to weaker binding of LRP1 and PDGFRB to 
Gal-1 and Gal-3 (figure 30).  
 
Figure 30: Complex-type N-glycosylation of Galectin-interactors is required for Galectin-binding. Gal-1 
and Gal-3 pull-down experiments with lysates of human RPE cells, treated or untreated with 10 µM 
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Kifunensine. The eluates were analysed by Western Blot with antibodies against PDGFRB and LRP1. 
10 µg of the whole cell extracts of the respective cell types were used as an input control for the pull-
down experiments and probed for GAPDH as loading control. Representative blots from three 
independent experiments are shown. 
Additionally, galectins bound less to cells treated with Kifunensine (figures 31A, C, E) and 
no lattice formation of the respective galectins with LRP1 (figures 31A4, C4), PDGFRB 
(figure 31E4) and ITGB1 (figures 31A3, C3, E3) was visible. Thus complex-type N-
glycosylation of LRP1 and PDGFRB is necessary for galectin-binding.  
 
Figure 31: Complex-type N-glycosylation of Galectin-interactors is necessary for Galectin induced cross-
linking of LRP1/PDGFR and ITGB1 on the cell surface of mesenchymal RPE cells. Immunocytochemical 
staining of human RPE cells, pretreated with 10 µM Kifunensine. Before fixation cells were pretreated 
with biotinylated Gal-1 or Gal-3 for 30 min. Galectin-binding was visualized with Streptavidin-Alexa488 
(green) (A-F), LRP1 and PDGFRB by Alexa647 (magenta) (A1-F1) and ITGB1 by Alexa568 (red) (A2-F2). 
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Overlay of LRP1/PDGFRB and galectin staining patterns is visible in white (A4-F4), overlay of ITGB1 and 
galectin staining patterns in yellow (A3-F3). For visualization of the clustering of galectin, LRP1 and 
ITGB1, LRP1 and PDGFRB staining was changed in silico to blue and the overlay is seen in white (A5-F5). 
Whereas addition of exogenous galectin led to clear co-localization of LRP1 and ITGB1 on human RPE 
cells not treated with Kifunensine (B-B5, D-D5 and F-F5), no crosslinking could be observed in RPE cells 
treated with Kifunensine (A-A5, C-C5, E-E5). Representative images from 2 independent experiments are 
shown. Scale bar: 10 µm. 
8.3.5. Endocytosis of Gal-1 and Gal-3 is glycosylation- and dynamin-dependent 
LRP1 mainly acts as an endocytotic receptor and associates with PDGFR in endosomal 
compartments. To find out whether Gal-1 and Gal-3 undergo endocytosis after 
clustering with those receptors, Gal-1 and Gal-3 were covalently coupled to NHS-
Fluorescein and ARPE19 cells were treated with those galectin-conjugates for 5, 15 and 
30 minutes at 37 °C to enable endocytosis. After trypsinisation of the cells to get rid of 
excessive Gal-1 and Gal-3, which was bound on the cell surface but not endocytosed, 
FACS analysis was performed. Both Gal-1 and Gal-3 endocytosis increased over time 
(figures 32A and B, blue lines). However, by pre-treatment of the cells with Kifunensine 
to inhibit complex-type N-glycan elongation, endocytosis of Gal-1 was completely 
inhibited and endosomal uptake of Gal-3 was decreased (figures 32A and B, red lines). 
Dynasore, an inhibitor of dynamin-mediated endocytosis by rapidly blocking coated 
vesicle formation within seconds200, decreased endosomal uptake of Gal-1 and Gal-3 
(figure 32C, black and blue lines). Transferrin was used as a positive control to verify 
dynasore-mediated endocytosis inhibition and its uptake was reduced by inhibition of 
dynamin (figure 32C, red lines).  
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Figure 32: Endocytosis of Gal-1 and Gal-3 is glycosylation- and dynamin- dependent. Flow cytometry 
analysis of Gal-1, Gal-3 and transferrin endocytosis in ARPE19 cells, untreated or treated with 10 µM 
Kifunensine or 400 µM dynasore. ARPE19 cells were treated for 5, 15 or 30 minutes with Gal-1-
Fluorescein-conjugates (A), Gal-3-Fluorescein-conjugates (B) or 30 minutes with Gal-1-, Gal-3- or 
transferrin-Fluorescein conjugates (C).  
8.3.6. Enhanced phosphorylation of ERK-1/2 and AKT-1/2/3 by binding of Gal-1 
and Gal-3 
To analyze functional and signal modulating effects of galectins on RPE cells, 
simultaneous determination of changes in phosphorylation profiles of distinct proteins 
due to galectin binding was performed. ARPE-19 cells were untreated or treated with 
Gal-1 and Gal-3 for 1, 15 or 30 minutes. Both Gal-1 and Gal-3 treatment significantly 
enhanced phosphorylation of the extracellular signal regulated kinase ERK-1/2 and the 
serine-threonine protein kinase Akt-1/2/3 (S473) (figures 33A and B). ERK-1 was 
phosphorylated at the threonine residue T202 and at the tyrosine residue Y204, ERK-2 at 
T185 and Y187. The corresponding Western Blot analysis (figure 33C) showed that 
phosphorylation of ERK1/2 was already enhanced after one minute treatment of ARPE-
19 cells with Gal-1 and Gal-3 and was still detectable after 30 minute treatment. The 
glycogen synthase kinase GSK-3α/β (S21/S9) and the proline-rich protein Pras-40 (T246) 
were also higher phosphorylated by galectin treatment (figures 33A and B).  
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Figure 33: Enhanced phosphorylation of ERK-1/2 and AKT-1/2/3 by binding of Gal-1 and Gal-3. Analysis 
of phosphorylation levels induced by Gal-1 or Gal-3 treatment. A+B: 300 µg of ARPE19 cell extracts 
untreated or treated with Gal-1 or Gal-3 for 15 minutes were incubated with a nitrocellulose membrane 
of the Human Phospho-Kinase Array. Profiling of phosphorylation levels revealed significant induction 
of ERK1/2, GSK-3α/β, Pras-40 and Akt-1/2/3 phosphorylation after treatment with Gal-1 or Gal-3. The 
amount of phosphorylated protein bound at the respective capture spot was visualized by signal 
development with chemiluminescent detection reagents (A) and mean pixel density was determined in 
duplicates (B). P-values lower than 0.05 were considered as significant (*), p-values lower than 0.01 as 
highly significant (**). C: 15 µg of whole cell extracts of ARPE19 cells untreated or treated with Gal-1 or 
Gal-3 for 1, 15 or 30 minutes were separated by SDS-PAGE (10% gels) and blotted onto PVDF 
membranes. Blots were incubated with antibodies against phospho-ERK p44/p42 and GAPDH. 
Representative blots from three independent experiments are shown. 
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9. Discussion 
 In vitro cell culture models for epithelial and mesenchymal RPE 
cells 
For studies of the physiology and pathophysiology of native tissue, cell culture models 
play an important role174. Especially investigating human RPE, where access to fresh 
native tissue is limited, suitable cell culture models are essential. Interestingly, RPE cells 
exhibit considerable phenotypic variation depending on their growth conditions32, 201. 
When cultivated in DMEM supplemented with 10% FCS at 37 °C, RPE cells lost their 
pigmentation, reduced their cell-cell contacts and changed their morphology into long, 
fibroblast-like cells during sub-cultivation (figure 15). This transition process from an 
epithelial to a mesenchymal-like phenotype is a natural process that occurs in the eye 
when the RPE is damaged to produce cells capable of propagating32, 202. Thus, cultivation 
of RPE cells on plastic in the presence of serum is an accepted in vitro model system for 
early PVR45. Here, we revealed in a proteome-wide screening approach that not only a 
complete change of phenotype, but also an entire expression level shift of 93% of all 
identified protein expression levels took place due to cultivation in vitro (figure 16). 
Accordingly, Hauck et al. 203 showed that retinal Müller glia (RMG) cells 
transdifferentiate from a multifunctional, differentiated glial cell to a dedifferentiated 
fibroblast-like phenotype in culture, which is accompanied by changes in the RMG 
proteome. Principal Component Analysis revealed that even though there was a 
biological variance in the different human samples, a clear difference in protein 
expression was visible between native and mesenchymal RPE cells (figure 16C). Yet, to 
reduce influence of biological variance and to analyze in more detail processes caused 
only by EMT, native and mesenchymal RPE cell samples deriving from the same human 
donor should be a better model. Therefore we tried to create a suitable cell culture 
method for cultivation of native RPE cells. In doing so it was important to keep the RPE 
cells in their epithelial phenotype for a long period of time – even over sub-cultivation – 
to get the required amount of cells and whole cell extracts as needed.  
Important factors influencing the severity and speed of morphologic changes are for 
instance cell culture medium composition, freshness of the cells when isolated from the 
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tissue, cell seeding density, incubation conditions and passage number32. In this study 
the influence of these parameters was analyzed in detail. Different cell culture media 
with different FCS concentrations were tested to prevent EMT processes of freshly 
isolated RPE cells. MEMα supplemented with non-essential amino acids, N1 supplement 
and a mix of triiodo-thyronine, hydrocortisone and taurine was described in the 
literature as suitable culture medium of RPE cells174. As shown in Maminishkis et al. 174, 
RPE cells exhibited a confluent monolayer, an epithelial morphology with apical 
membrane microvilli and pigmentation, when cultivated in MEMα. Various tight junction 
proteins could be identified and VEGF was mainly secreted on the basal side, whereas 
PEDF was mainly secreted into the apical space174. In this study, cultivation of RPE cells 
in MEMα resulted in strong morphologic changes and RPE cells didn’t attach to the 
surface of the cell culture dishes (figure 20). Yet, Maminishkis et al. 174 worked on the 
one hand with fetal RPE samples and on the other hand RPE cells were cultivated on cell 
culture inserts with extracellular matrix from human placenta as substrate coatings. 
Fetal RPE cell samples are not directly comparable with the human cadaver eyes of 
organ donors of unknown age, which we used in this study, regarding freshness and age-
related tissue transformation. Furthermore Maminishkis et al. 174 subcultivated RPE cells 
only once and used the confluent monolayer, which arose after 3 to 4 weeks, for further 
experiments. We also tried to cultivate native RPE cells on cell culture inserts and 
epithelial phenotype was kept for a distinct time, but by this cultivation technique it is 
not possible to get the required amount of cells and whole cell extracts for FACS 
analysis, functional scratch-assay set-ups, MS-based analyses, Western Blot validation 
and analysis of signal modulating effects as needed in this approach, because in most of 
the experiments different conditions (e.g. treatment with galectins or N-glycan synthesis 
inhibitors) had to be analyzed in parallel. Unfortunately, MEGM, which is often used for 
different kinds of mammary epithelial cells204, was also not suitable for long-lasting 
native RPE cell cultivation.  
Another important parameter for RPE cell cultivation is the amount of FCS added to the 
medium205. FCS is the most widely used primary medium supplement for cell cultures. It 
contains several important ingredients like albumin, antichymotrypsin, apolipoproteins, 
biotin and growth stimulatory factors205, 206. As complex natural product, FCS may vary 
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from different manufacturers but also from lot to lot even from a single producer205. 
Exact composition as well as quality, type, and concentration of the components of FCS 
lots is not completely revealed, but has an immense influence on cellular processes 
during cell cultivation205, 207. Growth stimulatory factors including TGFβ and other 
growth factors contained in FCS trigger EMT and thus negatively affect maintenance of 
native epithelial morphology. Regarding RPE cell culture, RPE cells didn’t attach to the 
surface of the cell culture dishes, they died and strong morphologic changes took place, 
when no FCS was added to the medium (figure 20).  
Dedifferentiation and morphologic changes of RPE cells are also very dependent on cell-
cell contacts. Disruption of such contacts triggers EMT, whereas intact and close cell-cell 
contacts maintain the epithelial phenotype of cells43, 45. In the RPE cell isolation protocol 
we used in this study, RPE cells were loosened and thus cell-cell-contacts were totally 
disrupted. Tamiya et al. 43 showed that mainly loss of cell-cell contacts initiates EMT in 
RPE cells and that TGFβ2 treatment promote EMT, but it has no effect on RPE cells when 
cell-cell contacts are retained. Therefore we seeded RPE cells at high cell densities, 
because cell culture conditions with lower cell densities enabled higher degrees of cell 
spreading and faster dedifferentiation of the cells. Establishing a stable cell culture 
model of epithelial RPE cells remains consequently challenging. By isolation of RPE cells 
from their native monolayer and following cultivation in cell culture dishes in DMEM 
(high glucose, pyruvate), which needs to be supplemented with a modest amount of FCS 
to verify cell attachment and growing, RPE cells are exposed to many different factors 
that trigger EMT.  
Therefore we tested different EMT-inhibitors: ROCK Inhibitor Y-27632, TGF-β inhibitor 
SB 431542 and Forskolin and added them to the standardly used DMEM supplemented 
with 10% FCS. We could show that we can prevent the transition to a mesenchymal 
phenotype of RPE cells by EMT-inhibitors verified by clear E-Cadherin expression even 
upon several sub-cultivation cycles and higher passage numbers (figure 21). All of the 
three different used EMT-inhibitors had different points of action in EMT signaling 
processes.  
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The TGFβ inhibitor SB 431542 inhibits activin receptor-like kinase (ALK)5, which is the 
TGF-β type I receptor208. Besides, it inhibits also ALK4 and ALK7, but no other ALK family 
members208. Thus, SB 431542 is a specific inhibitor of TGFβ signaling and endogenous 
activin, but does not interfere with ERK, JNK or p38 MAPK pathways208. TGFβ has a 
predominant role in EMT induction209 and TGFβ is often overexpressed as tumors 
evolve, which induces EMT of tumor cells, but TGFβ signaling can either suppress or 
promote tumor growth depending on the type of cancer210. Therefore, TGF-β receptor 
kinase inhibitors have been tested in preclinical studies as anti-tumor agents. Halder et 
al. 211 observed that SB 431542 inhibits TGF-β-induced transcription, gene expression, 
apoptosis, and growth suppression and attenuates the tumor-promoting effects of TGF-
β, including TGF-β-induced EMT, cell motility, migration and invasion, and vascular 
endothelial growth factor secretion in human cancer cell lines. In the vitreous of patients 
suffering from PVR TGFβ is overexpressed and present in the PVR membranes212, 213. The 
concentration of TGFβ2 correlates with the severity of PVR and contractility of PVR 
membranes30, 212. Intravitreal injection of TGFβ1 in combination with fibronectin induced 
increased formation of tractional retinal detachments and intraocular fibrosis in 
rabbits212. By blocking TGFβ signaling EMT processes could be inhibited as shown in 
many approaches214, 215. In our in vitro model SB 431542 was able to prevent phenotype 
transition of RPE cells (figure 21).  
Besides TGFβ itself we targeted a kinase downstream of TGFβ signaling: the ROCK 
kinase. EMT induced by TGFβ is mediated by a RhoA-dependent mechanism216. ROCK 
kinases are involved in proliferation, differentiation and apoptosis and play central roles 
in the organization of the actin cytoskeleton and thus are favored targets for the 
treatment of several human diseases217. Das et al. 218 showed for instance that a 
combination of ROCK inhibitor Y-27632 and TGF-β inhibitor SB 431542 led to reduced 
mesenchymal gene expression and increased E-Cadherin expression in renal tubular 
epithelial cells, which underwent EMT before. Reversal of EMT required both TGF-β 
inhibitor and ROCK inhibitor to re-establishing epithelial transcription and structural 
components218. Combinations of Y-27632, SB 431542 and Forskolin have also been 
tested in this study to prevent EMT of RPE cells (data not shown). Yet, combinations 
thereof were less successful in preventing EMT than single agents. In diverse studies the 
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inhibitory effect of Forskolin to TGFβ induced EMT could be shown in different cell 
types219, 220. Forskolin is a cAMP-elevating agent. It directly activates adenylate cylase to 
generate cAMP from ATP221. cAMP signaling has shown a number of antitumor effects, 
including the induction of mesenchymal-to-epithelial transition, inhibition of cell growth 
and migration220, 222. Concerning ophthalmology, forskolin has an antiglaucoma activity 
and is used as eye drops to reduce the intraocular pressure in clinical trials222, 223. 
Forskolin prevented in our study EMT of RPE cells in vitro (figure 21).  
Concluding, a lot of effort was invested in establishing suitable cell culture models for 
human native tissue that is only limited available. Of course, it always has to be 
considered that every cell culture model is only a simulation of natural processes and 
many factors during cultivation need to be considered32. Pathological and physiological 
processes are very complex and hard to mimic in vitro under cell culture conditions. A 
transformed cell culture is for example characterized by such morphologic and growth 
changes that presumably make the cells too different from naturally transformed RPE. 
Yet, cultivated mesenchymal RPE cells mimic status of early PVR and thus those cells 
have been used to identify galectin interactors and analyze functional effects of galectins 
on RPE cells. Keeping RPE cells after isolation from their native tissue with their natural 
epithelial properties is very difficult as shown here. All three tested EMT-inhibitors 
stabilized the epithelial phenotype of native RPE cells. Yet the drawback of this cell 
culture model was that the glycosylation pattern didn’t correlate to the pattern of native 
RPE cells as further discussed.  
 EMT in correlation with glycomic surface fingerprint 
EMT is mainly driven by extracellular growth factors such as transforming growth factor-
β (TGF-β), hepatocyte growth factor (HGF) and epidermal growth factor (EGF), but also 
by overexpression of transcription factors like for example SNAIL, SLUG and TWIST1 and 
intracellular signals of NFκB or WNT signaling activation for instance41, 42, 224. EMT is 
known to be accompanied by an aberrant expression of glycans for example in cancer 
development and progression225. Here, we could verify that in RPE cells a glycomic shift 
to complex-type β1,6-branched tri- and tetraantennary N-glycans took place upon EMT 
and that Gal-1 and Gal-3 bind preferentially to mesenchymal RPE cells (figure 18). In the 
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diversified field of glycan structures resulting from chain extensions with fucose, sulfate, 
polylactosamine or sialic acid residues as well as from glycan branching and modification 
by methylation or acetylation, only a small part of different glycan structures were 
analyzed here. Nevertheless our findings indicated that the glycomic profile of human 
RPE cells underwent a profound reorganization upon EMT in vitro116. And the finding 
that EMT is accompanied by an increase in complex-type N-glycan structures on the cell 
surface is consistent with other studies, showing a tissue-specific correlation of β1,6-
(GlcNAc)-branched N-glycans accumulation and carcinoma progression226-229. In 
correlation to that, the Golgi β1,6N-acetylglucosaminyltransferase V (Mgat5), which is 
required in the biosynthesis of β1,6-(GlcNAc)-branched N-linked glycans, is upregulated 
in different pathological processes and may correlate with disease progression227, 228. In 
Priglinger et al. 116 we could show an upregulation of Mgat5 upon EMT of RPE cells. Yet, 
the knowledge about molecular mechanisms that explain the correlation of altered 
glycan patterns in context of EMT is very limited225. Demetriou et al. 228 assumed based 
on their findings that β1,6-GlcNAc branching of N-linked oligosaccharides directly 
contributes to growth controls and reduces substratum adhesion in premalignant 
epithelial cells. Thus, inhibition of Mgat5 might be useful in the treatment of 
malignancies, as also described in Granovsky et al. 227. Still, Mgat5 is also named as a 
suppressor of both EMT and invasion in human lung cancer cells230. In the eye, 
Saravanan et al. 231 observed an increase of β1,6-GlcNAc branching and a 
downregulation of Mgat3 in healing corneas while Mgat5 expression was not changed. 
Mgat3 is also a Golgi N-acetylglucosaminyltransferase, which introduces bisecting 
β1,4GlcNAc and thereby suppresses β1,6GlcNAc branching by Mgat5. Thus, regulatory 
mechanisms for glycan expression seem to be tissue-specific and presumably different in 
both malignant and non-malignant tissues. In this study we could show that by 
treatment of RPE cells with N-glycosylation inhibitors the phenotype and thus EMT 
processes couldn’t be influenced (figure 21). In more detail, by inhibition of α-
mannosidase by treatment of the cells with Swainsonine directly after isolation, 
complex-type N-glycan synthesis could be prevented, but transition to a mesenchymal 
phenotype of RPE cells during cultivation could not. On the other hand, we could 
prevent the transition to a mesenchymal phenotype of RPE cells by EMT-inhibitors such 
as ROCK Inhibitor Y-27632, TGF-β inhibitor SB 431542 or Forskolin, yet a glycan change 
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to complex-type N-glycans nevertheless took place (figure 21). This leads to the 
conclusion that change of phenotype and change to an aberrant glycan-structure on the 
cell surface during EMT are independent multifactorial processes that can’t be 
controlled by intervening single growth-factor pathways or single glycosyltransferase 
activities.  
Galectins as carbohydrate-binding proteins with distinct glycan specificities could be the 
missing link between the complex-type N-glycans of cell surface glycoproteins and 
aberrant behavior of cells in malignant tissue. In previous studies, it could be shown that 
Gal-1 and Gal-3 are overexpressed in mesenchymal RPE cells and exogenously added 
Gal-1 and Gal-3 inhibit carbohydrate-dependent attachment and spreading of 
mesenchymal RPE cells113, 114, 117. Whether there is a link between the expression 
regulation of galectins and a glycomic shift on the cell surface to enhance galectin-
binding and thus accessibility to galectin-induced functional effects, was also analyzed in 
this study and will be discussed later in detail. Unfortunately, no direct influence of 
galectin knockdown on cellular behavior or glycomic structures was amenable. Even 
though it is not fully clarified yet, if and how altered glycan patterns influence EMT 
processes, the changed glycan-structures on the cell surface of mesenchymal RPE cells 
can have a useful prognostic value with respect to identify early stages of PVR229.   
 Functional impact of galectin in context of PVR 
Most galectin ligands are branched N-glycans on transmembrane proteins120. Of note, 
these glycans are upregulated during EMT of human RPE cells and these changes lead to 
increased binding of Gal-3 to mesenchymal RPE cells (figure 18)116. Consequently it can 
be assumed that EMT sensitizes the susceptibility of cell surface receptors to galectins 
and that complex-type-N-glycan structures are very important for galectin binding. 
Analyzing the mechanisms of these glycan-galectin interactions will provide evidence 
whether these glycan structures are a prerequisite for galectin binding and how they 
influence interaction processes. Here we could show that Gal-1 and Gal-3 inhibit 
migration of RPE cells carbohydrate-dependent (figure 24). In previous studies, it could 
be shown that Gal-1 and Gal-3 inhibit carbohydrate-dependently the attachment and 
spreading of mesenchymal RPE cells113, 114, 117. By elimination of complex-type β1,6-
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(GlcNAc)-branched N-glycans due to mannosidase inhibitor treatment, those cellular 
effects of galectins on RPE cells were reversed, pointing out the importance of glycomic 
structures of galectin interactors. Accordingly, we found that complex-type-N-
glycosylation of the identified galectin interactors LRP1 and PDGFRB is required for 
galectin-binding and lattice formation on the RPE cell surface (figures 30, 31). A direct 
influence of galectins on prevention of EMT processes couldn’t be proven here (figure 
21). Yet, this can also strengthen the hypothesis that specific glycomic fingerprints are 
necessary for functional galectin binding, because binding on epithelial RPE cells is very 
weak due to lack of complex-type N-glycans.  
Even though all members of the galectin family bind to galactose-β1,4-N-
acetylglucosamine, it is assumed that the structural differences in their CRD domains not 
only lead to different specificities for distinct glycoproteins, but also to distinct biological 
activities73-75. Whereas Gal-1 induces apoptosis in several cell types, Gal-3 is associated 
with antiapoptotic effects 76, 77. Yet, binding to different interactors does not necessarily 
mean that different downstream mechanisms are influenced. Gal-1 and Gal-3 can bind 
to distinct receptors but converge on similar downstream signaling in several analyses 
for induction of T cell death73 or of neutrophil respiratory burst79. This assumption is 
further underscored by the finding that Gal-1 and Gal-3 don’t show synergistic effects 
with respect to inhibition of RPE cell attachment and spreading when added 
simultaneously, suggesting that they may occupy a similar subset of cell surface 
receptors114. 
Interactome study revealed that Gal-1 and Gal-3 interactors are distributed in the same 
cellular components, mainly in membranes, and play a role in multiple binding processes 
(figure 28). GeneRanker analysis showed that both Gal-1 and Gal-3 interactors are 
involved in cell adhesion processes (table 3). Gal-3 interactors also play a role in ECM 
organization and cell migration, while Gal-1 interactors are involved in integrin-mediated 
signaling pathways. With respect to PVR, these biological processes are the key cellular 
processes in disease development, which is characterized by adhesion, migration and 
EMT of RPE and RMG cells2, 5, 11. The data monitored by our gene ranker analysis are of 
particular interest since target proteins of both Gal-1 and Gal-3 may play a role in the 
pathogenesis of PVR and thus be instrumental for influencing the disease process in 
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terms of a therapeutic approach. From recent studies it became evident that PVR is a 
multifactorial cellular process that can’t be attenuated by inhibition of single growth 
factors and their downstream signaling pathways or by anti-inflammatory or anti-
proliferative approaches alone24-31. As seen from our data, Gal-1 and Gal-3 may have the 
ability to orchestrate several cellular processes involved in PVR development 
simultaneously by interacting with a variety of distinct cell surface interactors, and thus 
provide a multimodal therapeutic concept. 
 Influence of intracellular expression of Gal-1 and Gal-3 on glycomic 
surface fingerprints 
In former studies, it was found that only Gal-1, Gal-3, Gal-8 and Gal-9 are expressed in 
human RPE cells and only those galectin isoforms are able to bind to the RPE cells 
surface exogenously (data unpublished). We also found that Gal-1 and Gal-3 are 
upregulated in mesenchymal RPE cells compared to native RPE cells with an epithelial 
phenotype (figure 25) and could thereby verify former results113. One objective of this 
work was to find out, if there is a link between the expression of galectins and the 
induction of a glycomic shift on the cell surface to thereby enhance galectin-binding and 
thus galectin-induced cellular events. Cao et al. 190 describe that exogenous Gal-3 
stimulates re-epithelialization of corneal wounds in wildtype mice but not in Gal-3 
knockout mice190. Intracellular Gal-3 may thus contribute significantly to the process of 
wound healing190. Yet, whether intracellular Gal-3 influences the expression of specific 
cell surface or ECM receptors, which in turn influence cell-matrix interactions and cell 
migration, or whether Gal-3 has a direct or indirect influence on glycan patterns of these 
receptors and thus on specific lectin binding, remains to be solved190. Modulated 
expression levels of galectins can be associated with pathological conditions like in 
cancer, fibrosis and inflammation66, 68, 81. Interestingly, mainly those cell types, that 
express low levels of galectins under normal physiological conditions, overexpress 
galectins in disease state66, 68, 81. In contrast to that, when cells normally express high 
levels of a specific galectin isoform, these galectins are downregulated when those cells 
become abnormal66. In breast carcinoma cells for instance Gal-3 was stably 
overexpressed and this was accompanied by increased levels of integrins and enhanced 
adhesion to laminin, fibronectin and vitronectin, which were known binding proteins of 
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Gal-3232, 233. Mucin2, which is also a major ligand of Gal-3, was overexpressed after 
transfection of a colon cancer carcinoma cell line with Gal-3234. Cao et al. 190 showed that 
the stimulatory effect of exogenous Gal-3 on re-epithelialization of wounds is inhibited 
by lactose, which gives a hint that intracellular expression of Gal-3 might have a 
regulatory effect on the glycosylation of proteins, which serve as galectin-ligands. 
Interaction of Gal-3 with nuclear matrix as well as DNA and RNA was proven and 
presumably explains how Gal-3 can influence complex biological processes110, 235. 
Unfortunately, we could not verify any dependencies between intrinsic galectin-
expression and external galectin reaction in RPE cells (figure 25). Stable knock-down of 
Gal-1 and Gal-3 was induced by the LentiCRISPR/Cas9 system in ARPE19 cells and could 
be verified by Western Blot analysis. By FACS analysis we tested binding of Gal-1 and 
Gal-3 on uninfected, Gal-1 ko and Gal-3 ko cells and couldn’t reveal any changes in 
galectin binding by galectin knockdown. To check for changes in complex-type N-
glycosylation on the cell surface induced by galectin, binding of the plant lectin PHAL 
was also investigated. Neither change in galectin-binding nor in glycosylation structures 
could be revealed by knockdown of Gal-1 and Gal-3. Concluding, intracellular expression 
of Gal-1 and Gal-3 may have influences on other cellular processes but not on complex-
type N-glycosylation processes in RPE cells.  
 Interactors of Gal-1 and Gal-3 
A proteome-wide interaction study was designed to identify specific interactors for Gal-1 
and Gal-3 on mesenchymal RPE cell surfaces to get deeper insights in the functional 
effects of galectins on RPE cells in context of PVR. It resulted in a total of 131 significant 
Gal-3 interacting binding partners while only 15 proteins remained as significant Gal-1 
ligands (figure 27). The unequal number of interactors can be explained by structural 
differences of Gal-1 and Gal-3 in their CRD domains. Gal-3 is the only known chimera 
type galectin and it cross-links glycoproteins by its C-terminal domain and multimerizes 
by its N-terminal domain after binding to saccharide ligands82, 102. In contrast to that, 
Gal-1 consists of one CRD and can form homodimers by its N-terminal domain61, 84, 87, 88. 
The rigid dimeric structure of Gal-1 and the flexible pentameric Gal-3 structure can 
reason the different numbers of glycoprotein ligands. The pentameric form of Gal-3 may 
facilitate to bind more different glycoprotein receptors on the RPE cell surface. Stillman 
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et al. 73 showed for instance, that lower concentrations of Gal-3 are required to trigger T 
cell death than of Gal-1, suggesting that Gal-3 is able to bind more ligands 
simultaneously.  
By coupling of galectins to sepharose beads, physiological multimerization is presumably 
hindered and this conformation change might influence the ability of the CRD domain to 
bind glycoproteins. However, the binding activity of Gal-1 and Gal-3 after coupling to the 
beads was confirmed by incubation with asialofetuin, a known interactor via β-
galactoside moieties (figure 26). In vivo, ligand binding occurs at the CRD domain while 
multimerization of galectins and formation of cross-linked lattices is triggered by the N-
terminal domain (figure 6)102, 109. Consequently, multimerization is in vivo not important 
for recognition of specific ligands and coupling of galectins to beads should not generally 
hinder identification of galectin interactors. However, we can’t exclude a different 
behavior of Gal-1 and Gal-3 with respect to forced monomerization through bead 
coupling, but Gal-1 and Gal-3 pull-down experiments were done in parallel under the 
same conditions with the same RPE cell lysates and multimerization is at least equally 
important for Gal-3 as compared to Gal-1. Thus, we assume that the lower numbers of 
Gal-1 interactors are not due to technical limitations, but rather reflect a reduced 
spectrum of interactors.  
Nevertheless, the identified Gal-1 and Gal-3 interactors have many common features. 
They are distributed in the same cellular components, mainly in membranes, and play a 
role in multiple binding processes (figure 28). In the analysis of galectin-interactors in 
whole RPE cell lysates, both intra- and extracellular interactors were revealed. It is 
known, that Gal-1 and Gal-3 are present both inside and outside the cell, and that Gal-1 
and Gal-3 interact also with intracellular proteins. For example, they are involved in 
processes like pre-mRNA splicing110, 236, but these processes are assumed to be based on 
protein-protein interactions rather than carbohydrate-lectin interactions on the cell 
surface or extracellular matrix (ECM)66. In this approach, interacting proteins were 
eluted with ß-lactose to verify carbohydrate-dependent binding on Galectins. Thus, we 
are focusing on the Gal-1 and Gal-3 interactors on cell-surface and ECM. Seven Gal-1 
interactors and 67 of the 131 identified Gal-3 interactors are localized in plasma 
membrane or on the cell surface, based on GeneRanker analysis (table 3). Figure 28 
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shows the distribution of the identified interactors on cellular components. Most of the 
interactors are localized in membranes, the extracellular space or intraluminal, 
validating that this approach mainly pulled down the carbohydrate-dependent 
interacting ligands.  
Several galectin interactors in different cell types are known so far141. Gal-3 interacts for 
instance with EGFR and TGF-βR in tumor cells124, 237. Both, Gal-1 and Gal-3, bind to β1-
integrins118, 238, 239 and extracellular matrix molecules like fibronectin and laminin94, 130, 
240. Besides, Gal-1 and Gal-3 can also bind to immune cell glycoproteins and to neural 
recognition molecules73, 76, 122, 241-244. ITGB1 and CD147 (BSG), the two previously 
identified counter-receptors for Gal-3 in RPE cells were confirmed with this approach118. 
Additionally, known interactors of Gal-1 or Gal-3 like laminin94, 130, LAMP1 and LAMP2245 
and integrins118, 238, 246 among others were confirmed. Most of these interactors were 
identified in distinct cell types, but not in RPE cells. Thus we could on the one hand 
confirm several of the known interactors in RPE cells, and on the other hand identify 
many new so far unknown interactors.  
9.5.1. LRP1 and PDGFRB as galectin interactors 
For validation we focused on two novel identified Gal-1 and Gal-3 interactors: LRP1 and 
PDGFRB. LRP1 (or CD91) is a 600kDa glycoprotein, consisting of an extracellular and a 
transmembrane domain247, 248. LRP1 recognizes at least 30 different ligands, among 
others lipoproteins249, the β-amyloid precursor protein191, and the protease inhibitor α2-
macroglobulin (α2M), which is responsible for the clearance of several growth factors 
and cytokines like for example TGF-β250-252. LRP1 recognizes extracellular ligands and 
induces endocytosis for degradation by lysosomes193. Thus, it is assumed that LRP1 also 
plays a significant role in the clearance of α2-M-associated growth factors and could 
potentially be involved in pathologic events during PVR development194. Hollborn et al. 
194 found that LRP1 mRNA levels are upregulated in human RPE cells, stimulated with 
TGF-β1, TGF-β2 or VEGF. They hypothesize that protease treatment aiming to induce 
α2M-mediated clearance of growth factors accompanied by increased LRP1-mediated 
endocytosis is a potential treatment strategy for PVR194. Yet, in PVR RPE and RMG cells 
are exposed to high amounts of growth factors and cytokines. Though Milenkovic et al. 
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253 found that α2M inhibited RMG cell proliferation, it remains unclear, whether it is 
possible to clear most of these growth factors by α2M activation or by intravitreal 
addition of α2M. It is also known that several signaling pathways - including ERK/MAPK, 
Akt and NF-κB - are activated by binding of α2M to LRP1 in distinct cell types including 
macrophages and RMG cells. Bonacci et al. 254 found that proliferation and MAPK-
ERK1/2 activation in a macrophage-derived cell-line is induced by binding of α2M to 
LRP1. They could verify that α2M promotes expression and secretion of matrix-
metalloproteinase MMP-9, which was also mediated by MAPK-ERK1/2 and NF- κB255. 
α2M activates also glial fibrillary acidic protein (GFAP) expression in RMG cells induced 
by LRP1, which is assumed to be mediated by the JAK/STAT signaling pathway256. 
Barcelona et al. 257 found that α2M - mediated by LRP1 - induces RMG cell migration by 
regulating MT1-MMP activity. We show here that α2M is a significant Gal-3 interactor 
with an enrichment factor over 30.9 and a p-value of 0.002 (table 2). Which effect 
binding of Gal-1 and Gal-3 on LRP1 or α2M has on cellular processes of RPE cells, 
remains to be solved.  
Interestingly, LRP1 can be tyrosine phosphorylated by the growth factor receptor 
PDGFR, which in turn regulates its activity by endocytosis and intracellular trafficking of 
LRP1258-260. Thus, LRP1 is predicted to interact as a co-receptor that modulates PDGFR 
initiated signal transduction pathways, like for example the control of cell migration258-
260. In this study, we identified Galectin-induced cross-linking of Gal-1 or Gal-3 with LRP1 
and ITGB1 and of Gal-3 with PDGFRB and ITGB1 (figure 29). PDGF and its receptor 
PDGFR are expressed in RPE and glial cells and are assumed to contribute to PVR 
development17. PDGF exists as a 30kDa dimer and it is distinguished between PDGF-AA, 
PDGF-BB, PDGF-AB, PDGF-CC and PDGF-DD. PDGF receptors also exist as α and β forms 
and can homo- and heterodimerize, resulting in the formation of PDGFR-αα, PDGFR-ββ 
and PDGFR-αβ261. Both PDGF and PDGFRs are present in epiretinal membranes isolated 
from patients with PVR and PDGF in vitreous is associated with PVR in clinical studies15, 
262, 263. PDGFs are the most abundant of all growth factors present in the vitreous of PVR 
patients22, 264. Blocking PDGFR reduced PVR associated cellular responses, but 
neutralizing PDGF failed to prevent PVR in vitro, because PDGFR is activated not only by 
PDGF but also by non-PDGF agents (like Insulin, EGF, FGF, HGF)14, 196. This indirect 
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activation of mainly PDGFRα by non-PDGFs is assumed to also involve reactive oxygen 
species (ROS) and a Src family kinase (SFK)14, 264. Taken together, it is assumed that 
activation of PDGF receptors and their signaling pathways play an important role in PVR 
development and thus they are attractive as a potential target to prevent development 
of PVR, but direct evidence of the influence of PDGFR among other factors for PVR 
remain to be elucidated22.  
 Galectin multimerization, lattice formation and signal transduction 
Galectin-glycoprotein lattices play major roles in regulating cell functions: organizing 
membrane domains, regulating the signaling threshold at the cell surface and 
determination of receptor residency time by inhibition or induction of endocytosis265. 
The galectin lattice also regulates the receptor kinase signaling and the functionality of 
membrane receptors including integrins72. Here we identified Galectin-induced cross-
linking of Gal-1 or Gal-3 with LRP1 and ITGB1 and of Gal-3 with PDGFRB and ITGB1 
(figure 29). The galectin-lattice regulated the distribution of glycoproteins at the cell 
surface. In cells treated with Gal-1 and Gal-3 large speckle staining patterns of both 
galectins, LRP1, PDGFRB and ITGB1 were revealed, whereas in untreated cells staining of 
these glycoproteins was more diffuse (figure 29). Thus, the galectin lattice is 
characterized by a phase transition from soluble complexes to a dynamic microdomain 
assembled as a gel-like polymer which orders glycoproteins on the cell surface102, 266. 
Besides, the galectin lattice is an additional layer of membrane organization, because N-
glycans on extracellular domains are often flexible and extend hundreds of Ångstroms 
away from the plasma membrane72. Chimera or tandem-repeat galectins are often more 
potent in lattice-formation and triggering cell responses than prototype galectins267. 
Compared to Gal-1, Gal-3 forms heterogenous, disorganized cross-linking complexes102. 
Yet, it is assumed that different galectin isoforms can compete or cooperate in lattice 
formation or might form segregated lattices, but about this phenomenon little is known 
so far72. 
The affinity of glycoproteins to the galectin lattice is dependent on the number and 
branching of their N-glycans and thus on the activity of Golgi N-
acetylglucosaminyltransferase-branching enzymes72, 268. Here we could show that 
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galectin lattice formation was N-glycan dependent. By treatment of cells with 
Kifunensine no cluster formation occurred any more (figure 31). The number of Asn-x-
Ser/Thr (NxS/T) N-glycan sites is proportional to the affinity of transmembrane 
glycoproteins for the galectin lattice105, 268, where x can be any amino acid except 
Proline. Because of the broad heterogeneity of N-glycan-branching pathways and the 
resulting diverse NxS/T sites in glycoproteins, the number of potential galectin-binding 
glycoforms can become very large72. Lau et al. 268 showed in a computational approach 
that the number of NxS/T in mammalian receptor kinases varies considerably, but 
receptor kinases involved in growth, oncogenesis and proliferation (e.g. EGFR) have by 
trend more NxS/T sites and longer extracellular domains. Receptors that mediate 
vasculature formation, organogenesis, differentiation and cell cycle arrest (e.g. TGFβ) 
have in general lower N-glycan multiplicities268. Thus, the glycome seems to have 
functional implications at the cellular level, because receptors with only one or few 
glycosylation sites are below the threshold for lattice association, whereas receptor 
kinases with five or more glycosylated sites are largely associated with the galectin 
lattice72, 268. Interestingly, activation of EGFR, which is equipped with eight N-glycans, 
stimulates for instance UDP-GlcNAc biosynthesis and enhances positive feedback to 
hexosamine/N-glycan processing72, 268. This leads to the recruitment of TGFβR (with two 
N-glycans) into the galectin lattice and induction of EMT processes72, 268. Therefore we 
assume that glycan structure is primarily important for functional effects of galectins on 
diverse cells.  
Interestingly, Gal-1 also induced clustering of PDGFRB and ITGB1 (data not shown), even 
though PDGFRB was not identified as Gal-1 interactor by the pull-down experiments, 
giving a hint that Gal-1 not only forms lattices with specific interactors, but larger 
interacting protein complexes might be included. The experimental set-up with the 
galectin pull-down assays results in an initial set of galectin interactors, but does not 
allow distinguishing between direct and indirect galectin interactors, which is a general 
problem in interactome studies based on pull-down approaches. The identified galectin 
interactor LRP1 is an endocytotic receptor and associates with PDGFR in endosomal 
compartments. Here we wanted to investigate, if Gal-1 and Gal-3 are endocytosed in 
RPE cells or if the galectin isoforms are retained on the cell surface due to clustering 
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with cell surface receptors. FACS analysis of Gal-1 and Gal-3 endocytosis studies 
revealed that Gal-1 and Gal-3 are endocytosed increasingly over time (figure 32). Many 
different theories of galectin endocytosis have been described and endocytosis 
processes seem to be different in distinct cell types. It is assumed that endocytic uptake 
of Gal-3 can be both carbohydrate-dependent and independent in different cell types 
and Gal-1 endocytosis is mediated with clathrin-coated vesicles but also by raft-
dependent endocytosis 269, 270. Straube et al. 271 showed that Gal-3 enters epithelial 
MDCK cells at the apical membrane via non-clathrin mediated mechanism and traverses 
endosomal organelles from where it is recycled back to the cell surface. Here, the 
analyzed endocytosis processes of Gal-1 and Gal-3 were both carbohydrate- and 
dynamin-dependent. Yet cellular mechanisms that are involved in galectin-uptake are 
poorly understood271. In the literature, many approaches describe that galectins 
determine receptor residency time by inhibition or induction of endocytosis. Markowska 
et al. 123 found that Gal-3 phosphorylates VEGFR2 in endothelial cells and retains the 
receptor on the plasma membrane, while in Mgat5 and Gal-3 knockout cells VEGFR2 was 
internalized. Gal-3 also interacts with EGF and TGF receptors by Mgat5-modified N-
glycans and delays their endocytic removal, which results in promoting EGF and TGF 
signaling124. In breast carcinoma cells, Gal-3 for example mediates the endocytosis of 
ITGB1 in a lactose-dependent manner129, 271.  
In depth characterization of downstream signals influenced by Gal-1 and Gal-3 
interaction with the identified glycan-dependent interactors will provide more insight 
how galectins modify RPE cell behavior. By simultaneous screening of changes in 
phosphorylation profiles of distinct protein kinases, we could show that both ERK/MAPK 
and Akt signaling pathways are affected by galectin binding (figure 33). ERK 
phosphorylation was stable up to 30 minute after galectin treatment. Akt, which is also 
called protein kinase B, is one of the main downstream targets of the 
phosphatidylinositol (PI) 3-kinase pathway272, 273. GSK-3α/β and Pras-40 are substrates of 
Akt272-274 and accordingly, both were also phosphorylated after galectin treatment. Since 
it is known that LRP1 and PDGFRB associate in endosomal compartments and affect 
MAPK and Akt/PI 3-kinase pathways195, we assume that galectin induced cluster 
formation of LRP1, ITGB1 and PDGFRB on the cell surface have an influence on those 
Discussion 
 
   123 
 
signaling pathways in RPE cells. In many biological systems of autoimmune disease, T-
cell development and cancer cell biology, it is described that clustering of ordered arrays 
of galectins and their glycoprotein ligands on the cell surface is required for cellular 
signaling and adhesion processes72. The interplay between the different ligands – direct 
or indirect – is very important to get deeper insights in the functional effects of galectins 
on RPE cells. 
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10. Perspectives 
In conclusion, analyzing the EMT process of RPE cells with a focus on glycan structures 
emphasized the high impact of glycomic fingerprints for the pathogenesis of PVR and for 
functional effects of galectins. To find the missing link between the transition to a 
mesenchymal phenotype and an aberrant glycostructure upon PVR pathology, altered 
expression profiles of glycosyltransferases might be helpful to analyze. Galectins are 
involved in many cellular but also in many pathological processes. In most galectin-
based therapeutic approaches galectins themselves are targeted to prevent pathological 
disorders. Our strategy in preventing PVR associated cellular events was to use 
exogenously Gal-1 and Gal-3 as therapeutic agent assuming a specific surface 
glycosylation pattern as therapeutic target. We identified the functionally relevant 
oligosaccharide determinants, namely β1,6(GlcNAc)-branched N-glycans, and in a 
proteome-wide comprehensive Gal-1 and Gal-3 interactome screening approach we 
identified individual glycoproteins carrying the relevant glycoform for galectin-binding.  
Finally, clinical relevance of galectins has to be evaluated. Because of the relative 
selectivity of Gal-1 and Gal-3 for the myofibroblastic RPE phenotype together with its 
capability to inhibit early PVR-associated cellular events carbohydrate-dependently, we 
speculate that from a therapeutic perspective targeting β1,6(GlcNAc)-branched N-
glycans by recombinant Gal-1 or Gal-3 or other carbohydrate-based drugs may allow to 
selectively target transdifferentiated cells present in the vitreous and thus provide a 
novel concept for prophylaxis of PVR. Therefore, Gal-1 and Gal-3 have to be stabilized or 
galectin-mimetics have to be designed and tested for cytotoxicity and immunogenicity 
under in vivo conditions in a suitable animal model for PVR.  
From a diagnostic perspective, results from these studies may provide a basis for 
diagnostic glycophenotyping of cells isolated from the vitreous of patients suffering from 
early PVR. Consequently this can contribute to the development of plant lectin- or 
galectin-carbohydrate-interaction based prognostic markers to define the individual risk 
for development of PVR.   
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11. Abbreviations 
α2M: alpha-2-macroglobulin 
α-SMA: α -smooth muscle actin 
ABC: ammonium bicarbonate 
Akt: protein kinase b 
Asn: asparagine 
BCA: bicinchoninic acid assay 
BSG: Basigin 
CAD: collision-activated dissociation 
cAMP: Cyclic adenosine monophosphate 
CBP: Carbohydrate Binding Protein 
CD: cluster of differentiation 
CMLE: classic maximum likelihood estimation 
CNBr: cyanogen bromide 
CNX: Calnexin 
ConA: Concanavalin A 
CRD: carbohydrate recognition domain 
DAPI: 4',6-diamidino-2-phenylindole 
DB: Database 
DDA: data-dependent analysis 
DIA: data-independent analysis 
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DMEM: Dulbecco’s  modified Eagles medium 
DMNJ: deoxymannojirimycin 
DNA: Deoxyribonucleic acid 
DTT: dithiothreitol 
ECM: extracellular matrix 
EGF: epidermal growth factor 
EMT: epithelial-to-mesenchymal transition 
ER: Endoplasmic reticulum  
ERK: extracellular signal-regulated kinases 
ESI: electrospray ionization 
FACS: fluorescence-activated cell scanning 
FastAP: Fast Alkaline Phosphatase 
FC: fold change 
FCS: fetal calf serum 
FDR: False Discovery Rate 
FGF: fibroblast growth factor 
FT: Fourier transformation 
Gal-1: Galectin-1 
Gal-3: Galectin-3 
GalNAc: N-acetylgalactosamine 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase 
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GCNT1: 2 N-acetylglucosaminyltransferase 1 
GFAP: glial fibrillary acidic protein 
GFP: green fluorescent protein 
GlcNAc: N-acetylglucosamine 
GnT5: N-acetylglucosaminyltransferase 5 
GO: gene ontology 
GSK-3α/β: glycogen synthase kinase  
HCD: Higher-energy collisional dissociation 
HGF: hepatocyte growth factor 
HPLC: high-performance liquid chromatography 
HRP: horseradish peroxidase 
Ig: immunoglobulin 
IL: interleukin 
INF: interferon 
ITGB1: integrin beta 1 
JAK: janus kinase 
Kif: Kifunensine 
LacNAc: N-acetyllactosamine 
LAMP: lysosomal-membrane-associated glycoprotein 
LRP1: low-density lipoprotein receptor  
LV: lentivirus 
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Mac-2: macrophage surface antigen 
Mal2: Maackia Amurensis Lectin-2 
MALDI: matrix-assisted laser desorption/ionization 
MAPK: mitogen-activated protein kinase 
MEGM: mammary epithelial cell growth medium 
MEMα: minimum essential medium 
Mes: mesenchymal 
MET: mesenchymal-to-epithelial-transition 
Mgat5: β-N-acetylglucosaminyltransferase 5 
MRM: multiple reaction monitoring 
MS: mass spectrometry 
MUC1: Mucin 1 
Nat: native 
NCAM: neural cell adhesion molecule 
NFκB: nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
PBS: phosphate-buffered saline 
PDGFRB: platelet-derived growth factor receptor beta  
PEDF: pigment epithelium-derived growth factor 
PHAL: phytohemagglutinin-L 
PI3-K: phosphatidyl inositol 3-kinase 
PMF: peptide mass fingerprinting 
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PNA: peanut agglutinin 
Pras: proline-rich protein 
PVR: proliferative vitreoretinopathy 
RBC: red blood cell 
RF: radio frequency 
RMG: retinal Müller glial cells  
RNA: Ribonucleic acid   
ROS: reactive oxygen species 
RP: reverse phase 
RPE: retinal pigment epithelial cells 
RT: room temperature 
Ser: serine 
SFK: Src family kinase 
SRM: selected reaction monitoring 
SP: signal peptide 
STAT: signal transducer and activator of transcription 
ST3Gal1: 2,3 sialyltransferase 1 
ST6Gal1: 2,6 sialyltransferase 1 
TFA: trifluoroacetic acid 
TGF-β: transforming growth factor beta 
THT: triiodo-thyronin 
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Thr: threonine 
TMD: transmembrane domain 
TNF: tumor necrosis factor 
TOF: time-of-flight 
TXR: texas red 
UA: urea 
VEGF: vascular endothelial growth factor 
XIC: extracted ion chromatogram 
ZO-1: zonula occludens-1 
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